Publications

Members of the Metabolic Continuum Roundtable™ contribute important research to the public domain through peer-reviewed articles in medical journals. Below is a selection of recent research co-authored by Roundtable contributors. For a comprehensive search of metabolic-related research by Roundtable contributors and others, visit pubmed.gov.

Filter


MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials.

Zannad F, Sanyal AJ, Butler J, Ferreira JP, Girerd N, Miller V, Pandey A, Parikh CR, Ratziu V, Younossi ZM, Harrison SA. J Intern Med. 2024 Jul;296(1):24-38. doi: 10.1111/joim.13793.

View Publication

Is digital pathology the new standard in MASH trials?

Wang Y, Wong VW. Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000967.

View Publication

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD).

Vacca M, Kamzolas I, Harder LM, Oakley F, Trautwein C, Hatting M, Ross T, Bernardo B, Oldenburger A, Hjuler ST, Ksiazek I, Lindén D, Schuppan D, Rodriguez-Cuenca S, Tonini MM, Castañeda TR, Kannt A, Rodrigues CMP, Cockell S, Govaere O, Daly AK, Allison M, Honnens de Lichtenberg K, Kim YO, Lindblom A, Oldham S, Andréasson AC, Schlerman F, Marioneaux J, Sanyal A, Afonso MB, Younes R, Amano Y, Friedman SL, Wang S, Bhattacharya D, Simon E, Paradis V, Burt A, Grypari IM, Davies S, Driessen A, Yashiro H, Pors S, Worm Andersen M, Feigh M, Yunis C, Bedossa P, Stewart M, Cater HL, Wells S, Schattenberg JM, Anstee QM; LITMUS Investigators; Tiniakos D, Perfield JW, Petsalaki E, Davidsen P, Vidal-Puig A. Nat Metab. 2024 Jun 12. doi: 10.1038/s42255-024-01043-6.

View Publication

The fibroblast hormone endotrophin is a biomarker of mortality in chronic diseases.

Genovese F, Bager C, Frederiksen P, Vazquez D, Sand JMB, Jenkins RG, Maher TM, Stewart ID, Molyneaux PL, Fahy WA, Wain LV, Vestbo J, Nanthakumar C, Shaker SB, Hoyer N, Leeming DJ, George J, Trebicka J, Rasmussen DGK, Hansen MK, Cockwell P, Kremer D, Bakker SJ, Selby NM, Reese-Petersen AL, González A, Núñez J, Rossing P, Nissen NI, Boisen MK, Chen IM, Zhao L, Karsdal MA, Schuppan D. Matrix Biol. 2024 Jun 11:S0945-053X(24)00085-4. doi: 10.1016/j.matbio.2024.06.003.

View Publication

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Nat Med. 2024 Jun 10. doi: 10.1038/s41591-024-03018-2.

View Publication

Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.

Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, Yoneda M, Behling C, Cummings OW, Tang Y, Brouwers B, Robins DA, Nikooie A, Bunck MC, Haupt A, Sanyal AJ; SYNERGY-NASH Investigators. N Engl J Med. 2024 Jun 8. doi: 10.1056/NEJMoa2401943.

View Publication

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz EBugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Noureddin M, Alkhouri N, Younes R; 1404-0043 Trial Investigators. N Engl J Med. 2024 Jun 7. doi: 10.1056/NEJMoa2401755.

View Publication

Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.

Lawitz EJ, Fraessdorf M, Neff GW, Schattenberg JM, Noureddin M, Alkhouri N, Schmid B, Andrews CP, Takács I, Hussain SA, Fenske WK, Gane EJ, Hosseini-Tabatabaei A, Sanyal AJ, Mazo DF, Younes R; NCT05296733 Investigators. J Hepatol. 2024 Jun 7:S0168-8278(24)02303-1. doi: 10.1016/j.jhep.2024.06.003.

View Publication

Envisioning how to advance the MASH field.

Allen AM, Younossi ZM, Diehl AM, Charlton MR, Lazarus JV. Nat Rev Gastroenterol Hepatol. 2024 Jun 4. doi: 10.1038/s41575-024-00938-9.

View Publication

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes.

Bridi L, Agrawal S, Tesfai K, Madamba E, Bettencourt R, Richards LM, Khera AV, Loomba R, Ajmera V. Aliment Pharmacol Ther. 2024 Jun 2. doi: 10.1111/apt.18099.

View Publication

Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis – prevalence, clinical impact, economic implications and management strategies.

Golabi P, Owrangi S, Younossi ZM. Aliment Pharmacol Ther. 2024 Jun;59 Suppl 1:S1-S9. doi: 10.1111/apt.17833.

View Publication

Diagnosis and non-invasive assessment of MASLD in type 2 diabetes and obesity.

Chan WK, Petta S, Noureddin M, Goh GBB, Wong VW. Aliment Pharmacol Ther. 2024 Jun;59 Suppl 1:S23-S40. doi: 10.1111/apt.17866.

View Publication

LiverAI: New tool in the landscape for liver health.

Marti-Aguado D, Pazó J, Diaz-Gonzalez A, de Las Heras Páez de la Cadena B, Conthe A, Gallego Duran R, Rodríguez-Gandía MA, Turnes J, Romero-Gomez M. Gastroenterol Hepatol. 2024 Jun-Jul;47(6):646-648. doi: 10.1016/j.gastrohep.2024.04.001.

View Publication

New and emerging treatments for metabolic dysfunction-associated steatohepatitis.

Tincopa MA, Anstee QM, Loomba R. Cell Metab. 2024 Jun 4;36(6):1430. doi: 10.1016/j.cmet.2024.04.016.

View Publication

A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.

Tincopa MA, Anstee QM, Loomba R. Cell Metab. 2024 Jun 4;36(6):1430. doi: 10.1016/j.cmet.2024.04.016.

View Publication

A prospective study on the prevalence of at-risk MASH in patients with type 2 diabetes mellitus in the United States.

Mittal N, Siddiqi H, Madamba E, Richards L, Bettencourt R, Ajmera V, Loomba R. Aliment Pharmacol Ther. 2024 Jun;59(12):1571-1578. doi: 10.1111/apt.17997.

View Publication

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease.

Noureddin N, Huang DQ, Bettencourt R, Siddiqi H, Majzoub AM, Nayfeh T, Tamaki N, Izumi N, Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Gidener T, Allen AM, Ajmera V, Loomba R. Aliment Pharmacol Ther. 2024 Jun;59(12):1521-1526. doi: 10.1111/apt.17981.

View Publication

Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases.

Giannakogeorgou A, Roden M. Aliment Pharmacol Ther. 2024 Jun;59 Suppl 1:S52-S75. doi: 10.1111/apt.17848.

View Publication

Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.

Noureddin N, Copur-Dahi N, Loomba R. Aliment Pharmacol Ther. 2024 Jun;59 Suppl 1(Suppl 1):S41-S51. doi: 10.1111/apt.17752.

View Publication

The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.

Abdelmalek MF, Harrison SA, Sanyal AJ. Diabetes Obes Metab. 2024 Jun;26(6):2001-2016. doi: 10.1111/dom.15524.

View Publication

Changing from NAFLD to MASLD: The implications for health-related quality of life data.

Hashida R, Nakano D, Kawaguchi M, Younossi ZM, Kawaguchi T. J Hepatol. 2024 Jun;80(6):e249-e251. doi: 10.1016/j.jhep.2024.02.010.

View Publication

Short-term reduction of dietary gluten improves metabolic-dysfunction associated steatotic liver disease: A randomised, controlled proof-of-concept study.

Armandi A, Bespaljko H, Mang A, Huber Y, Michel M, Labenz C, Galle PR, Neerukonda M, Bugianesi E, Schuppan D, Schattenberg JM. Aliment Pharmacol Ther. 2024 May;59(10):1212-1222. doi: 10.1111/apt.17941.

View Publication

The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD).

Henry L, Paik JM, Younossi ZM. J Hepatol. 2024 May 22:S0168-8278(24)00359-3. doi: 10.1016/j.jhep.2024.05.024.

View Publication

Integrating genetic and socioeconomic data to predict the progression of nonalcoholic fatty liver disease.

Rieman-Klingler MC, Jung J, Tesfai K, Loomba R, Non AL. Am J Biol Anthropol. 2024 May 22:e24979. doi: 10.1002/ajpa.24979.

View Publication

Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.

Vuppalanchi R, Loomba R, Sanyal AJ, Nikooie A, Tang Y, Robins DA, Brouwers B, Hartman ML. Aliment Pharmacol Ther. 2024 Jul;60(1):17-32. doi: 10.1111/apt.18042.

View Publication

Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?

Huttasch M, Roden M, Kahl S. Metabolism. 2024 May 21:155937. doi: 10.1016/j.metabol.2024.155937.

View Publication

Increases and decreases in liver stiffness measurements are independently associated with the risk of liver-related events in NAFLD.

Gawrieh S, Vilar-Gomez E, Wilson LA, Pike F, Kleiner DE, Neuschwander-Tetri BA, Diehl AM, Dasarathy S, Kowdley KV, Hameed B, Tonascia J, Loomba R, Sanyal AJ, Chalasani N; NASH Clinical Research Network. J Hepatol. 2024 May 16:S0168-8278(24)00343-X. doi: 10.1016/j.jhep.2024.05.008.

View Publication

The new hepatic steatosis nomenclature. No more NAFLD!

Castro-Narro GE, Rinella ME. Rev Gastroenterol Mex (Engl Ed). 2024 Apr-Jun;89(2):312-313. doi: 10.1016/j.rgmxen.2024.02.002.

View Publication

Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction-associated steatohepatitis.

Younossi ZM, Mangla KK, Berentzen TL, Grau K, Kjær MS, Ladelund S, Nitze LM, Coolbaugh C, Hsu CY, Hagström H. Hepatol Commun. 2024 May 10;8(6):e0423. doi: 10.1097/HC9.0000000000000423.

View Publication

High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort.

Barritt AS 4th, Yu F, Mospan AR, Newsome PN, Roden M, Morris HL, Loomba R, Neuschwander-Tetri BA; TARGET-NASH investigators. Am J Gastroenterol. 2024 May 9. doi: 10.14309/ajg.0000000000002796.

View Publication

Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis.

Shankar SS, Daniels SJ, Robertson D, Sarv J, Sánchez J, Carter D, Jermutus L, Challis B, Sanyal AJ. Clin Gastroenterol Hepatol. 2024 May 9:S1542-3565(24)00424-5. doi: 10.1016/j.cgh.2024.04.017.

View Publication

Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome.

Gato S, García-Fernández V, Gil-Gómez A, Rojas Á, Montero-Vallejo R, Muñoz-Hernández R, Romero-Gómez M. Eur Cardiol. 2024 May 9;19:e03. doi: 10.15420/ecr.2023.26.

View Publication

Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.

Qi X, Li J, Caussy C, Teng GJ, Loomba R. Hepatology. 2024 May 8. doi: 10.1097/HEP.0000000000000913.

View Publication

Health-related quality of life in non-alcoholic fatty liver disease: A cross-cultural study between Spain and the United Kingdom.

Funuyet-Salas J, Martín-Rodríguez A, Pérez-San-Gregorio MÁ, Vale L, Robinson T, Anstee QM, Romero-Gómez M. PLoS One. 2024 May 6;19(5):e0300362. doi: 10.1371/journal.pone.0300362.

View Publication

Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.

Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Hepatology. 2024 May 1;79(5):1212-1219. doi: 10.1097/HEP.0000000000000670.

View Publication

BCG Vaccination-Associated Lower HbA1c and Increased CD25 Expression on CD8+ T Cells in Patients with Type 1 Diabetes in Ghana.

Aniagyei W, Mohayideen S, Sarfo-Kantanka O, Bittner S, Vivekanandan MM, Arthur JF, Boateng AO, Yeboah A, Ahor HS, Asibey SO, Owusu E, Herebian D, Huttasch M, Burkart V, Wagner R, Roden M, Adankwah E, Owusu DO, Mayatepek E, Jacobsen M, Phillips RO, Seyfarth J. Vaccines (Basel). 2024 Apr 24;12(5):452. doi: 10.3390/vaccines12050452.

View Publication

Cost-effectiveness of diagnosis and treatment of early gestational diabetes mellitus: economic evaluation of the TOBOGM study, an international multicenter randomized controlled trial.

Haque MM, Tannous WK, Herman WH, Immanuel J, Hague WM, Teede H, Enticott J, Cheung NW, Hibbert E, Nolan CJ, Peek MJ, Wong VW, Flack JR, Mclean M, Sweeting A, Gianatti E, Kautzky-Willer A, Jürgen Harreiter, Mohan V, Backman H, Simmons D; TOBOGM Consortium. EClinicalMedicine. 2024 Apr 24;71:102610. doi: 10.1016/j.eclinm.2024.102610.

View Publication

PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.

Chalasani N, Vilar-Gomez E, Loomba R, Yates KP, Diehl AM, Neuschwander-Tetri BA, Dasarathy S, Kowdley KV, Terrault N, Wilson LA, Tonascia J, Sanyal AJ. Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000896.

View Publication

Use of non-invasive diagnostic tools for metabolic dysfunction-associated steatohepatitis: A qualitative exploration of challenges and barriers.

Tsochatzis EA, Valenti L, Thiele M, Péloquin S, Lazure P, Masson MH, Allen AM, Lazarus JV, Noureddin M, Rinella M, Tacke F, Murray S. Liver Int. 2024 Apr 18. doi: 10.1111/liv.15941.

View Publication

The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease.

Barrera F, Uribe J, Olvares N, Huerta P, Cabrera D, Romero-Gómez M. Ann Hepatol. 2024 Apr 15:101501. doi: 10.1016/j.aohep.2024.101501.

View Publication

The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.

Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Albillos A, Francés R, Fernández-Rodríguez C, Maya-Miles D, Diago M, Poca M, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Hernández-Guerra M, Pareja-Megia MJ, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Turnes J, Romero-Gómez M; HEPAmet Registry. J Gastroenterol. 2024 Apr 15. doi: 10.1007/s00535-024-02098-8.

View Publication

Potential Therapeutic Targets in Obesity, Sleep Apnea, Diabetes, and Fatty Liver Disease.

Gu C, Bernstein N, Mittal N, Kurnool S, Schwartz H, Loomba R, Malhotra A. J Clin Med. 2024 Apr 12;13(8):2231. doi: 10.3390/jcm13082231.

View Publication

Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis.

Mózes FE, Lee JA, Vali Y, Selvaraj EA, Jayaswal ANA, Boursier J, de Lédinghen V, Lupșor-Platon M, Yilmaz Y, Chan WK, Mahadeva S, Karlas T, Wiegand J, Shalimar, Tsochatzis E, Liguori A, Wong VW, Lee DH, Holleboom AG, van Dijk AM, Mak AL, Hagström H, Akbari C, Hirooka M, Lee DH, Kim W, Okanoue T, Shima T, Nakajima A, Yoneda M, Thuluvath PJ, Li F, Berzigotti A, Mendoza YP, Noureddin M, Truong E, Fournier-Poizat C, Geier A, Tuthill T, Yunis C, Anstee QM, Harrison SA, Bossuyt PM, Pavlides M. Liver Int. 2024 Apr 4. doi: 10.1111/liv.15914.

View Publication

Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction.

Krag A, Rinella ME. Nat Med. 2024 Apr;30(4):933-936. doi: 10.1038/s41591-024-02849-3.

View Publication

Metabolic dysfunction-associated steatohepatitis (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) require urgent attention by primary care physicians and endocrinologists.

Mauricio D, Escalada J, Pérez A, Romero-Gómez MCusi K, Younoussi ZM, Lazarus JV. Endocrinol Diabetes Nutr (Engl Ed). 2024 Apr;71(4):149-151. doi: 10.1016/j.endien.2024.01.007.

View Publication

Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting.

Allen AM, Charlton M, Cusi K, Harrison SA, Kowdley KV, Noureddin M, Shubrook JH. Postgrad Med. 2024 Apr;136(3):229-245. doi: 10.1080/00325481.2024.2325332.

View Publication

Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.

Alkhouri N, LaCerte C, Edwards J, Poordad F, Lawitz E, Lee L, Karan S, Sawhney S, Erickson M, MacConell L, Zaru L, Chen J, Campagna J. Liver Int. 2024 Apr;44(4):966-978. doi: 10.1111/liv.15816.

View Publication

Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.

Armandi A, Bugianesi E. Eur J Intern Med. 2024 Apr;122:20-27. doi: 10.1016/j.ejim.2024.01.005.

View Publication

Emerging Combination of Saroglitazar and Vitamin E for the Treatment of NAFLD and NASH.

Tavaglione F, Loomba R. J Clin Exp Hepatol. 2024 Sep-Oct;14(5):101449. doi: 10.1016/j.jceh.2024.101449.

View Publication

Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial.

Noureddin M, Khan S, Portell F, Jorkasky D, Dennis J, Khan O, Johansson L, Johansson E, Sanyal AJ. Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1094-1105. doi: 10.1016/S2468-1253(23)00198-X.

View Publication

Nutrition assessment and MASH severity in children using the Healthy Eating Index.

Jain AK, Buchannan P, Yates KP, Belt P, Schwimmer JB, Rosenthal P, Murray KF, Molleston JP, Scheimann A, Xanthakos SA, Behling CA, Hertel P, Nilson J, Neuschwander-Tetri BA, Tonascia J, Vos MB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Hepatol Commun. 2023 Dec 7;7(12):e0320. doi: 10.1097/HC9.0000000000000320.

View Publication

Impact of Type 2 Diabetes on the Outcomes of Solid Organ Transplantations in the U.S.: Data From a National Registry.

Stepanova M, Kumar A, Brandt P, Gundurao N, Cusi K, Al Qahtani S, Younossi ZM. Diabetes Care. 2023 Dec 1;46(12):2162-2170. doi: 10.2337/dc23-1085.

View Publication

Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease.

Odenwald MA, Lin H, Lehmann C, Dylla NP, Cole CG, Mostad JD, Pappas TE, Ramaswamy R, Moran A, Hutchison AL, Stutz MR, Dela Cruz M, Adler E, Boissiere J, Khalid M, Cantoral J, Haro F, Oliveira RA, Waligurski E, Cotter TG, Light SH, Beavis KG, Sundararajan A, Sidebottom AM, Reddy KG, Paul S, Pillai A, Te HS, Rinella ME, Charlton MR, Pamer EG, Aronsohn AI. Nat Microbiol. 2023 Nov;8(11):2033-2049. doi: 10.1038/s41564-023-01493-w.

View Publication

The Impact and Burden of Dietary Sugars on the Liver.

Huneault HE, Ramirez Tovar A, Sanchez-Torres C, Welsh JA, Vos MB. Hepatol Commun. 2023 Nov 6;7(11):e0297. doi: 10.1097/HC9.0000000000000297.

View Publication

A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis.

Newsome PN, Sanyal AJ, Neff G, Schattenberg JM, Ratziu V, Ertle J, Link J, Mackie A, Schoelch C, Lawitz E; BI 1467335 NASH Phase IIa trial team. Nat Commun. 2023 Nov 6;14(1):7151. doi: 10.1038/s41467-023-42398-w.

View Publication

Diabetes mellitus, energy metabolism and COVID-19.

Conte C, Cipponeri E, Roden M. Endocr Rev. 2023 Nov 2:bnad032. doi: 10.1210/endrev/bnad032. Online ahead of print.PMID: 37934800

View Publication

A nutrigenetic precision approach for the management of non-alcoholic fatty liver disease.

Perez-Diaz-Del-Campo N, Dileo E, Castelnuovo G, Nicolosi A, Guariglia M, Caviglia GP, Rosso C, Armandi A, Bugianesi E. Clin Nutr. 2023 Nov;42(11):2181-2187. doi: 10.1016/j.clnu.2023.09.022.

View Publication

Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS).

Sandforth A, von Schwartzenberg RJ, Arreola EV, Hanson RL, Sancar G, Katzenstein S, Lange K, Preißl H, Dreher SI, Weigert C, Wagner R, Kantartzis K, Machann J, Schick F, Lehmann R, Peter A, Katsouli N, Ntziachristos V, Dannecker C, Fritsche L, Perakakis N, Heni M, Nawroth PP, Kopf S, Pfeiffer AFH, Kabisch S, Stumvoll M, Schwarz PEH, Hauner H, Lechner A, Seissler J, Yurchenko I, Icks A, Solimena M, Häring HU, Szendroedi J, Schürmann A, de Angelis MH, Blüher M, Roden M, Bornstein SR, Stefan N, Fritsche A, Birkenfeld AL. Lancet Diabetes Endocrinol. 2023 Nov;11(11):798-810. doi: 10.1016/S2213-8587(23)00235-8.

View Publication

Looking for the best algorithm in diabetes population for advanced fibrosis detection: The best is the enemy of the good.

Stepanova M, Kumar A, Brandt P, Gundurao N, Cusi K, Al Qahtani S, Younossi ZM. Diabetes Care. 2023 Dec 1;46(12):2162-2170. doi: 10.2337/dc23-1085.

View Publication

Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease.

Li J, Delamarre A, Wong VW, de Lédinghen V. United European Gastroenterol J. 2023 Nov 21. doi: 10.1002/ueg2.12491.

View Publication

Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality.

Lee SW, Huang DQ, Bettencourt R, Ajmera V, Tincopa M, Noureddin N, Amangurbanova M, Siddiqi H, Madamba E, Majzoub AM, Nayfeh T, Tamaki N, Izumi N, Nakajima A, Yoneda M, Idilman R, Gumussoy M, Oz DK, Erden A, Loomba R. Aliment Pharmacol Ther. 2023 Nov 15. doi: 10.1111/apt.17783.

View Publication

Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.

Younossi ZM, AlQahtani SA, Alswat K, Yilmaz Y, Keklikkiran C, Funuyet-Salas J, Romero-Gómez M, Fan JG, Zheng MH, El-Kassas M, Castera L, Liu CJ, Wai-Sun Wong V, Zelber-Sagi S, Allen AM, Lam B, Treeprasertsuk S, Hameed S, Takahashi H, Kawaguchi T, Schattenberg JM, Duseja A, Newsome P, Francque S, Spearman CW, Castellanos Fernández MI, Burra P, Roberts SK, Chan WK, Arrese M, Silva M, Rinella M, Singal AK, Gordon S, Fuchs M, Alkhouri N, Cusi K, Loomba R, Ranagan J, Eskridge W, Kautz A, Ong JP, Kugelmas M, Eguchi Y, Diago M, Yu ML, Gerber L, Fornaresio L, Nader F, Henry L, Racila A, Golabi P, Stepanova M, Carrieri P, Lazarus JV; Global NASH Council. J Hepatol. 2023 Nov 18:S0168-8278(23)05279-0. doi: 10.1016/j.jhep.2023.11.004.

View Publication

Risk factors for fibrosis progression in non-alcoholic steatohepatitis: analysis of the European cohort in the real-world GAIN study.

Shaikh A, Pedra G, Ruiz-Casas L, Franks B, Dhillon H, Fernandes JDDR, Mangla KK, Augusto M, Romero-Gómez M, Schattenberg JM. Gastroenterol Hepatol. 2023 Oct 25:S0210-5705(23)00451-X. doi: 10.1016/j.gastrohep.2023.10.005.

View Publication

Homeostasis Model Assessment of β-Cell Function for Diagnosis of Insulinoma.

Bódis K, Schön M, Dauben L, Wilker M, Strassburger K, Burkart V, Roden M, Müssig K. J Clin Endocrinol Metab. 2023 Oct 27:dgad618. doi: 10.1210/clinem/dgad618.

View Publication

Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score.

Marti-Aguado D, Arnouk J, Liang JX, Lara-Romero C, Behari J, Furlan A, Jimenez-Pastor A, Ten-Esteve A, Alfaro-Cervello C, Bauza M, Gallen-Peris A, Gimeno-Torres M, Merino-Murgui V, Perez-Girbes A, Benlloch S, Pérez-Rojas J, Puglia V, Ferrández-Izquierdo A, Aguilera V, Giesteira B, França M, Monton C, Escudero-García D, Alberich-Bayarri Á, Serra MA, Bataller R, Romero-Gomez M, Marti-Bonmati L. Liver Int. 2023 Oct 30. doi: 10.1111/liv.15766.

View Publication

Impact of physical fitness and exercise training on subcutaneous adipose tissue beiging markers in humans with and without diabetes and a high-fat diet-fed mouse model.

Bódis K, Breuer S, Crepzia-Pevzner A, Zaharia OP, Schön M, Saatmann N, Altenhofen D, Springer C, Szendroedi J, Wagner R, Al-Hasani H, Roden M, Pesta D, Chadt A; GDS Group. Diabetes Obes Metab. 2023 Oct 23. doi: 10.1111/dom.15322.

View Publication

Precise glucose measurement in sodium fluoride-citrate plasma affects estimates of prevalence in diabetes and prediabetes.

Heilmann G, Trenkamp S, Möser C, Bombrich M, Schön M, Yurchenko I, Strassburger K, Rodríguez MM, Zaharia OP, Burkart V, Wagner R, Roden M. Clin Chem Lab Med. 2023 Oct 24. doi: 10.1515/cclm-2023-0770.

View Publication

Reduced Insulin Clearance Differently Relates to Increased Liver Lipid Content and Worse Glycemic Control in Recent-Onset Type 2 and Type 1 Diabetes.

Zaharia OP, Antoniou S, Bobrov P, Karusheva Y, Bódis K, Kupriyanova Y, Schrauwen-Hinderling V, Gastaldelli A, Szendroedi J, Wagner R, Burkart V, Roden M; GDS Group. Diabetes Care. 2023 Oct 24:dc231267. doi: 10.2337/dc23-1267.

View Publication

A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis.

Campion D, Ponzo P, Risso A, Caropreso P, Caviglia GP, Sanavia T, Frigo F, Bonetto S, Giovo I, Rizzo M, Martini S, Bugianesi E, Mengozzi G, Marzano A, Manca A, Saracco GM, Alessandria C. J Hepatol. 2023 Oct 20:S0168-8278(23)05176-0. doi: 10.1016/j.jhep.2023.10.010.

View Publication

Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions.

Ratziu V, Hompesch M, Petitjean M, Serdjebi C, Iyer JS, Parwani AV, Tai D, Bugianesi E, Cusi K, Friedman SL, Lawitz E, Romero-Gómez M, Schuppan D, Loomba R, Paradis V, Behling C, Sanyal AJ. J Hepatol. 2023 Oct 23:S0168-8278(23)05182-6. doi: 10.1016/j.jhep.2023.10.015.

View Publication

Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.

Ajmera V, Tesfai K, Sandoval E, Lopez S, Cervantes V, Madamba E, Bettencourt R, Manousou P, Richards L, Loomba R. Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000635.

View Publication

Long-term follow-up of web-based and group-based behavioural intervention in NAFLD in a real world clinical setting.

Petroni ML, Colosimo S, Brodosi L, Armandi A, Bertini F, Montesi D, Bugianesi E, Marchesini G. Aliment Pharmacol Ther. 2023 Oct 16. doi: 10.1111/apt.17768.

View Publication

Inter-organ crosstalk during development and progression of type 2 diabetes mellitus.

Xourafa G, Korbmacher M, Roden M. Nat Rev Endocrinol. 2023 Oct 16. doi: 10.1038/s41574-023-00898-1.

View Publication

Nutrition could prevent or promote non-alcoholic fatty liver disease: an opportunity for intervention.

Romero-Gómez M, Zelber-Sagi S, Martín F, Bugianesi E, Soria B. BMJ. 2023 Oct 9;383:e075179. doi: 10.1136/bmj-2023-075179.

View Publication

Correlates of Skeletal Muscle Mass and Differences Between Novel Subtypes in Recent-onset Diabetes.

Herder C, Maalmi H, Saatmann N, Zaharia OP, Strassburger K, Burkart V, Norman K, Roden M. J Clin Endocrinol Metab. 2023 Oct 13:dgad605. doi: 10.1210/clinem/dgad605.

View Publication

Risk of severe infection in patients with non-alcoholic fatty liver disease: Implication on clinical management.

Wang MY, Wong VW, Yip TC. Liver Int. 2023 Oct;43(10):2057-2059. doi: 10.1111/liv.15696.

View Publication

Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions.

Ratziu V, Hompesch M, Petitjean M, Serdjebi C, Iyer JS, Parwani AV, Tai D, Bugianesi E, Cusi K, Friedman SL, Lawitz E, Romero-Gómez M, Schuppan D, Loomba R, Paradis V, Behling C, Sanyal AJ. Hepatology. 2023 Oct 24. doi:10.1016/j.jhep.2023.10.015.

View Publication

Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.

Cherubini A, Ostadreza M, Jamialahmadi O, Pelusi S, Rrapaj E, Casirati E, Passignani G, Norouziesfahani M, Sinopoli E, Baselli G, Meda C, Dongiovanni P, Dondossola D, Youngson N, Tourna A, Chokshi S, Bugianesi E; EPIDEMIC Study Investigators; Della Torre S, Prati D, Romeo S, Valenti L. Nat Med. 2023 Sep 25. doi: 10.1038/s41591-023-02553-8.

View Publication

A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis.

Rinella ME, Lieu HD, Kowdley KV, Goodman ZD, Alkhouri N, Lawitz E, Ratziu V, Abdelmalek MF, Wong VW, Younes ZH, Sheikh AM, Brannan D, Freilich B, Membreno F, Sinclair M, Melchor-Khan L, Sanyal AJ, Ling L, Harrison SA. Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000607.

View Publication

Impact of Type 2 Diabetes on the Outcomes of Solid Organ Transplantations in the U.S.: Data From a National Registry.

Stepanova M, Kumar A, Brandt P, Gundurao N, Cusi K, Al Qahtani S, Younossi ZM. Diabetes Care. 2023 Sep 25:dc231085. doi: 10.2337/dc23-1085.

View Publication

MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease.

Cheung JTK, Zhang X, Wong GL, Yip TC, Lin H, Li G, Leung HH, Lai JC, Mahadeva S, Nik Mustapha NR, Wang XD, Liu WY, Wong VW, Chan WK, Zheng MH. Aliment Pharmacol Ther. 2023 Sep 19. doi: 10.1111/apt.17722.

View Publication

Brain insulin action on peripheral insulin sensitivity in women depends on menstrual cycle phase.

Hummel J, Benkendorff C, Fritsche L, Prystupa K, Vosseler A, Gancheva S, Trenkamp S, Birkenfeld AL, Preissl H, Roden M, Häring HU, Fritsche A, Peter A, Wagner R, Kullmann S, Heni M. Nat Metab. 2023 Sep;5(9):1475-1482. doi: 10.1038/s42255-023-00869-w.

View Publication

Global Epidemiology of Cirrhosis: Changing Etiological Basis and Comparable Burden of NASH between Males and Females.

Tan D, Chan KE, Wong ZY, Ng CH, Xiao J, Lim WH, Tay P, Tang A, Fu CE, Muthiah M, Nah B, Tan EX, Teng MLP, Siddiqui MS, Dan YY, Lim SG, Loomba R, Huang DQ. Dig Dis. 2023 Sep 13. doi: 10.1159/000533946.

View Publication

Pegozafermin for NASH – A Sprint to Start a Marathon.

Rinella ME. N Engl J Med. 2023 Sep 14;389(11):1044-1046. doi: 10.1056/NEJMe2307249.

View Publication

Association of thyroid function with non-alcoholic fatty liver disease in recent-onset diabetes.

Saatmann N, Schön M, Zaharia OP, Huttasch M, Strassburger K, Trenkamp S, Kupriyanova Y, Schrauwen-Hinderling V, Kahl S, Burkart V, Wagner R, Roden M; GDS Group. Liver Int. 2023 Sep 12. doi: 10.1111/liv.15723.

View Publication

Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis.

Alkhouri N, Lazas D, Loomba R, Frias JP, Feng S, Tseng L, Balic K, Agollah GD, Kwan T, Iyer JS, Morrow L, Mansbach H, Margalit M, Harrison SA. Aliment Pharmacol Ther. 2023 Sep 18. doi: 10.1111/apt.17709.

View Publication

Accuracy, reliability and comprehensiveness of ChatGPT generated medical responses for patients with NAFLD.

Pugliese N, Wong VW, Schattenberg JM, Romero-Gomez M, Sebastiani G; NAFLD Expert Chatbot Working Group; Aghemo A. Clin Gastroenterol Hepatol. 2023 Sep 14:S1542-3565(23)00704-8. doi: 10.1016/j.cgh.2023.08.033.

View Publication

NAFLD: Diagnostics and New Nomenclature.

Kanagalingam G, Sanyal AJ. J Clin Exp Hepatol. 2023 Sep-Oct;13(5):723-724. doi: 10.1016/j.jceh.2023.07.003.

View Publication

Utilization of Food-Derived β-Glucans to Prevent and Treat Non-Alcoholic Fatty Liver Disease (NAFLD).

Kei N, Wong VWS, Lauw S, You L, Cheung PCK. Foods. 2023 Sep 1;12(17):3279. doi: 10.3390/foods12173279.

View Publication

Pioneering the path to NASH biomarker approval.

Krag A, Rinella ME. Nat Med. 2023 Sep 7. doi: 10.1038/s41591-023-02527-w.

View Publication

Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis.

Sanyal AJ, Shankar SS, Yates KP, Bolognese J, Daly E, Dehn CA, Neuschwander-Tetri B, Kowdley K, Vuppalanchi R, Behling C, Tonascia J, Samir A, Sirlin C, Sherlock SP, Fowler K, Heymann H, Kamphaus TN, Loomba R, Calle RA. Nat Med. 2023 Sep 7. doi: 10.1038/s41591-023-02539-6.

View Publication

The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysis.

Danpanichkul P, Ng CH, Muthiah MD, Duangsonk K, Yong JN, Tan DJH, Lim WH, Wong ZY, Syn N, Tsusumi T, Takahashi H, Siddiqui MS, Wong VW, Mantzoros CS, Huang DQ, Noureddin M, Loomba R, Sanyal AJ, Wijarnpreecha K. Aliment Pharmacol Ther. 2023 Sep 11. doi: 10.1111/apt.17714.

View Publication

Effects of TM6SF2 rs58542926 polymorphism on hepatocellular lipids and insulin resistance in early type 2 diabetes.

Bódis K, Bombrich M, Schön M, Knebel B, Zaharia OP, Bönhof G, Karusheva Y, Strassburger K, Kupriyanova Y, Kotzka J, Guthoff R, Schrauwen-Hinderling V, Al-Hasani H, Burkart V, Szendroedi J, Wagner R, Markgraf DF, Roden M; GDS study group. Nutr Metab Cardiovasc Dis. 2023 Sep;33(9):1785-1796. doi: 10.1016/j.numecd.2023.06.004.

View Publication

NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study.

Harrison SA, Ratziu V, Magnanensi J, Hajji Y, Deledicque S, Majd Z, Rosenquist C, Hum DW, Staels B, Anstee QM, Sanyal AJ. J Hepatol. 2023 Sep;79(3):758-767. doi: 10.1016/j.jhep.2023.04.031.

View Publication

Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.

Golabi P, Paik JM, Kumar A, Al Shabeeb R, Eberly KE, Cusi K, GunduRao N, Younossi ZM. Metabolism. 2023 Sep;146:155642. doi: 10.1016/j.metabol.2023.155642.

View Publication

Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease.

Pennisi G, Enea M, Viganò M, Schepis F, de Ledinghen V, Berzigotti A, Wai-Sun Wong V, Fracanzani AL, Sebastiani G, Lara-Romero C, Bugianesi E, Svegliati-Baroni G, Marra F, Aghemo A, Valenti L, Calvaruso V, Colecchia A, Di Maria G, La Mantia C, Lin H, Mendoza YP, Pugliese N, Ravaioli F, Romero-Gomez M, Saltini D, Craxì A, Di Marco V, Cammà C, Petta S. JHEP Rep. 2023 Jun 7;5(9):100809. doi: 10.1016/j.jhepr.2023.100809.

View Publication

Progression of nonalcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.

Simon TG, Roelstraete B, Hagström H, Loomba R, Ludvigsson JF. J Hepatol. 2023 Aug 19:S0168-8278(23)05063-8. doi: 10.1016/j.jhep.2023.08.008.

View Publication

Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.

Serra-Burriel M, Juanola A, Serra-Burriel F, Thiele M, Graupera I, Pose E, Pera G, Grgurevic I, Caballeria L, Piano S, van Kleef L, Reichert M, Roulot D, Pericàs JM, Schattenberg JM, Tsochatztis EA, Guha IN, Garcia-Retortillo M, Hernández R, Hoyo J, Fuentes M, Expósito C, Martínez A, Such P, Madir A, Detlefsen S, Tonon M, Martini A, Ma AT, Pich J, Bonfill E, Juan M, Soria A, Carol M, Gratacós-Ginès J, Morillas RM, Toran P, Navarrete JM, Torrejón A, Fournier C, Llorca A, Arslanow A, de Koning HJ, Cucchietti F, Manns M, Newsome PN, Hernáez R, Allen A, Angeli P, de Knegt RJ, Karlsen TH, Galle P, Wong VW, Fabrellas N, Castera L, Krag A, Lammert F, Kamath PS, Ginès P; LiverScreen Consortium Investigators. Lancet. 2023 Aug 9:S0140-6736(23)01174-1. doi: 10.1016/S0140-6736(23)01174-1.

View Publication

Semaglutide in NASH-related cirrhosis: still a long way to go? – Authors’ reply.

Loomba R, Newsome PN. Lancet Gastroenterol Hepatol. 2023 Aug;8(8):694-695. doi: 10.1016/S2468-1253(23)00160-7.

View Publication

Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial.

Zhang X, Yip TC, Wong GL, Leow WX, Liang LY, Lim LL, Li G, Ibrahim L, Lin H, Lai JCT, Chim AM, Chan HLY, Kong AP, Chan WK, Wong VW. Gut. 2023 Aug 7:gutjnl-2023-330269. doi: 10.1136/gutjnl-2023-330269.

View Publication

Advanced liver fibrosis predicts heart failure and hospitalizations in people with type 2 diabetes: A prospective cohort study from Hong Kong Diabetes Register.

Kong AP, Lau ES, O CK, Luk AO, Yip TC, Chow EY, Kwok R, Lee HW, Wong GL, Ma RC, Chan HL, Wong VW, Chan JC. Diabetes Res Clin Pract. 2023 Aug;202:110825. doi: 10.1016/j.diabres.2023.110825.

View Publication

Editorial: Will MRI-PDFF become the new standard for steatosis assessment in NAFLD? Authors’ reply.

Huang DQ, Loomba R. Aliment Pharmacol Ther. 2023 Aug;58(3):366-367. doi: 10.1111/apt.17619.

View Publication

AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.

Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. Gastroenterology. 2023 Aug 4:S0016-5085(23)00881-8. doi: 10.1053/j.gastro.2023.06.013.

View Publication

Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD.

Ratziu V, Boursier J; AFEF Group for the Study of Liver Fibrosis. J Hepatol. 2023 Aug 3:S0168-8278(23)04996-6. doi: 10.1016/j.jhep.2023.07.017.

View Publication

Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver disease.

Armandi A, Michel M, Gjini K, Emrich T, Bugianesi E, Schattenberg JM. Expert Rev Mol Diagn. 2023 Aug 1:1-12. doi: 10.1080/14737159.2023.2242779.

View Publication

Hepatic, Extra-hepatic Outcomes and Causes of Mortality in NAFLD – An Umbrella Overview of Systematic Review of Meta-Analysis.

Xiao J, Ng CH, Chan KE, Fu C, Tay P, Yong JN, Lim WH, Tan DJH, Syn N, Wong ZY, Tseng M, Chew N, Huang DQ, Dan YY, Wong VWLoomba R, Siddiqui MS, Sanyal AJ, Noureddin M, Muthiah MD. J Clin Exp Hepatol. 2023 Jul-Aug;13(4):656-665. doi: 10.1016/j.jceh.2022.11.006.

View Publication

Alterations of hepatic energy metabolism in murine models of obesity, diabetes and fatty liver diseases.

Dewidar B, Mastrototaro L, Englisch C, Ress C, Granata C, Rohbeck E, Pesta D, Heilmann G, Wolkersdorfer M, Esposito I, Reina Do Fundo M, Zivehe F, Yavas A, Roden M. EBioMedicine. 2023 Aug;94:104714. doi: 10.1016/j.ebiom.2023.104714.

View Publication

At the dawn of potent therapeutics for fatty liver disease – introducing the miniseries on promising pharmacological targets for NASH.

Ratziu V, Tacke F. J Hepatol. 2023 Aug;79(2):261-262. doi: 10.1016/j.jhep.2023.04.003.

View Publication

A global action agenda for turning the tide on fatty liver disease.

View Publication

The effects of extracellular vesicles and their cargo on metabolism and its adaptation to physical exercise in insulin resistance and type 2 diabetes.

Mastrototaro L, Roden M. Proteomics. 2023 Jul 31:e2300078. doi: 10.1002/pmic.202300078.

View Publication

Serum identification of At-Risk MASH: The Metabolomics-Advanced steatohepatitis fibrosis score (MASEF).

Noureddin M, Truong E, Mayo R, Martínez-Arranz I, Mincholé I, Banales JM, Arrese M, Cusi K, Arias-Loste MT, Bruha R, Romero-Gómez M, Iruzubieta P, Aller R, Ampuero J, Calleja JL, Ibañez-Samaniego L, Aspichueta P, Marín-Duce A, Kushner T, Ortiz P, Harrison SA, Anstee QM, Crespo J, Mato JM, Sanyal AJ. Hepatology. 2023 Jul 24. doi: 10.1097/HEP.0000000000000542.

View Publication

Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.

En Li Cho E, Ang CZ, Quek J, Fu CE, Lim LKE, Heng ZEQ, Tan DJH, Lim WH, Yong JN, Zeng R, Chee D, Nah B, Lesmana CRA, Bwa AH, Win KM, Faulkner C, Aboona MB, Lim MC, Syn N, Kulkarni AV, Suzuki H, Takahashi H, Tamaki N, Wijarnpreecha K, Huang DQ, Muthiah M, Ng CH, Loomba R. Gut. 2023 Jul 25:gutjnl-2023-330110. doi: 10.1136/gutjnl-2023-330110.

View Publication

Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis.

Sanyal AJ, Ratziu V, Loomba R, Anstee QM, Kowdley KV, Rinella ME, Sheikh MY, Trotter JF, Knapple W, Lawitz EJ, Abdelmalek MF, Newsome PN, Boursier J, Mathurin P, Dufour JF, Berrey MM, Shiff SJ, Sawhney S, Capozza T, Leyva R, Harrison SA, Younossi ZM. J Hepatol. 2023 Jul 28:S0168-8278(23)04993-0. doi: 10.1016/j.jhep.2023.07.014.

View Publication

Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes Mellitus.

Schön M, Zaharia OP, Strassburger K, Kupriyanova Y, Bódis K, Heilmann G, Strom A, Bönhof GJ, Michelotti F, Yurchenko I, Möser C, Huttasch M, Bombrich M, Kelm M, Burkart V, Schrauwen-Hinderling VB, Wagner R, Roden M; GDS group. Diabetes. 2023 Jul 21:db230353. doi: 10.2337/db23-0353.

View Publication

Impact of Chronotype and Mediterranean Diet on the Risk of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.

Noureddin M, Truong E, Mayo R, Martínez-Arranz I, Mincholé I, Banales JM, Arrese M, Cusi K, Arias-Loste MT, Bruha R, Romero-Gómez M, Iruzubieta P, Aller R, Ampuero J, Calleja JL, Ibañez-Samaniego L, Aspichueta P, Marín-Duce A, Kushner T, Ortiz P, Harrison SA, Anstee QM, Crespo J, Mato JM, Sanyal AJ. Hepatology. 2023 Jul 24. doi: 10.1097/HEP.0000000000000542.

View Publication

Nonalcoholic fatty liver disease mortality may not be decreasing: A need for careful interpretation of GBD 2019 estimates of liver deaths.

Paik JM, Henry L, Younossi ZM. Cell Metab. 2023 Jul 11;35(7):1087-1088. doi: 10.1016/j.cmet.2023.06.012.

View Publication

Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes.

Kuo SZ, Cepin S, Bergstrom J, Siddiqi H, Jung J, Lopez S, Huang DQ, Taub P, Amangurbanova M, Loomba R. Aliment Pharmacol Ther. 2023 Jul 11. doi: 10.1111/apt.17637.

View Publication

Metabolic dysfunction: The silenced connection with fatty liver disease.

Ramírez-Mejía MM, Qi X, Abenavoli L, Romero-Gómez M, Eslam M, Méndez-Sánchez N. Ann Hepatol. 2023 Jul 17;28(6):101138. doi: 10.1016/j.aohep.2023.101138.

View Publication

Identification of High Risk NAFLD Patients in Endocrinology Clinics.

Younossi ZM, Henry L, Isaacs S, Cusi K. Endocr Pract. 2023 Jul 3:S1530-891X(23)00469-X. doi: 10.1016/j.eprac.2023.06.012.

View Publication

Post-Transplant Diabetes Mellitus: Recent Developments in Pharmacological Management of Hyperglycemia.

Munoz Pena JM, Cusi K. J Clin Endocrinol Metab. 2023 Jul 6:dgad395. doi: 10.1210/clinem/dgad395.

View Publication

Impact of Health Related QoL and Mediterranean Diet on Liver Fibrosis in Patients with NAFLD.

Perez-Diaz-Del-Campo N, Castelnuovo G, Rosso C, Nicolosi A, Guariglia M, Dileo E, Armandi A, Caviglia GP, Bugianesi E. Nutrients. 2023 Jul 2;15(13):3018. doi: 10.3390/nu15133018.

View Publication

Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis.

Huang DQ, Noureddin N, Ajmera V, Amangurbanova M, Bettencourt R, Truong E, Gidener T, Siddiqi H, Majzoub AM, Nayfeh T, Tamaki N, Izumi N, Yoneda M, Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Allen AM, Noureddin M, Loomba R. Lancet Gastroenterol Hepatol. 2023 Jul 4:S2468-1253(23)00157-7. doi: 10.1016/S2468-1253(23)00157-7.

View Publication

How to Identify Advanced Nonalcoholic Fatty Liver Disease in the Primary Care Setting.

Golabi P, Shah D, Younossi ZM. Semin Liver Dis. 2023 Jul 6. doi: 10.1055/s-0043-1770984.

View Publication

Lifestyle interventions in nonalcoholic fatty liver disease.

Younossi ZM, Zelber-Sagi S, Henry L, Gerber LH. Nat Rev Gastroenterol Hepatol. 2023 Jul 4. doi: 10.1038/s41575-023-00800-4.

View Publication

Development and Validation of the NAFLD Familial Risk Score to Detect Advanced Fibrosis: a Prospective, Multicenter Study.

Huang DQ, Ahlholm N, Luukkonen PK, Porthan K, Amangurbanova M, Madamba E, Bettencourt R, Siddiqi H, Cervantes V, Hernandez C, Lopez SJ, Richards L, Nemes K, Isoniemi H, Yki-Järvinen H, Loomba R. Clin Gastroenterol Hepatol. 2023 Jul 3:S1542-3565(23)00505-0. doi: 10.1016/j.cgh.2023.06.020.

View Publication

Identification of High Risk NAFLD Patients in Endocrinology Clinics.

Younossi ZM, Zelber-Sagi S, Henry L, Gerber LH. Nat Rev Gastroenterol Hepatol. 2023 Jul 4. doi: 10.1038/s41575-023-00800-4.

View Publication

Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLD.

Kim BK, Bernstein N, Huang DQ, Tamaki N, Imajo K, Yoneda M, Sutter N, Jung J, Nguyen K, Nguyen L, Le T, Madamba E, Richards L, Valasek MA, Behling C, Sirlin CB, Nakajima A, Loomba R. Aliment Pharmacol Ther. 2023 Jul;58(2):229-237. doi: 10.1111/apt.17564.

View Publication

Addendum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67.

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Cusi K, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA; American Diabetes Association. Diabetes Care. 2023 Jun 25:dc23ad09. doi: 10.2337/dc23-ad09.

View Publication

Erratum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67.

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Cusi K, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA; American Diabetes Association. Diabetes Care. 2023 Jun 25:dc23er09a. doi: 10.2337/dc23-er09a.

View Publication

Natural history of NASH cirrhosis in liver transplant waitlist registrants.

Lim WH, Ng CH, Tan D, Tseng M, Xiao J, Yong JN, Zeng RW, Cho E, Tay P, Ang CZ, Koh JH, Teng M, Syn N, Kow A, Huang DQ, Tan EX, Rinella ME, Sanyal A, Muthiah M, Siddiqui MS. J Hepatol. 2023 Jun 10:S0168-8278(23)00412-9. doi: 10.1016/j.jhep.2023.05.034.

View Publication

How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials.

Kuss O, Opitz ME, Brandstetter LV, Schlesinger S, Roden M, Hoyer A. Diabetologia. 2023 Jun 20. doi: 10.1007/s00125-023-05951-2.

View Publication

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.

Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, Bedossa P, Harrison SA, Lazas D, Barish R, Gottwald MD, Feng S, Agollah GD, Hartsfield CL, Mansbach H, Margalit M, Abdelmalek MF. N Engl J Med. 2023 Jun 24. doi: 10.1056/NEJMoa2304286.

View Publication

Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.

Golabi P, Paik JM, Kumar A, Al Shabeeb R, Eberly KE, Cusi K, GunduRao N, Younossi ZM. Metabolism. 2023 Jun 26;146:155642. doi: 10.1016/j.metabol.2023.155642.

View Publication

Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial.

Romero-Gómez M, Armstrong MJ, Funuyet-Salas J, Mangla KK, Ladelund S, Sejling AS, Shrestha I, Sanyal AJ. Aliment Pharmacol Ther. 2023 Jun 16. doi: 10.1111/apt.17598.

View Publication

The sugar-free paradox: cardiometabolic consequences of erythritol.

Pafili K, Roden M. Signal Transduct Target Ther. 2023 Jun 16;8(1):251. doi: 10.1038/s41392-023-01504-6.

View Publication

Evaluation of 2-year outcomes in infants born to mothers with and without NAFLD in pregnancy.

Gross A, Lange M, Rosenbluth E, Carroll C, Sperling R, Juliano C, Sigel K, Friedman SL, Argiriadi PA, Chu J, Kushner T. Eur J Pediatr. 2023 Jun 13. doi: 10.1007/s00431-023-05044-7.

View Publication

Dynamic Glucose-Enhanced Imaging of the Liver Using Breath-Hold Black Blood Quantitative T1ρ MRI at 3.0 T.

Qian Y, Wong VWS, Wang YX, Hou J, Jiang B, Zhang X, Wong GLH, Chan Q, Yu SCH, Chu WCW, Chen W. J Magn Reson Imaging. 2023 Jun 14. doi: 10.1002/jmri.28829.

View Publication

MIC26 and MIC27 are bona fide subunits of the MICOS complex in mitochondria and do not exist as glycosylated apolipoproteins.

Lubeck M, Derkum NH, Naha R, Strohm R, Driessen MD, Belgardt BF, Roden M, Stühler K, Anand R, Reichert AS, Kondadi AK. PLoS One. 2023 Jun 6;18(6):e0286756. doi: 10.1371/journal.pone.0286756.

View Publication

Agile3+ and Agile4: two diagnostic scores that synergize for the prognostic assessment in NAFLD.

Boursier J, Roux M, Sanyal AJ. J Hepatol. 2023 Jun 9:S0168-8278(23)00409-9. doi: 10.1016/j.jhep.2023.05.033.

View Publication

Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight and obese patients with co-morbidities.

Shin W, Hompesch M, Byeon J, Kang S, Choi J, Baek S. Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15162.

View Publication

A Phase 2a active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with nonalcoholic fatty liver disease.

Romero-Gómez MLawitz E, Shankar RR, Chaudhri E, Liu J, Lam RLH, Kaufman KD, Engel SS; MK-6024 P001 Study Group. J Hepatol. 2023 Jun 5:S0168-8278(23)00342-2. doi: 10.1016/j.jhep.2023.05.013.

View Publication

Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD.

Muñoz-Hernández R, Gato S, Gil-Gómez A, Aller R, Rojas A, Morán L, Gallego J, Blázquez-López E, Gallego-Durán R, Montero-Vallejo R, García-Fernández V, Maya-Miles D, Rico MDC, Cubero FJ, Vaquero J, Ampuero J, Bañares R, Romero-Gómez M. Liver Int. 2023 Jun 8. doi: 10.1111/liv.15604.

View Publication

Measuring NAFLD models of care.

Allen AM, Younossi ZM, Tsochatzis EA, Alazawi W, Zelber-Sagi S, Arab JP, Cusi K, Lazarus JV. Nat Rev Gastroenterol Hepatol. 2023 Jun 8. doi: 10.1038/s41575-023-00798-9.

View Publication

Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.

Mózes FE, Lee JA, Vali Y, Alzoubi O, Staufer K, Trauner M, Paternostro R, Stauber RE, Holleboom AG, van Dijk AM, Mak AL, Boursier J, de Saint Loup M, Shima T, Bugianesi E, Gaia S, Armandi A, Shalimar, Lupșor-Platon M, Wong VW, Li G, Wong GL, Cobbold J, Karlas T, Wiegand J, Sebastiani G, Tsochatzis E, Liguori A, Yoneda M, Nakajima A, Hagström H, Akbari C, Hirooka M, Chan WK, Mahadeva S, Rajaram R, Zheng MH, George J, Eslam M, Petta S, Pennisi G, Viganò M, Ridolfo S, Aithal GP, Palaniyappan N, Lee DH, Ekstedt M, Nasr P, Cassinotto C, de Lédinghen V, Berzigotti A, Mendoza YP, Noureddin M, Truong E, Fournier-Poizat C, Geier A, Martic M, Tuthill T, Anstee QM, Harrison SA, Bossuyt PM, Pavlides M; LITMUS investigators. Lancet Gastroenterol Hepatol. 2023 Jun 5:S2468-1253(23)00141-3. doi: 10.1016/S2468-1253(23)00141-3.

View Publication

Trajectories of glycaemic traits exhibit sex-specific associations with hepatic iron and fat content: Results from the KORA-MRI study.

Niedermayer F, Su Y, von Krüchten R, Thorand B, Peters A, Rathmann W, Roden M, Schlett CL, Bamberg F, Nattenmüller J, Rospleszcz S. Liver Int. 2023 Jun 3. doi: 10.1111/liv.15635.

View Publication

A Phase 2a active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with nonalcoholic fatty liver disease.

Romero-Gómez M, Lawitz E, Shankar RR, Chaudhri E, Liu J, Lam RLH, Kaufman KD, Engel SS; MK-6024 P001 Study Group. J Hepatol. 2023 Jun 5:S0168-8278(23)00342-2. doi: 10.1016/j.jhep.2023.05.013.

View Publication

Special Population: Pediatric Nonalcoholic Fatty Liver Disease.

Dybbro E, Vos MB, Kohli R. Clin Liver Dis. 2023 May;27(2):471-482. doi: 10.1016/j.cld.2023.01.012.  

View Publication

Economic Burden and Patient-Reported Outcomes of Nonalcoholic Fatty Liver Disease.

Stepanova M, Henry L, Younossi ZM. Clin Liver Dis. 2023 May;27(2):483-513. doi: 10.1016/j.cld.2023.01.007.   

View Publication

Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Cardiovascular Diseases.

Armandi A, Bugianesi E. Clin Liver Dis. 2023 May;27(2):239-250. doi: 10.1016/j.cld.2023.01.018.   

View Publication

Nonalcoholic Fatty Liver Disease: Disease Burden and Disease Awareness.

Golabi P, Isakov V, Younossi ZM. Clin Liver Dis. 2023 May;27(2):173-186. doi: 10.1016/j.cld.2023.01.001.  

View Publication

Noninvasive Tests Used in Risk Stratification of Patients with Nonalcoholic Fatty Liver Disease.

Henry L, Eberly KE, Shah D, Kumar A, Younossi ZM. Clin Liver Dis. 2023 May;27(2):373-395. doi: 10.1016/j.cld.2023.01.022.  

View Publication

Research Priorities for Precision Medicine in NAFLD.

Iruzubieta P, Bataller R, Arias-Loste MT, Arrese M, Calleja JL, Castro-Narro G, Cusi K, Dillon JF, Martínez-Chantar ML, Mateo M, Pérez A, Rinella ME, Romero-Gómez M, Schattenberg JM, Zelber-Sagi S, Crespo J, Lazarus JV. Clin Liver Dis. 2023 May;27(2):535-551. doi: 10.1016/j.cld.2023.01.016.  

View Publication

Metabolic Syndrome and Its Association with Nonalcoholic Steatohepatitis.

Bril F, Sanyal A, Cusi K. Clin Liver Dis. 2023 May;27(2):187-210. doi: 10.1016/j.cld.2023.01.002.  

View Publication

Nonalcoholic Fatty Liver Disease: A Unique Entity or Part of the Metabolic Syndrome or Both.

Yip TC, Wong GL, Wong VW, Goh GB, Chan WK. Med Clin North Am. 2023 May;107(3):449-463. doi: 10.1016/j.mcna.2022.12.003.  

View Publication

Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease.

Francque S, Ratziu V. Clin Liver Dis. 2023 May;27(2):429-449. doi: 10.1016/j.cld.2023.01.010.   

View Publication

Roles of Radiological Tests in Clinical Trials and the Clinical Management of Nonalcoholic Fatty Liver Disease.

Dunn W, Castera L, Loomba R. Clin Liver Dis. 2023 May;27(2):363-372. doi: 10.1016/j.cld.2023.01.020.   

View Publication

Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease.

Rosso C, Caviglia GP, Birolo G, Armandi A, Pennisi G, Pelusi S, Younes R, Liguori A, Perez-Diaz-Del-Campo N, Nicolosi A, Govaere O, Castelnuovo G, Olivero A, Abate ML, Ribaldone DG, Fariselli P, Valenti L, Miele L, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. Clin Gastroenterol Hepatol. 2023 May 4:S1542-3565(23)00324-5. doi: 10.1016/j.cgh.2023.04.024.

View Publication

A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis.

Mak LY, Gane E, Schwabe C, Yoon KT, Heo J, Scott R, Lee JH, Lee JI, Kweon YO, Weltman M, Harrison SA, Neuschwander-Tetri BA, Cusi K, Loomba R, Given BD, Christianson DR, Garcia-Medel E, Yi M, Hamilton J, Yuen MF.J Hepatol. 2023 Apr;78(4):684-692. doi: 10.1016/j.jhep.2022.11.025.

View Publication

Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study.

Abdelmalek MF, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Lawitz EJ, Harrison SA, Jacobson IM, Imajo K, Gunn N, Halegoua-DeMarzio D, Akahane T, Boone B, Yamaguchi M, Chatterjee A, Tirucherai GS, Shevell DE, Du S, Charles ED, Loomba R. Clin Gastroenterol Hepatol. 2023 Apr 21:S1542-3565(23)00311-7. doi: 10.1016/j.cgh.2023.04.012.  

View Publication

Recurrent NAFLD post LT: sisyphus’ boulder or proteus’ parable?

Odenwald MA, Rinella ME. Liver Transpl. 2023 Apr 19. doi: 10.1097/LVT.0000000000000161.  

View Publication

It’s time to expand the fatty liver disease community of practice.

Lazarus JV, Kopka CJ, Younossi ZM, Allen AM. Hepatology. 2023 Apr 18. doi: 10.1097/HEP.0000000000000411.  

View Publication

Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.).

Paik JM, Eberly KE, Kabbara K, Harring M, Younossi Y, Henry L, Verma M, Younossi ZM. Ann Hepatol. 2023 Apr 21:101108. doi: 10.1016/j.aohep.2023.101108.  

View Publication

Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study.

Loomba R, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Harrison SA, Lawitz EJ, Gunn N, Imajo K, Ravendhran N, Akahane T, Boone B, Yamaguchi M, Chatterjee A, Tirucherai GS, Shevell DE, Du S, Charles ED, Abdelmalek MF. Clin Gastroenterol Hepatol. 2023 Apr 21:S1542-3565(23)00310-5. doi: 10.1016/j.cgh.2023.04.011.  

View Publication

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.

Tacke F, Puengel T, Loomba RFriedman SL. J Hepatol. 2023 Apr 13:S0168-8278(23)00218-0. doi: 10.1016/j.jhep.2023.03.038.  

View Publication

Non-invasive assessment of liver fibrosis in NAFLD.

Sanyal AJ, Castéra L, Wai-Sun Wong V. Clin Gastroenterol Hepatol. 2023 Apr 14:S1542-3565(23)00266-5. doi: 10.1016/j.cgh.2023.03.042.  

View Publication

Global and national prevalence of nonalcoholic fatty liver disease in adolescents: an analysis of the global burden of disease study 2019.

Hartmann P, Zhang X, Loomba R, Schnabl B. Hepatology. 2023 Apr 10. doi: 10.1097/HEP.0000000000000383.  

View Publication

Clinical Trial Landscape in NASH.

Harrison SA, Loomba R, Dubourg J, Ratziu V, Noureddin M. Clin Gastroenterol Hepatol. 2023 Apr 12:S1542-3565(23)00265-3. doi: 10.1016/j.cgh.2023.03.041.  

View Publication

Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Tincopa MA, Loomba R.Lancet Gastroenterol Hepatol. 2023 Apr 12:S2468-1253(23)00066-3. doi: 10.1016/S2468-1253(23)00066-3. Online ahead of print.PMID: 37060912 

View Publication

Validation of the blood test MACK-3 for the noninvasive diagnosis of fibrotic NASH: an international study with 1,924 patients.

Canivet CM, Zheng MH, Qadri S, Vonghia L, Chuah KH, Costentin C, George J, Armandi A, Adams LA, Lange NF, Blanchet O, Moal V, Younes R, Roux M, Chan WK, Sturm N, Eslam M, Bugianesi E, Wang Z, Dufour JF, Francque S, Yki-Järvinen H, Zheng KI, Boursier J. Clin Gastroenterol Hepatol. 2023 Apr 7:S1542-3565(23)00240-9. doi: 10.1016/j.cgh.2023.03.032.  

View Publication

A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures.

Govaere O, Hasoon M, Alexander L, Cockell S, Tiniakos D, Ekstedt M, Schattenberg JM, Boursier J, Bugianesi E, Ratziu V; LITMUS Investigators; Daly AK, Anstee QM. Nat Metab. 2023 Apr 10. doi: 10.1038/s42255-023-00775-1.  

View Publication

Study protocol for a randomized, controlled trial using a novel, family-centered diet treatment to prevent NAFLD in Hispanic children.

Welsh JA, Pyo E, Huneault H, Gonzalez Ramirez L, Alazraki A, Alli R, Dunbar SB, Khanna G, Knight-Scott J, Pimentel A, Reed B, Rodney-Somersall C, Santoro N, Umpierrez G, Vos MB. Contemp Clin Trials. 2023 Apr 3;129:107170.  

View Publication

Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review.

Torosian K, Lal E, Kavanaugh A, Loomba R, Ajmera V, Guma M.Semin Arthritis Rheum. 2023 Apr;59:152165. doi: 10.1016/j.semarthrit.2023.152165.

View Publication

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.

Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L.Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004.

View Publication

NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned.

Rasmussen DGK, Anstee QM, Torstenson R, Golding B, Patterson SD, Brass C, Thakker P, Harrison S, Billin AN, Schuppan D, Dufour JF, Andersson A, Wigley I, Shumbayawonda E, Dennis A, Schoelch C, Ratziu V, Yunis C, Bossuyt P, Karsdal MA.J Hepatol. 2023 Apr;78(4):852-865. doi: 10.1016/j.jhep.2022.11.028.

View Publication

Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence.

Bril F, Kalavalapalli S, Lomonaco R, Cusi K.Diabetes Obes Metab. 2023 Apr;25(4):1112-1116. doi: 10.1111/dom.14936.

View Publication

Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.

Pennisi G, Enea M, Falco V, Aithal GP, Palaniyappan N, Yilmaz Y, Boursier J, Cassinotto C, de Lédinghen V, Chan WK, Mahadeva S, Eddowes P, Newsome P, Karlas T, Wiegand J, Wong VW, Schattenberg JM, Labenz C, Kim W, Lee MS, Lupsor-Platon M, Cobbold JFL, Fan JG, Shen F, Staufer K, Trauner M, Stauber R, Nakajima A, Yoneda M, Bugianesi E, Younes R, Gaia S, Zheng MH, Cammà C, Anstee QM, Mózes FE, Pavlides M, Petta S.Hepatology. 2023 Mar 17. doi: 10.1097/HEP.0000000000000351.

View Publication

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment.

Llovet JM, Willoughby CE, Singal AG, Greten TF, Heikenwälder M, El-Serag HB, Finn RS, Friedman SL.Nat Rev Gastroenterol Hepatol. 2023 Mar 17. doi: 10.1038/s41575-023-00754-7.

View Publication

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.

Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N, Lawitz E, Ratziu V, Sanyal AJ, Schattenberg JM, Newsome PN; NN9931-4492 investigators. Lancet Gastroenterol Hepatol. 2023 Mar 16:S2468-1253(23)00068-7. doi: 10.1016/S2468-1253(23)00068-7.

View Publication

Review article: The need for more efficient and patient-oriented drug development pathways in NASH-setting the scene for platform trials.

Pericàs JM, Di Prospero NA, Anstee QM, Mesenbrinck P, Kjaer MS, Rivera-Esteban J, Koenig F, Sena E, Pais R, Manzano R, Genescà J, Tacke F, Ratziu V; EU-PEARL NASH Investigators. Aliment Pharmacol Ther. 2023 Mar 14. doi: 10.1111/apt.17456.  

View Publication

Implications of comorbidities in nonalcoholic fatty liver disease.

Song SJ, Wong VW. Clin Mol Hepatol. 2023 Mar 14. doi: 10.3350/cmh.2023.0066.  

View Publication

Corrigendum to: “Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort<sup>☆</sup>” [J Hepatol (2020) 505-515].

Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, Burt AD, Bedossa P, Palmer J, Liu YL, Aithal GP, Allison M, Yki-Järvinen H, Vacca M, Dufour JF, Invernizzi P, Prati D, Ekstedt M, Kechagias S, Francque S, Petta S, Bugianesi E, Clement K, Ratziu V, Schattenberg JM, Valenti L, Day CP, Cordell HJ, Daly AK; EPoS Consortium Investigators. J Hepatol. 2023 Mar 13:S0168-8278(23)00160-5. doi: 10.1016/j.jhep.2023.02.028.   

View Publication

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. Hepatology. 2023 Mar 17. doi: 10.1097/HEP.0000000000000323.

View Publication

Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease.

Castelnuovo G, Perez-Diaz-Del-Campo N, Guariglia M, Poggiolini I, Armandi A, Rosso C, Caviglia GP, Bugianesi E. Minerva Gastroenterol (Torino). 2023 Mar 9. doi: 10.23736/S2724-5985.23.03361-2.

View Publication

Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints.

Meyer EL, Mesenbrink P, Di Prospero NA, Pericàs JM, Glimm E, Ratziu V, Sena E, König F; EU-PEARL NASH Investigators. PLoS One. 2023 Mar 9;18(3):e0281674. doi: 10.1371/journal.pone.0281674.

View Publication

The global burden of metabolic disease: Data from 2000 to 2019.

Chew NWS, Ng CH, Tan DJH, Kong G, Lin C, Chin YH, Lim WH, Huang DQ, Quek J, Fu CE, Xiao J, Syn N, Foo R, Khoo CM, Wang JW, Dimitriadis GK, Young DY, Siddiqui MS, Lam CSP, Wang Y, Figtree GA, Chan MY, Cummings DE, Noureddin M, Wong VW, Ma RCW, Mantzoros CS, Sanyal A, Muthiah MD. Cell Metab. 2023 Mar 7;35(3):414-428.e3. doi: 10.1016/j.cmet.2023.02.003.

View Publication

Validation of a Clinical Risk-Based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort.

Sanyal AJ, Munoz B, Cusi K, Barritt AS 4th, Muthiah M, Mospan AR, Reddy KR, Firpi-Morell R, Thuluvath PJ, Bhamidimarri KR, Fried MW; TARGET-NASH Investigators. Clin Gastroenterol Hepatol. 2023 Mar 3:S1542-3565(23)00167-2. doi: 10.1016/j.cgh.2023.02.024.

View Publication

Prevalence of non-alcoholic fatty liver disease in patients with rheumatoid arthritis: A systematic review and meta-analysis.

Zamani M, Alizadeh-Tabari S, Chitkara P, Singh S, Loomba R. Clin Gastroenterol Hepatol. 2023 Mar 3:S1542-3565(23)00164-7. doi: 10.1016/j.cgh.2023.02.021.

View Publication

Using Real-World Electronic Health Record Data to Assess Chronic Disease Screening in Children: A Case Study of Non-Alcoholic Fatty Liver Disease.

Kraus EM, Pierce SL, Porter R, Kompaniyets L, Vos MB, Blanck HM, King RJ, Goodman AB. Child Obes. 2023 Mar 1. doi: 10.1089/chi.2022.0208.

View Publication

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.

Loomba R, Huang DQ, Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Ding D, Ma L, Jia C, Billin A, Huss RS, Chung C, Goodman Z, Wong VW, Okanoue T, Romero-Gómez M, Abdelmalek MF, Muir A, Afdhal N, Bosch J, Harrison S, Younossi ZM, Myers RP. Gut. 2023 Mar;72(3):581-589. doi: 10.1136/gutjnl-2022-327777.

View Publication

Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.

Vali Y, Lee J, Boursier J, Petta S, Wonders K, Tiniakos D, Bedossa P, Geier A, Francque S, Allison M, Papatheodoridis G, Cortez-Pinto H, Pais R, Dufour JF, Leeming DJ, Harrison SA, Chen Y, Cobbold JF, Pavlides M, Holleboom AG, Yki-Jarvinen H, Crespo J, Karsdal M, Ostroff R, Zafarmand MH, Torstenson R, Duffin K, Yunis C, Brass C, Ekstedt M, Aithal GP, Schattenberg JM, Bugianesi E, Romero-Gomez M, Ratziu V, Anstee QM, Bossuyt PM; Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) consortium investigators. Lancet Gastroenterol Hepatol. 2023 Mar 20:S2468-1253(23)00017-1. doi: 10.1016/S2468-1253(23)00017-1.  

View Publication

Machine learning algorithm improves detection of NASH (NAS-based) and at-risk NASH, a development and validation study.

Lee J, Westphal M, Vali Y, Boursier J, Ostroff R, Alexander L, Chen Y, Fournier C, Geier A, Francque S, Wonders K, Tiniakos D, Bedossa P, Allison M, Papatheodoridis G, Cortez-Pinto H, Pais R, Dufour JF, Leeming DJ, Harrison S, Cobbold J, Holleboom AG, Yki-Järvinen H, Crespo J, Ekstedt M, Aithal GP, Bugianesi E, Romero-Gomez M, Karsdal M, Yunis C, Schattenberg JM, Schuppan D, Ratziu V, Brass C, Duffin K, Zwinderman K, Pavlides M, Anstee QM, Bossuyt PM; LITMUS investigators. Hepatology. 2023 Mar 31. doi: 10.1097/HEP.0000000000000364.  

View Publication

Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.

Pennisi G, Enea M, Falco V, Aithal GP, Palaniyappan N, Yilmaz Y, Boursier J, Cassinotto C, de Lédinghen V, Chan WK, Mahadeva S, Eddowes P, Newsome P, Karlas T, Wiegand J, Wong VW, Schattenberg JM, Labenz C, Kim W, Lee MS, Lupsor-Platon M, Cobbold JFL, Fan JG, Shen F, Staufer K, Trauner M, Stauber R, Nakajima A, Yoneda M, Bugianesi E, Younes R, Gaia S, Zheng MH, Cammà C, Anstee QM, Mózes FE, Pavlides M, Petta S. Hepatology. 2023 Mar 17. doi: 10.1097/HEP.0000000000000351.  

View Publication

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Schnell O, Battelino T, Bergenstal R, Birkenfeld AL, Ceriello A, Cheng A, Davies M, Edelman S, Forst T, Giorgino F, Green J, Groop PH, Hadjadj S, J L Heerspink H, Hompesch M, Izthak B, Ji L, Kanumilli N, Mankovsky B, Mathieu C, Miszon M, Mustafa R, Nauck M, Pecoits-Filho R, Pettus J, Ranta K, Rodbard HW, Rossing P, Ryden L, Schumm-Draeger PM, Solomon SD, Škrha J, Topsever P, Vilsbøll T, Wilding J, Standl E. Cardiovasc Diabetol. 2023 Mar 16;22(1):59. doi: 10.1186/s12933-023-01788-6.

View Publication

Prognostic Value of Simple Non-Invasive Tests for the Risk Stratification of Incident Hepatocellular Carcinoma in Cirrhotic Individuals with Non-Alcoholic Fatty Liver Disease.

D'Amato D, Ribaldone DG, Saracco GM, Bugianesi E. Cancers (Basel). 2023 Mar 8;15(6):1659. doi: 10.3390/cancers15061659.

View Publication

Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients.

Siddiqui MS, Parmar D, Shaikh F, Forsgren M, Patel S, Bui AT, Boyett S, Patel V, Sanyal AJ.Liver Transpl. 2023 Feb 28. doi: 10.1097/LVT.0000000000000110.

View Publication

Lower Hepatic Fat Is Associated With Improved Insulin Secretion in a High-Risk Prediabetes Subphenotype During Lifestyle Intervention.

Wagner R, Heni M, Kantartzis K, Sandforth A, Machann J, Schick F, Peter A, Fritsche L, Szendrödi J, Pfeiffer AFH, Schürmann A, Blüher M, Hauner H, Seissler J, Bornstein S, Roden M, Stefan N, Birkenfeld AL, White MF, Häring HU, Fritsche A. Diabetes. 2023 Mar 1;72(3):362-366. doi: 10.2337/db22-0441.

View Publication

Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).

Harrison SA, Thang C, Bolze S, Dewitt S, Hallakou-Bozec S, Dubourg J, Bedossa P, Cusi K, Ratziu V, Grouin JM, Moller DE, Fouqueray P. J Hepatol. 2023 Feb 18:S0168-8278(23)00091-0. doi: 10.1016/j.jhep.2023.02.004.

View Publication

Trends in risk factor control and treatment among patients with non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory-wide study.

Zhang X, Yip TC, Tse YK, Hui VW, Li G, Lin H, Liang LY, Lai JC, Lai MS, Cheung JTK, Chan HL, Chan SL, Kong AP, Wong GL, Wong VW. Aliment Pharmacol Ther. 2023 Feb 23. doi: 10.1111/apt.17428.

View Publication

Lifestyle Intervention in NAFLD: Long-Term Diabetes Incidence in Subjects Treated by Web- and Group-Based Programs.

Petroni ML, Brodosi L, Armandi A, Marchignoli F, Bugianesi E, Marchesini G. Nutrients. 2023 Feb 3;15(3):792. doi: 10.3390/nu15030792.

View Publication

Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial.

Sanyal AJ, Lopez P, Lawitz EJ, Lucas KJ, Loeffler J, Kim W, Goh GBB, Huang JF, Serra C, Andreone P, Chen YC, Hsia SH, Ratziu V, Aizenberg D, Tobita H, Sheikh AM, Vierling JM, Kim YJ, Hyogo H, Tai D, Goodman Z, Schaefer F, Carbarns IRI, Lamle S, Martic M, Naoumov NV, Brass CA. Nat Med. 2023 Feb;29(2):392-400. doi: 10.1038/s41591-022-02200-8.

View Publication

Recent Research and Insights on the Disease Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Younossi ZM. Gastroenterol Hepatol (N Y). 2023 Feb;19(2):108-110.

View Publication

Genomic analysis of lean individuals with NAFLD identifies monogenic disorders in a prospective cohort study.

Zheng M, Huang DQ, Konkwo C, Agrawal S, Khera AV, Loomba R, Vilarinho S, Ajmera V. JHEP Rep. 2023 Feb 2;5(4):100692. doi: 10.1016/j.jhepr.2023.100692.

View Publication

Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.

Loomba RLawitz EJ, Frias JP, Ortiz-Lasanta G, Johansson L, Franey BB, Morrow L, Rosenstock M, Hartsfield CL, Chen CY, Tseng L, Charlton RW, Mansbach H, Margalit M. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):120-132. doi: 10.1016/S2468-1253(22)00347-8.

View Publication

Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties.

Allen AM, Lazarus JV, Younossi ZM. J Hepatol. 2023 Feb 3:S0168-8278(23)00079-X. doi: 10.1016/j.jhep.2023.01.026.

View Publication

Sarcopenia Among Patients with Nonalcoholic Fatty Liver Disease (NAFLD) is Associated with Advanced Fibrosis.

Harring M, Golabi P, Paik JM, Shah D, Racila A, Cable R, Srishord M, Younossi ZM. Clin Gastroenterol Hepatol. 2023 Feb 25:S1542-3565(23)00155-6. doi: 10.1016/j.cgh.2023.02.013.

View Publication

A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis.

Younossi Z, Alkhouri N, Cusi K, Isaacs S, Kanwal F, Noureddin M, Loomba R, Ravendhran N, Lam B, Nader K, Racila A, Nader F, Henry L. Aliment Pharmacol Ther. 2023 Feb;57(3):304-312. doi: 10.1111/apt.17346.

View Publication

The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis.

Sanyal A, Shankar S, Yates K, Bolognese J, Daly E, Dehn C, Neuschwander-Tetri B, Kowdley K, Vuppalanchi R, Behling CA, Tonascia J, Samir A, Sirlin C, Sherlock S, Fowler K, Heymann H, Kamphaus T, Loomba R, Calle R. Res Sq. 2023 Jan 19:rs.3.rs-2492725. doi: 10.21203/rs.3.rs-2492725/v1.

View Publication

Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease.

Liu AN, Xu CF, Liu YR, Sun DQ, Jiang L, Tang LJ, Zhu PW, Chen SD, Liu WY, Wang XD, Targher G, Byrne CD, Wong VW, Fu J, Su MM, Loomba R, Zheng MH, Ni Y. Aliment Pharmacol Ther. 2023 Jan 20. doi: 10.1111/apt.17362.

View Publication

Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.

Armandi A, Rosso C, Younes R, Leeming DJ, Karsdal MA, Caviglia GP, Pérez-Diaz-Del-Campo N, D'Amato D, Abdulle A, Nicolosi A, Castelnuovo G, Saracco GM, Ribaldone DG, Bugianesi E. J Clin Med. 2023 Jan 13;12(2):650. doi: 10.3390/jcm12020650.

View Publication

Nonalcoholic Fatty Liver Disease Is Independently Associated With Higher All-Cause and Cause-Specific Mortality.

de Avila L, Henry L, Paik JM, Ijaz N, Weinstein AA, Younossi ZM. Clin Gastroenterol Hepatol. 2023 Jan 13:S1542-3565(23)00037-X. doi: 10.1016/j.cgh.2023.01.006.

View Publication

Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study.

Julián MT, Ballesta S, Pera G, Pérez-Montes de Oca A, Soldevila B, Caballería L, Morillas R, Expósito C, Martínez-Escudé A, Puig-Domingo M, Franch-Nadal J, Torán P, Cusi K, Julve J, Mauricio D, Alonso N. Front Endocrinol (Lausanne). 2023 Jan 13;13:1051958. doi: 10.3389/fendo.2022.1051958.

View Publication

Diabetes and cirrhosis: Current concepts on diagnosis and management.

Castera L, Cusi K. Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000263.

View Publication

The Predictive Role of Extracellular NAPRT for the Detection of Advanced Fibrosis in Biopsy-Proven Non-Alcoholic Fatty Liver Disease.

Armandi A, Colombo G, Rosso C, Caviglia GP, Olivero A, Abate ML, Guariglia M, Perez Diaz Del Campo N, Castelnuovo G, Ribaldone DG, Saracco GM, Genazzani AA, Bugianesi E. Int J Mol Sci. 2023 Jan 7;24(2):1172. doi: 10.3390/ijms24021172.

View Publication

Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.

Brown EA, Minnich A, Sanyal AJLoomba R, Du S, Schwarz J, Ehman RL, Karsdal M, Leeming DJ, Cizza G, Charles ED. JHEP Rep. 2023 Jan 7;5(4):100661. doi: 10.1016/j.jhepr.2022.100661.

View Publication

Rational combination therapy for NASH: Insights from clinical trials and error.

Armandi A, Colombo G, Rosso C, Caviglia GP, Olivero A, Abate ML, Guariglia M, Perez Diaz Del Campo N, Castelnuovo G, Ribaldone DG, Saracco GM, Genazzani AA, Bugianesi E. Int J Mol Sci. 2023 Jan 7;24(2):1172. doi: 10.3390/ijms24021172.

View Publication

Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD.

Linge J, Nasr P, Sanyal AJ, Dahlqvist Leinhard O, Ekstedt M. JHEP Rep. 2022 Dec 24;5(3):100663. doi: 10.1016/j.jhepr.2022.100663.

View Publication

Exercise Training Is Associated With Treatment Response in Liver Fat Content by Magnetic Resonance Imaging Independent of Clinically Significant Body Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Stine JG, DiJoseph K, Pattison Z, Harrington A, Chinchilli VM, Schmitz KH, Loomba R. Am J Gastroenterol. 2022 Dec 23. doi: 10.14309/ajg.0000000000002098.

View Publication

Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH.

Fraser DA, Harrison SA, Schuppan D. Expert Opin Investig Drugs. 2022 Dec;31(12):1269-1278. doi: 10.1080/13543784.2022.2159804.

View Publication

A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia

Xiao J, Ng CH, Chin YH, Tan DJH, Lim WH, Lim G, Quek J, Tang ASP, Chan KE, Soong RY, Chew N, Tay B, Huang DQ, Tamaki N, Foo R, Chan MY, Noureddin M, Siddiqui MS, Sanyal AJ, Muthiah MD. J Clin Transl Hepatol. 2022 Dec 28;10(6):1042-1049. doi: 10.14218/JCTH.2022.00095.  

View Publication

Vigorous physical activity provides protection against all-cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)

Henry A, Paik JM, Austin P, Eberly KE, Golabi P, Younossi I, Henry L, Gerber L, Younossi ZM. Aliment Pharmacol Ther. 2022 Nov 15. doi: 10.1111/apt.17308. 

View Publication

MAFLD vs. NAFLD not an emotional political process – rather Evidence-Based Medicine

Muthiah M, Sanyal AJ, Noureddin M. Ann Hepatol. 2022 Nov 29:100883. doi: 10.1016/j.aohep.2022.100883.

View Publication

A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes

Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, Madamba E, Bettencourt R, Richards L, Behling C, Sirlin CB, Loomba R. J Hepatol. 2022 Nov 18:S0168-8278(22)03302-5. doi: 10.1016/j.jhep.2022.11.010.  

View Publication

Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients with Type 2 Diabetes and NAFLD

Kalavalapalli S, Leiva EG, Lomonaco R, Chi X, Shrestha S, Dillard R, Budd J, Romero JP, Li C, Bril F, Samraj G, Pennington J, Townsend P, Orlando F, Shetty S, Mansour L, Silva-Sombra LR, Bedossa P, Malaty J, Barb D, Gurka MJ, Cusi K. J Clin Endocrinol Metab. 2022 Nov 16:dgac660. doi: 10.1210/clinem/dgac660.  

View Publication

Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis

Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, Tan DJH, Tang ASP, Tay P, Xiao J, Yong JN, Zeng RW, Chew NWS, Nah B, Kulkarni A, Siddiqui MS, Dan YY, Wong VWSanyal AJ, Noureddin M, Muthiah M, Ng CH. Lancet Gastroenterol Hepatol. 2022 Nov 15:S2468-1253(22)00317-X. doi: 10.1016/S2468-1253(22)00317-X.  

View Publication

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores

Sanyal AJ, Foucquier J, Younossi ZM, Harrison SA, Newsome PN, Chan WK, Yilmaz Y, De Ledinghen V, Costentin C, Zheng MH, Wong VW, Elkhashab M, Huss RS, Myers RP, Roux M, Labourdette A, Destro M, Fournier-Poizat C, Miette V, Sandrin L, Boursier J.J Hepatol. 2022 Nov 11:S0168-8278(22)03293-7. doi: 10.1016/j.jhep.2022.10.034. Online ahead of print.PMID: 36375686 

View Publication

Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD

Amangurbanova M, Huang DQ, Loomba R.Aliment Pharmacol Ther. 2022 Nov 9. doi: 10.1111/apt.17292. Online ahead of print.PMID: 36349732

View Publication

Restoration of CD4+ T Cells during NAFLD without Modulation of the Hepatic Immunological Pattern Is Not Sufficient to Prevent HCC

Isbell M, Mirshahi F, Aqbi HF, Guo C, Saneshaw M, Koelsch N, Idowu MO, Austin D, Gelber C, Wang XY, Sanyal AJ, Manjili MH.Cancers (Basel). 2022 Nov 9;14(22):5502. doi: 10.3390/cancers14225502.PMID: 36428596

View Publication

Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis

Shen W, Middleton MS, Cunha GM, Delgado TI, Wolfson T, Gamst A, Fowler KJ, Alazraki A, Trout AT, Ohliger MA, Shah SN, Bashir MR, Kleiner DE, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Zhou J, Sirlin CB, Lavine JE.J Hepatol. 2022 Nov 8:S0168-8278(22)03284-6. doi: 10.1016/j.jhep.2022.10.027. Online ahead of print.PMID: 36368598

View Publication

Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes

Wolff G, Lin Y, Akbulut C, Brockmeyer M, Parco C, Hoss A, Sokolowski A, Westenfeld R, Kelm M, Roden M, Schlesinger S, Kuss O.ESC Heart Fail. 2022 Nov 7. doi: 10.1002/ehf2.14213. Online ahead of print.PMID: 36337026 

View Publication

Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH

Ratziu V, Harrison SA, Loustaud-Ratti V, Bureau C, Lawitz E, Abdelmalek M, Alkhouri N, Francque S, Girma H, Darteil R, Couchoux H, Wolf M, Sanyal A, Vonderscher J, Scalfaro P.J Hepatol. 2022 Nov 2:S0168-8278(22)03160-9. doi: 10.1016/j.jhep.2022.10.023. Online ahead of print.PMID: 36334688

View Publication

Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease

Tamaki N, Ahlholm N, Luukkonen PK, Porthan K, Sharpton SR, Ajmera V, Kono Y, Dave S, Ahmed A, Sundaram V, Wilkinson MJ, Patton H, Gupta H, Cervantes V, Hernandez C, Lopez SJ, Loomba R, Baumgartner A, Richards L, Arkkila PE, Nemes K, Isoniemi H, Yki-Järvinen H, Loomba R. J Clin Invest. 2022 Nov 1;132(21):e162513. doi: 10.1172/JCI162513. 

View Publication

MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials

Nedrud MA, Chaudhry M, Middleton MS, Moylan CA, Lerebours R, Luo S, Farjat A, Guy C, Loomba R, Abdelmalek MF, Sirlin CB, Bashir MR. Radiology. 2022 Nov 1:220743. doi: 10.1148/radiol.220743.  

View Publication

Dietary Recommendations for the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Nutritional Geometry Perspective

Romero-Gómez M, Aller R, Martín-Bermudo F. Semin Liver Dis. 2022 Nov;42(4):434-445. doi: 10.1055/s-0042-1757711. 

View Publication

Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis

Sharpton SR, Oh TG, Madamba E, Wang C, Yu RT, Atkins AR, Huan T, Downes M, Evans RM, Loomba R. Aliment Pharmacol Ther. 2022 Nov;56(10):1475-1485. doi: 10.1111/apt.17236.

View Publication

Vitality, mental health and role-physical mediate the influence of coping on depressive symptoms and self-efficacy in patients with non-alcoholic fatty liver disease: A cross-sectional study

Funuyet-Salas J, Pérez-San-Gregorio MÁ, Martín-Rodríguez A, Romero-Gómez M. J Psychosom Res. 2022 Nov;162:111045. doi: 10.1016/j.jpsychores.2022.111045.

View Publication

Approach to the Patient with Nonalcoholic Fatty Liver Disease

Belfort-DeAguiar R, Lomonaco R, Cusi K. J Clin Endocrinol Metab. 2022 Oct 28:dgac624. doi: 10.1210/clinem/dgac624.

View Publication

Non-alcoholic steatohepatitis

Romero-Gómez M. Med Clin (Barc). 2022 Oct 28;159(8):388-395. doi: 10.1016/j.medcli.2022.06.017.

View Publication

Accuracy of Noninvasive Diagnostic Tests for the Detection of Significant and Advanced Fibrosis Stages in Nonalcoholic Fatty Liver Disease: A Systematic Literature Review of the US Studies

Gosalia D, Ratziu V, Stanicic F, Vukicevic D, Zah V, Gunn N, Halegoua-DeMarzio D, Tran T. Diagnostics (Basel). 2022 Oct 27;12(11):2608. doi: 10.3390/diagnostics12112608.

View Publication

A Meta-Analysis on Associated Risk of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD)

Fu CE, Ng CH, Yong JN, Chan KE, Xiao J, Nah B, Bong SHS, Win KM, Bwa AH, Lim WH, Tan DJH, Zeng RW, Chew N, Teng ML, Siddiqui MS, Oben JA, Sanyal AJ, Wai-Sun Wong V, Noureddin M, Muthiah M. Endocr Pract. 2022 Oct 20:S1530-891X(22)00648-6. doi: 10.1016/j.eprac.2022.10.007.

View Publication

Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis

Jacobson IM, Wong VW, Castera L, Anstee QM, Noureddin M, Cusi K, Harrison SA, Bugianesi E, Younossi ZM. J Clin Gastroenterol. 2022 Oct 17. doi: 10.1097/MCG.0000000000001780.

View Publication

Prevalence of non-alcoholic fatty liver disease (NAFLD) in a cohort of patients with type 2 diabetes: the PHIGNA-DM2 study

Martínez-Ortega AJ, Piñar Gutiérrez A, Lara-Romero C, Remón Ruiz PJ, Ampuero-Herrojo J, de Lara-Rodríguez I, Romero-Gómez M, García Luna PP, Soto-Moreno A. Nutr Hosp. 2022 Oct 17;39(5):1012-1018. doi: 10.20960/nh.03969.

View Publication

NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?

Chen B, Tang WHW, Rodriguez M, Corey KE, Sanyal AJ, Kamath PS, Bozkurt B, Virk HUH, Pressman GS, Lazarus JV, El-Serag HB, Krittanawong C. Semin Liver Dis. 2022 Oct 14. doi: 10.1055/s-0042-1757712.

View Publication

RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression

Wang Y, Tai YL, Way G, Zeng J, Zhao D, Su L, Jiang X, Jackson KG, Wang X, Gurley EC, Liu J, Liu J, Chen W, Wang XY, Sanyal AJ, Hylemon PB, Zhou H. Cell Biosci. 2022 Oct 12;12(1):172. doi: 10.1186/s13578-022-00910-7.

View Publication

Impaired Myocardial Mitochondrial Respiration in Humans With Prediabetes: A Footprint of Prediabetic Cardiomyopathy

Zweck E, Scheiber D, Schultheiss HP, Kuss O, Kelm M, Roden M, Westenfeld R, Szendroedi J. Circulation. 2022 Oct 11;146(15):1189-1191. doi: 10.1161/CIRCULATIONAHA.122.058995.

View Publication

Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and Cons

Pericàs JM, Tacke F, Anstee QM, Di Prospero NA, Skalshøj Kjær M, Mesenbrink P, Koenig F, Genescà J, Ratziu V; EU-PEARL NASH Investigators. J Hepatol. 2022 Oct 7:S0168-8278(22)03131-2. doi: 10.1016/j.jhep.2022.09.021.

View Publication

The Spectrum and Impact of Metabolic Dysfunction in MAFLD. A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals

Chan KE, Ng CH, Fu CE, Quek J, Kong G, Goh YJ, Zeng RW, Tseng M, Aggarwal M, Nah B, Chee D, Wong ZY, Zhang S, Wang JW, Chew NW, Dan YY, Siddiqui MS, Noureddin M, Sanyal AJ, Muthiah M. Clin Gastroenterol Hepatol. 2022 Oct 3:S1542-3565(22)00926-0. doi: 10.1016/j.cgh.2022.09.028.

View Publication

Relative validity of a glycemic index extended food-frequency questionnaire

Goletzke J, Weber KS, Kössler T, Zaharia OP, Bódis K, Müssig K, Szendroedi J, Burkart V, Stutz B, Nöthlings U, Buyken AE, Roden M; GDS Group. Nutr Metab Cardiovasc Dis. 2022 Oct;32(10):2310-2320. doi: 10.1016/j.numecd.2022.07.007.

View Publication

Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials of new antidiabetic drugs: a meta-analysis of digitalized individual patient data

Kuss O, Akbulut C, Schlesinger S, Georgiev A, Kelm M, Roden M, Wolff G. Acta Diabetol. 2022 Oct;59(10):1349-1359. doi: 10.1007/s00592-022-01917-9. Epub 2022 Jul 25.

View Publication

Placebo Adverse Events in Non-Alcoholic Steatohepatitis Clinical Trials. A Pooled Analysis of 2,944 Participants

Lin Tay PW, Ng CH, Lin SY, Chin YH, Xiao J, Lim WH, Lim SY, Fu CE, Chan KE, Quek J, Hao Tan DJ, Chew N, Syn N, Keitoku T, Tamaki N, Siddiqui MS, Noureddin M, Muthiah M, Huang DQ, Loomba R. Am J Gastroenterol. 2022 Sep 30. doi: 10.14309/ajg.0000000000002042.

View Publication

Hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in humans with type 2 diabetes: a randomised placebo-controlled crossover trial

Sarabhai T, Mastrototaro L, Kahl S, Bönhof GJ, Jonuscheit M, Bobrov P, Katsuyama H, Guthoff R, Wolkersdorfer M, Herder C, Meuth SG, Dreyer S, Roden M. Diabetologia. 2022 Sep 30. doi: 10.1007/s00125-022-05797-0.

View Publication

Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus Non-alcoholic fatty liver disease: A longitudinal cohort analysis

Muthiah M, Ng CH, Chan KE, Fu CE, Lim WH, Tan DJH, Nah B, Kong G, Xiao J, Yong JN, Tan B, Syn N, Wang JW, Sayed N, Tan E, Chew NW, Dan YY, Siddiqui MS, Sanyal AJ, Noureddin M. Ann Hepatol. 2022 Sep 29;28(1):100762. doi: 10.1016/j.aohep.2022.100762.

View Publication

A poor perspective of self weight significantly increases adverse outcomes in non-alcoholic fatty liver disease (NAFLD)

Fu CE, Ng CH, Chew NWS, Heng ZEQ, Chin YH, Quek J, Lim WH, Xiao J, Chan KE, Tan DJH, Tan C, Zhang S, Koh TK, Nah B, Dan YY, Syn N, Siddiqui MS, Sanyal AJ, Noureddin M, Muthiah M. Front Med (Lausanne). 2022 Sep 28;9:977552. doi: 10.3389/fmed.2022.977552.

View Publication

Metabolic Factors Predict Changes in Endothelial Function During the Early Course of Type 1 and Type 2 Diabetes

Zaharia OP, Schön M, Löffler L, Strassburger K, Möser C, Yurchenko I, Bódis K, Antoniou S, Karusheva Y, Szendroedi J, Burkart V, Roden M. J Clin Endocrinol Metab. 2022 Sep 28;107(10):e4167-e4176. doi: 10.1210/clinem/dgac480.

View Publication

NAFLD and thyroid function: pathophysiological and therapeutic considerations

Hatziagelaki E, Paschou SA, Schön M, Psaltopoulou T, Roden M. Trends Endocrinol Metab. 2022 Sep 26:S1043-2760(22)00160-6. doi: 10.1016/j.tem.2022.08.001.

View Publication

The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease: Data from National Health and nutrition examination survey 2005-2010 and 2017-2018

Younossi ZM, Paik JM, Golabi P, Younossi Y, Henry L, Nader F. Liver Int. 2022 Sep 26. doi: 10.1111/liv.15437.

View Publication

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

O'Farrell M, Duke G, Crowley R, Buckley D, Martins EB, Bhattacharya D, Friedman SL, Kemble G. Sci Rep. 2022 Sep 19;12(1):15661. doi: 10.1038/s41598-022-19459-z.

View Publication

The Cost of Diagnosing and Managing Non-alcoholic Steatohepatitis in Europe and the United States

Geier A, Heinz S, Balp MM, Brass C, Pedrosa M, Cai J, Hoad R, Sayadian AC, Rinella M, Ratziu V. J Gastrointestin Liver Dis. 2022 Sep 15;31(3):317-322. doi: 10.15403/jgld-4275.

View Publication

Clinical Utility of Combined MRI-PDFF and ALT Response in Predicting Histologic Response in Nonalcoholic Fatty Liver Disease

Huang DQ, Sharpton SR, Amangurbanova M, Tamaki N, Sirlin CB, Loomba R; NAFLD Research Study Group. Clin Gastroenterol Hepatol. 2022 Sep 5:S1542-3565(22)00832-1. doi: 10.1016/j.cgh.2022.08.036.

View Publication

Geographical similarity and differences in the burden and genetic predisposition of NAFLD

Yip TC, Vilar-Gomez E, Petta S, Yilmaz Y, Wong GL, Adams LA, de Lédinghen V, Sookoian S, Wong VW. Hepatology. 2022 Sep 5. doi: 10.1002/hep.32774.

View Publication

Non-alcoholic steatohepatitis

Romero-Gómez M. Med Clin (Barc). 2022 Sep 5:S0025-7753(22)00403-1. doi: 10.1016/j.medcli.2022.06.017.

View Publication

Interactive Role of Surrogate Liver Fibrosis Assessment and Insulin Resistance on the Incidence of Major Cardiovascular Events

Martinez-Urbistondo D, D'Avola D, Navarro-González D, Sanchez-Iñigo L, Fernandez-Montero A, Perez-Diaz-Del-Campo N, Bugianesi E, Martinez JA, Pastrana JC. J Clin Med. 2022 Sep 1;11(17):5190. doi: 10.3390/jcm11175190.

View Publication

Analysis of a Simulation Model to Estimate Long-term Outcomes in Patients with Nonalcoholic Fatty Liver Disease

Chhatwal J, Dalgic OO, Chen W, Samur S, Bethea ED, Xiao J, Hur C, Corey KE, Loomba R. JAMA Netw Open. 2022 Sep 1;5(9):e2230426. doi: 10.1001/jamanetworkopen.2022.30426.

View Publication

Diagnostic scores and scales for appraising Nonalcoholic fatty liver disease and omics perspectives for precision medicine

Perez-Diaz-Del-Campo N, Martínez-Urbistondo D, Bugianesi E, Martínez JA. Curr Opin Clin Nutr Metab Care. 2022 Sep 1;25(5):285-291. doi: 10.1097/MCO.0000000000000849. Epub 2022 Jul 5.

View Publication

Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world

Henry L, Paik J, Younossi ZM. Aliment Pharmacol Ther. 2022 Sep;56(6):942-956. doi: 10.1111/apt.17158. Epub 2022 Jul 26.

View Publication

Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH

Tan DJH, Setiawan VW, Ng CH, Lim WH, Muthiah MD, Tan EX, Dan YY, Roberts LR, Loomba R, Huang DQ. Hepatology. 2022 Aug 29. doi: 10.1002/hep.32758.

View Publication

Shared mechanisms between cardiovascular disease and NAFLD

Huang D, Downes M, Evans R, Witztum J, Glass C, Loomba R. Semin Liver Dis. 2022 Aug 25. doi: 10.1055/a-1930-6658.

View Publication

Management of NAFLD in primary care settings

Wong VWS, Zelber-Sagi S, Cusi K, Carrieri P, Wright E, Crespo J, Lazarus JV. Liver Int. 2022 Aug 20. doi: 10.1111/liv.15404

View Publication

Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease

Sen P, Govaere O, Sinioja T, McGlinchey A, Geng D, Ratziu V, Bugianesi E, Schattenberg JM, Vidal-Puig A, Allison M, Cockell S, Daly AK, Hyötyläinen T, Anstee QM, Orešič M. iScience. 2022 Aug 15;25(9):104949. doi: 10.1016/j.isci.2022.104949.

View Publication

Metabolic factors predict changes in endothelial function during the early course of type 1 and type 2 diabetes

Zaharia OP, Schön M, Löffler L, Strassburger K, Möser C, Yurchenko I, Bódis K, Antoniou S, Karusheva Y, Szendroedi J, Burkart V, Roden M. J Clin Endocrinol Metab. 2022 Aug 15:dgac480. doi: 10.1210/clinem/dgac480.

View Publication

Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD

Kim BK, Tamaki N, Imajo K, Yoneda M, Sutter N, Jung J, Lin T, Tu XM, Bergstrom J, Nguyen K, Nguyen L, Le T, Madamba E, Richards L, Valasek MA, Behling C, Sirlin CB, Nakajima A, Loomba R. J Hepatol. 2022 Aug 13:S0168-8278(22)02984-1. doi: 10.1016/j.jhep.2022.07.020.

View Publication

Historical Changes in Weight Classes and the Influence of NAFLD Prevalence: A Population Analysis of 34,486 Individuals

Nah BKY, Ng CH, Chan KE, Tan C, Aggarwal M, Zeng RW, Xiao J, Chin YH, Tan EXX, Ren YP, Chee D, Neo J, Chew NWS, Tseng M, Siddiqui MS, Sanyal AJ, Dan YY, Muthiah M. Int J Environ Res Public Health. 2022 Aug 11;19(16):9935. doi: 10.3390/ijerph19169935.

View Publication

Developing and pilot testing an oral health screening tool for diabetes care providers

George A, Poudel P, Kong A, Villarosa A, Calache H, Arora A, Griffiths R, Wong VW, Gussy M, Martin RE, Lau P. BMC Prim Care. 2022 Aug 11;23(1):202. doi: 10.1186/s12875-022-01798-5.

View Publication

Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality

Ng CH, Wong ZY, Chew NWS, Chan KE, Xiao J, Sayed N, Lim WH, Tan DJH, Loke RWK, Tay PWL, Yong JN, Kong G, Huang DQ, Wang JW, Chan M, Dalakoti M, Tamaki N, Noureddin M, Siddiqui MS, Sanyal AJ, Muthiah M. Front Cardiovasc Med. 2022 Aug 8;9:942753. doi: 10.3389/fcvm.2022.942753.

View Publication

Living in the non-alcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients’ perspectives

Ng CH, Lim WH, Chin YH, Yong JN, Zeng RW, Chan KE, Tan DJH, Fu CE, Tang ASP, Goh LH, Devi K, Chew NWS, Mak LL, Tamaki N, Huang DQ, Noureddin M, Siddiqui MS, Loomba R, Sanyal AJ, Muthiah M. Aliment Pharmacol Ther. 2022 Aug;56(4):570-579. doi: 10.1111/apt.17121.

View Publication

The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database

Alkhouri N, Almomani A, Le P, Payne JY, Asaad I, Sakkal C, Vos M, Noureddin M, Kumar P. BMC Gastroenterol. 2022 Jul 30;22(1):366. doi: 10.1186/s12876-022-02430-7.

View Publication

Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals

Saponaro C, Sabatini S, Gaggini M, Carli F, Rosso C, Positano V, Armandi A, Caviglia GP, Faletti R, Bugianesi E, Gastaldelli A. Liver Int. 2022 Jul 28. doi: 10.1111/liv.15377.

View Publication

Treatments for obesity in the context of nonalcoholic steatohepatitis and mental health

Sharma A, Albhaisi S, Sanyal AJ. Clin Liver Dis (Hoboken). 2022 Jul 16;20(2):48-51. doi: 10.1002/cld.1219.

View Publication

Behavioral health disorders related to nonalcoholic steatohepatitis

Sharma A, Albhaisi S, Sanyal AJ. Clin Liver Dis (Hoboken). 2022 Jul 16;20(2):43-47. doi: 10.1002/cld.1211.

View Publication

Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients

Lawitz EJ, Li KW, Nyangau E, Field TJ, Chuang JC, Billin A, Wang L, Wang Y, Huss RS, Chung C, Subramanian GM, Myers RP, Hellerstein MK. J Lipid Res. 2022 Jul 11;63(9):100250. doi: 10.1016/j.jlr.2022.100250.

View Publication

Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey

Rinella M, Cryer DR, Articolo A, Fisher T, Schneider J, Nadolsky K. BMC Gastroenterol. 2022 Jul 10;22(1):335. doi: 10.1186/s12876-022-02410-x.

View Publication

The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting

Thrift AP, Nguyen TH, Pham C, Balakrishnan M, Kanwal F, Loomba R, Duong HT, Ramsey D, El-Serag HB. Clin Gastroenterol Hepatol. 2022 Jul 8:S1542-3565(22)00603-6. doi: 10.1016/j.cgh.2022.05.046.

View Publication

Liver stiffness accuracy by MR elastography in histologically proven non-alcoholic fatty liver disease patients: a Spanish cohort

Lara Romero C, Liang JX, Fernández Lizaranzazu I, Ampuero Herrojo J, Castell J, Del Prado Alba C, Domínguez Pascual I, Romero Gómez M. Rev Esp Enferm Dig. 2022 Jul 6. doi: 10.17235/reed.2022.8777/2022.

View Publication

Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease

Lin H, Yip TC, Zhang X, Li G, Tse YK, Hui VW, Liang LY, Lai JC, Chan SL, Chan HL, Wong GL, Wong VW. Hepatology. 2022 Jul 5. doi: 10.1002/hep.32633

View Publication

Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer

Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Cell Metab. 2022 Jul 5;34(7):969-977.e2. doi: 10.1016/j.cmet.2022.05.003.

View Publication

The scaffold-dependent function of RIPK1 in experimental non-alcoholic steatohepatitis

Pistorio V, Tokgozoglu J, Ratziu V, Gautheron J. J Mol Med (Berl). 2022 Jul;100(7):1039-1042. doi: 10.1007/s00109-022-02217-z.

View Publication

Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants

Ajmera V, Kim BK, Yang K, Majzoub AM, Nayfeh T, Tamaki N, Izumi N, Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Quach NE, Tu X, Zhang X, Noureddin M, Allen AM, Loomba R. Gastroenterology. 2022 Jul 2:S0016-5085(22)00735-1. doi: 10.1053/j.gastro.2022.06.073.

View Publication

Fatty liver indices and their association with glucose metabolism in pregnancy – An observational cohort study.

Linder T, Eppel D, Kotzaeridi G, Rosicky I, Yerlikaya-Schatten G, Kiss H, Weißhaupt K, Henrich W, Bozkurt L, Tura A, Roden M, Göbl CS. Diabetes Res Clin Pract. 2022 Jul;189:109942. doi: 10.1016/j.diabres.2022.109942.

View Publication

A Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Insulin Dimer

Walford GA, Duncan KE, Hernandez M, Vaddady P, Hompesch M, Morrow L, Stoch SA. Clin Pharmacol Ther. 2022 Jul;112(1):125-132. doi: 10.1002/cpt.2607.

View Publication

Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH

Naoumov NV, Brees D, Loeffler J, Chng E, Ren Y, Lopez P, Tai D, Lamle S, Sanyal AJ. J Hepatol. 2022 Jun 30:S0168-8278(22)00412-3. doi: 10.1016/j.jhep.2022.06.018.

View Publication

Current therapies and new developments in NASH

Dufour JF, Anstee QM, Bugianesi E, Harrison S, Loomba R, Paradis V, Tilg H, Wong VW, Zelber-Sagi S. Gut. 2022 Jun 16:gutjnl-2021-326874. doi: 10.1136/gutjnl-2021-326874.

View Publication

Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores

Wu Y, Yang X, Morris HL, Gurka MJ, Shenkman EA, Cusi K, Bril F, Donahoo WT. JMIR Med Inform. 2022 Jun 6;10(6):e36997. doi: 10.2196/36997.

View Publication

Breakthroughs in therapies for NASH and remaining challenges

Ratziu V, Francque S, Sanyal A. J Hepatol. 2022 Jun;76(6):1263-1278. doi: 10.1016/j.jhep.2022.04.002.

View Publication

A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation

Vujkovic M, Ramdas S, Lorenz KM, Guo X, Darlay R, Cordell HJ, He J, Gindin Y, Chung C, Myers RP, Schneider CV, Park J, Lee KM, Serper M, Carr RM, Kaplan DE, Haas ME, MacLean MT, Witschey WR, Zhu X, Tcheandjieu C, Kember RL, Kranzler HR, Verma A, Giri A, Klarin DM, Sun YV, Huang J, Huffman JE, Townsend Creasy K, Hand NJ, Liu CT, Long MT, Yao J, Budoff M, Tan J, Li X, Lin HJ, Chen YI, Taylor KD, Chang RK, Krauss RM, Vilarinho S, Brancale J, Nielsen JB, Locke AE, Jones MB, Verweij N, Baras A, Reddy KR, Neuschwander-Tetri BA, Schwimmer JB, Sanyal AJ, Chalasani N, Ryan KA, Mitchell BD, Gill D, Wells AD, Manduchi E, Saiman Y, Mahmud N, Miller DR, Reaven PD, Phillips LS, Muralidhar S, DuVall SL, Lee JS, Assimes TL, Pyarajan S, Cho K, Edwards TL, Damrauer SM, Wilson PW, Gaziano JM, O'Donnell CJ, Khera AV, Grant SFA, Brown CD, Tsao PS, Saleheen D, Lotta LA, Bastarache L, Anstee QM, Daly AK, Meigs JB, Rotter JI, Lynch JA; Regeneron Genetics Center; Geisinger-Regeneron DiscovEHR Collaboration; EPoS Consortium; VA Million Veteran Program, Rader DJ, Voight BF, Chang KM. Nat Genet. 2022 Jun 2. doi: 10.1038/s41588-022-01078-z.

View Publication

Clinical features and outcomes of NAFLD-related hepatocellular carcinoma – Authors’ reply

Tan DJH, Ng CH, Muthiah MD, Loomba R, Huang DQ. Lancet Oncol. 2022 Jun;23(6):e244. doi: 10.1016/S1470-2045(22)00265-0.

View Publication

African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population

Cavalcante LN, Porto J, Mazo D, Longatto-Filho A, Stefano JT, Lyra AC, Carrilho FJ, Reis RM, Alves VAF, Sanyal AJ, Oliveira CP. Ann Hepatol. 2022 Jun 13:100728. doi: 10.1016/j.aohep.2022.100728.

View Publication

Incidence of Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease

Newton KP, Wilson LA, Crimmins NA, Fishbein MH, Molleston JP, Xanthakos SA, Behling C, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network. Clin Gastroenterol Hepatol. 2022 Jun 13:S1542-3565(22)00556-0. doi: 10.1016/j.cgh.2022.05.028.

View Publication

Artificial Intelligence Improves Pathologist Agreement for Fibrosis Scores in Nonalcoholic Steatohepatitis Patients

Soon GST, Liu F, Leow WQ, Wee A, Wei L, Sanyal AJ. Clin Gastroenterol Hepatol. 2022 Jun 10:S1542-3565(22)00555-9. doi: 10.1016/j.cgh.2022.05.027.

View Publication

Hepatic Stellate Cell-Immune Interactions in NASH

Carter JK, Friedman SL. Front Endocrinol (Lausanne). 2022 Jun 9;13:867940. doi: 10.3389/fendo.2022.867940.

View Publication

Comorbidities in Recent-Onset Adult Type 1 Diabetes: A Comparison of German Cohorts

Zaharia OP, Lanzinger S, Rosenbauer J, Karges W, Müssig K, Meyhöfer SM, Burkart V, Hummel M, Raddatz D, Roden M, Szendroedi J, Holl RW. Front Endocrinol (Lausanne). 2022 Jun 3;13:760778. doi: 10.3389/fendo.2022.760778.

View Publication

Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool

Marañón P, Fernández-García CE, Isaza SC, Rey E, Gallego-Durán R, Montero-Vallejo R, de Cía JR, Ampuero J, Romero-Gómez M, García-Monzón C, González-Rodríguez Á. Biomark Res. 2022 May 25;10(1):35. doi: 10.1186/s40364-022-00383-3.

View Publication

The Effect of Diabetes and Prediabetes on the Prevalence, Complications and Mortality in Non-alcoholic Fatty Liver Disease

Ng CH, Chan KE, Chin YH, Zeng RW, Tsai PC, Lim WH, Tan DJH, Khoo CM, Goh LH, Ling ZJ, Kulkarni A, Mak LL, Huang DQ, Chan M, Chew NW, Siddiqui MS, Sanyal AJ, Muthiah M. Clin Mol Hepatol. 2022 May 19. doi: 10.3350/cmh.2022.0096.

View Publication

Prevalence estimation of significant fibrosis due to NASH in Spain combining transient elastography and histology

Calleja JL, Rivera-Esteban J, Aller R, Hernández Conde M, Abad J, Pericàs JM, Gonzalo Benito H, Serra MÁ, Escudero A, Ampuero J, Lucena A, Sánchez Y, Arias-Loste MT, Iruzubieta P, Romero-Gómez M, Augustin S, Crespo J. Liver Int. 2022 May 28. doi: 10.1111/liv.15323.

View Publication

Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis

Sharpton SR, Podlaha O, Chuang JC, Gindin Y, Myers RP, Loomba R. Therap Adv Gastroenterol. 2022 May 18;15:17562848221098243. doi: 10.1177/17562848221098243.

View Publication

Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study

Vali Y, Eijk R, Hicks T, Jones WS, Suklan J, Holleboom AG, Ratziu V, Langendam MW, Anstee QM, Bossuyt PMM; LITMUS Investigators. J Clin Med. 2022 May 11;11(10):2707. doi: 10.3390/jcm11102707.

View Publication

Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD

Smirnova E, Muthiah MD, Narayan N, Siddiqui MS, Puri P, Luketic VA, Contos MJ, Idowu M, Chuang JC, Billin AN, Huss RS, Myers RP, Boyett S, Seneshaw M, Min HK, Mirshahi F, Sanyal AJ. Hepatology. 2022 May 13. doi: 10.1002/hep.32568.

View Publication

Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018

Truong E, Yeo YH, Cook-Wiens G, Muthiah M, Yang JD, Sundaram V, Chang D, Todo T, Kim IK, Lu SC, Setiawan VW, Wong VWS, Harrison SA, Alkhouri N, Noureddin M. Hepatol Commun. 2022 May 9. doi: 10.1002/hep4.1981.

View Publication

Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease

Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Curr Atheroscler Rep. 2022 May 4. doi: 10.1007/s11883-022-01027-5.

View Publication

Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis

Sinakos E, Liava C, Loomba R. Ann Gastroenterol. 2022 May-Jun;35(3):213-225. doi: 10.20524/aog.2022.0704.

View Publication

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)

Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.

View Publication

NAFLD/NASH

Bugianesi E, Petta S. J Hepatol. 2022 May 2:S0168-8278(22)00081-2. doi: 10.1016/j.jhep.2022.02.006.

View Publication

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)

Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.

View Publication

Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis

Ng CH, Lim WH, Hui Lim GE, Hao Tan DJ, Syn N, Muthiah MD, Huang DQ, Loomba R. Clin Gastroenterol Hepatol. 2022 May 2:S1542-3565(22)00439-6. doi: 10.1016/j.cgh.2022.04.014.

View Publication

Response to: “Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?”

Barb D, Cusi K. Obesity (Silver Spring). 2022 May;30(5):971-972. doi: 10.1002/oby.23422.

View Publication

Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH

Vilalta A, Gutiérrez JA, Chaves S, Hernández M, Urbina S, Hompesch M. Endocrinol Diabetes Metab. 2022 May;5(3):e00335. doi: 10.1002/edm2.335.

View Publication

A global view of the interplay between non-alcoholic fatty liver disease and diabetes.

Stefan N, Cusi K. Lancet Diabetes Endocrinol. 2022 Apr;10(4):284-296. doi: 10.1016/S2213-8587(22)00003-1.

View Publication

Impaired Hepatic Mitochondrial Capacity in Nonalcoholic Steatohepatitis Associated With Type 2 Diabetes.

Gancheva S, Kahl S, Pesta D, Mastrototaro L, Dewidar B, Strassburger K, Sabah E, Esposito I, Weiß J, Sarabhai T, Wolkersdorfer M, Fleming T, Nawroth P, Zimmermann M, Reichert AS, Schlensak M, Roden M. Diabetes Care. 2022 Apr 1;45(4):928-937. doi: 10.2337/dc21-1758.

View Publication

Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study.

Huang DQ, Fowler KJ, Liau J, Cunha GM, Louie AL, An JY, Bettencourt R, Jung J, Gitto Z, Hernandez C, Lopez SJ, Gupta H, Sirlin CB, Marks RM, Loomba R. Aliment Pharmacol Ther. 2022 Apr;55(7):820-827. doi: 10.1111/apt.16844.

View Publication

A nutrigenetic tool for precision dietary management of NAFLD deeming insulin resistance markers

Perez-Diaz-Del-Campo N, Riezu-Boj JI, Marin-Alejandre BA, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Milagro FI, Bugianesi E, Tur JA, Martinez JA, Abete I, Zulet MA. Panminerva Med. 2022 Apr 19. doi: 10.23736/S0031-0808.22.04590-6.

View Publication

Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science

Fouad Y, Palmer M, Chen M, Regev A, Banerjee R, Myers R, Riccio R, Torstenson R, Younes R, Arora PS, Landgren H, Karsdal MA, Blake M, Shapiro DA, Gruss HJ, Sheikh MY, Attia D, Bollipo S, Smith AD, Freilich B, Gish RG, Schuppan D. J Clin Transl Hepatol. 2022 Apr 28;10(2):374-382. doi: 10.14218/JCTH.2021.00408.

View Publication

Greater ectopic fat deposition and liver fibroinflammation, and lower skeletal muscle mass in people with type 2 diabetes

Waddell T, Bagur A, Cunha D, Thomaides-Brears H, Banerjee R, Cuthbertson DJ, Brown E, Cusi K, Després JP, Brady M. Obesity (Silver Spring). 2022 Apr 27. doi: 10.1002/oby.23425.

View Publication

Risk of liver-related events by age and diabetes duration in diabetic patients with non-alcoholic fatty liver disease.

Zhang X, Wong GL, Yip TC, Cheung JTK, Tse YK, Hui VW, Lin H, Lai JC, Chan HL, Kong AP, Wong VW. Hepatology. 2022 Mar 25. doi: 10.1002/hep.32476.

View Publication

Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD.

Jung J, Han A, Madamba E, Bettencourt R, Loomba RR, Boehringer AS, Andre MP, Erdman JW Jr, O'Brien WD Jr, Fowler KJ, Sirlin CB, Loomba R. Radiology. 2022 Mar 29:211131. doi: 10.1148/radiol.211131.

View Publication

Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease.

Tamaki N, Kurosaki M, Huang DQ, Loomba R. Hepatol Res. 2022 Mar 30. doi: 10.1111/hepr.13764.

View Publication

Non-Alcoholic fatty liver disease-associated DNA methylation and gene expression alterations in the livers of Collaborative Cross mice fed an obesogenic high-fat and high-sucrose diet.

Cusi K. J Clin Endocrinol Metab. 2022 Mar 25:dgac186. doi: 10.1210/clinem/dgac186.

View Publication

A Simple Test to Identify the Risk of NASH and Cirrhosis in People with Obesity or Diabetes: The Time to Screen is Now.

Cusi K. J Clin Endocrinol Metab. 2022 Mar 25:dgac186. doi: 10.1210/clinem/dgac186.

View Publication

Reliability of Histologic Assessment for NAFLD and Development of an Expanded NAFLD Activity Score.

Pai RK, Jairath V, Hogan M, Zou G, Adeyi OA, Anstee QM, Aqel BA, Behling C, Carey EJ, Clouston AD, Corey K, Feagan BG, Kleiner DE, Ma C, McFarlane SC, Noureddin M, Ratziu V, Valasek MA, Younossi ZM, Harrison SA, Loomba R. Hepatology. 2022 Mar 25. doi: 10.1002/hep.32475.

View Publication

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.

Harrison SA, Abdelmalek MF, Neff G, Gunn N, Guy CD, Alkhouri N, Bashir MR, Freilich B, Kohli A, Khazanchi A, Sheikh MY, Leibowitz M, Rinella ME, Siddiqui MS, Kipnes M, Moussa SE, Younes ZH, Bansal M, Baum SJ, Borg B, Ruane PJ, Thuluvath PJ, Gottwald M, Khan M, Chen C, Melchor-Khan L, Chang W, DePaoli AM, Ling L, Lieu HD. Lancet Gastroenterol Hepatol. 2022 Mar 21:S2468-1253(22)00017-6. doi: 10.1016/S2468-1253(22)00017-6.

View Publication

Is lean non-alcoholic fatty liver disease a distinct entity?

Lin H, Wong VW. Hepatol Int. 2022 Mar 24. doi: 10.1007/s12072-022-10324-9.

View Publication

Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.

Ampuero J, Gallego-Durán R, Maya-Miles D, Montero R, Gato S, Rojas Á, Gil A, Muñoz R, Romero-Gómez M. J Gastroenterol. 2022 Mar 24. doi: 10.1007/s00535-022-01860-0.

View Publication

Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis.

Ng CH, Muthiah MD, Xiao J, Chin YH, Lim G, Lim WH, Tay P, Tan DJH, Yong JN, Pan XH, Koh JWH, Chew N, Syn N, Tan E, Huang DQ, Siddiqui MS, Loomba R, Sanyal AJ, Noureddin M. Aliment Pharmacol Ther. 2022 Mar 14. doi: 10.1111/apt.16808.

View Publication

Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

Deckmyn O, Poynard T, Bedossa P, Paradis V, Peta V, Pais R, Ratziu V, Thabut D, Brzustowski A, Gautier JF, Cacoub P, Valla D. Biomedicines. 2022 Mar 17;10(3):699. doi: 10.3390/biomedicines10030699.

View Publication

Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD).

Brandman D, Boyle M, McPherson S, Van Natta ML, Sanyal AJ, Kowdley K, Neuschwander-Tetri B, Chalasani N, Abdelmalek MF, Terrault NA, McCullough A, Bettencourt R, Caussy C, Kleiner DE, Behling C, Tonascia J, Anstee QM, Loomba R; Members of the Nonalcoholic Steatohepatitis Clinical Research Network. Aliment Pharmacol Ther. 2022 Mar 17. doi: 10.1111/apt.16874.

View Publication

Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.

Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, Quek J, Xiao J, Dan YY, Siddiqui MS, Sanyal AJ, Muthiah MD, Loomba R, Huang DQ. Lancet Oncol. 2022 Mar 4:S1470-2045(22)00078-X. doi: 10.1016/S1470-2045(22)00078-X.

View Publication

Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease.

Castillo-Leon E, Morris HL, Schoen C, Bilhartz J, McKiernan P, Miloh T, Palle S, Kabbany MN, Munoz B, Mospan AR, Rudolph B, Xanthakos SA, Vos MB, Target-Nash Investigators. Children (Basel). 2022 Mar 8;9(3):374. doi: 10.3390/children9030374.

View Publication

Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.

Zamani M, Alizadeh-Tabari S, Singh S, Loomba R. Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16879.

View Publication

NAFLD increases Risk of Carotid Atherosclerosis and Ischemic Stroke. An Updated Meta-Analysis with 135,602 Individuals.

Tang ASP, Chan KE, Quek J, Xiao J, Tay P, Teng M, Lee KS, Lin SY, Myint MZ, Tan B, Sharma VK, Tan DJH, Lim WH, Kaewdech A, Huang D, Chew NW, Siddiqui MS, Sanyal AJ, Muthiah M, Ng CH. Clin Mol Hepatol. 2022 Mar 2. doi: 10.3350/cmh.2021.0406.

View Publication

Global multi-stakeholder endorsement of the MAFLD definition.

Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2022 Mar 3:S2468-1253(22)00062-0. doi: 10.1016/S2468-1253(22)00062-0.

View Publication

A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease.

Pennisi G, Pipitone RM, Cabibi D, Enea M, Romero-Gomez M, Viganò M, Bugianesi E, Wong VW, Fracanzani AL, Sebastiani G, Berzigotti A, Di Salvo F, Giannone AG, La Mantia C, Lupo G, Porcasi R, Vernuccio F, Zito R, Di Marco V, Cammà C, Craxì A, de Ledinghen V, Grimaudo S, Petta S. Liver Int. 2022 Mar 4. doi: 10.1111/liv.15232.

View Publication

Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation.

Gallego-Durán R, Ampuero J, Pastor-Ramírez H, Álvarez-Amor L, Del Campo JA, Maya-Miles D, Montero-Vallejo R, Cárdenas-García A, Pareja MJ, Gato-Zambrano S, Millán R, Del Carmen Rico M, Luque-Sierra A, Gil-Gómez A, Rojas Á, Muñoz-Hernández R, García-Lozano M, Aller R, Andrade RJ, García-Monzón C, Andreola F, Martín F, Jalan R, Romero-Gómez M. Sci Rep. 2022 Mar 1;12(1):3418. doi: 10.1038/s41598-022-06614-9.

View Publication

Association of Obesity, Diabetes, and Alcohol Use With Liver Fibrosis Among US Adults With Hepatitis C Virus Infection.

Migdal AL, Jagannathan R, Qayed E, Cusi K, McCoy RG, Pasquel FJ, Miller LS. JAMA Netw Open. 2022 Mar 1;5(3):e2142282. doi: 10.1001/jamanetworkopen.2021.42282.

View Publication

Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project.

Sanyal AJ, Shankar SS, Calle RA, Samir AE, Sirlin CB, Sherlock SP, Loomba R, Fowler KJ, Dehn CA, Heymann H, Kamphaus TN. Nat Med. 2022 Mar;28(3):430-432. doi: 10.1038/s41591-021-01652-8.

View Publication

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease

McGlinchey AJ, Govaere O, Geng D, Ratziu V, Allison M, Bousier J, Petta S, de Oliviera C, Bugianesi E, Schattenberg JM, Daly AK, Hyötyläinen T, Anstee QM, Orešič M. JHEP Rep. 2022 Mar 26;4(5):100477. doi: 10.1016/j.jhepr.2022.100477.

View Publication

JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk

Wyne KL, Litwin SE, Cusi K, Guyton JR. J Clin Lipidol. 2022 Mar-Apr;16(2):115-127. doi: 10.1016/j.jacl.2022.03.007.

View Publication

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.

Martínez-Arranz I, Bruzzone C, Noureddin M, Gil-Redondo R, Mincholé I, Bizkarguenaga M, Arretxe E, Iruarrizaga-Lejarreta M, Fernández-Ramos D, Lopitz-Otsoa F, Mayo R, Embade N, Newberry E, Mittendorf B, Izquierdo-Sánchez L, Smid V, Arnold J, Iruzubieta P, Pérez Castaño Y, Krawczyk M, Marigorta UM, Morrison MC, Kleemann R, Martín-Duce A, Hayardeny L, Vitek L, Bruha R, Aller de la Fuente R, Crespo J, Romero-Gomez M, Banales JM, Arrese M, Cusi KBugianesi E, Klein S, Lu SC, Anstee QM, Millet O, Davidson NO, Alonso C, Mato JM. Hepatology. 2022 Feb 26. doi: 10.1002/hep.32427.

View Publication

Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients.

Stepanova M, Kabbara K, Mohess D, Verma M, Roche-Green A, AlQahtani S, Ong J, Burra P, Younossi ZM. Hepatol Commun. 2022 Feb 28. doi: 10.1002/hep4.1915.

View Publication

Differential fuel utilization in liver transplant recipients and its relationship with non-alcoholic fatty liver disease.

Siddiqui MS, Patel S, Forsgren M, Bui AT, Shen S, Syed T, Boyett S, Chen S, Sanyal AJ, Wolver S, Kirkman D, Celi FS, Bhati CS. Liver Int. 2022 Feb 7. doi: 10.1111/liv.15178.

View Publication

Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium.

Rinella ME, Satapathy SK, Brandman D, Smith C, Elwir S, Xia J, Gibson M, Figueredo C, Angirekula M, Vanatta JM, Sarwar R, Jiang Y, Gregory D, Agostini T, Ko J, Podila P, Gallo G, Watt KD, Siddiqui MS. Clin Gastroenterol Hepatol. 2022 Feb 18:S1542-3565(22)00184-7. doi: 10.1016/j.cgh.2022.02.028.

View Publication

Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease.

Karl M, Hasselwander S, Zhou Y, Reifenberg G, Kim YO, Park KS, Ridder DA, Wang X, Seidel E, Hövelmeyer N, Straub BK, Li H, Schuppan D, Xia N. Hepatology. 2022 Feb 26. doi: 10.1002/hep.32428.

View Publication

Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD.

Tamaki N, Imajo K, Sharpton SR, Jung J, Sutter N, Kawamura N, Yoneda M, Valasek MA, Behling C, Sirlin CB, Kurosaki M, Izumi N, Nakajima A, Loomba R. Clin Gastroenterol Hepatol. 2022 Feb 2:S1542-3565(22)00077-5. doi: 10.1016/j.cgh.2022.01.023.

View Publication

Meaning of non-overlapping patients between the MAFLD and NAFLD definitions.

Chan WK, Wong VW. Liver Int. 2022 Feb;42(2):271-273. doi: 10.1111/liv.15142.

View Publication

Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis.

Younossi ZM, Henry L. Endocr Pract. 2022 Feb;28(2):204-213. doi: 10.1016/j.eprac.2021.12.010. Epub 2021 Dec 22.

View Publication

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.

Johnson K, Leary PJ, Govaere O, Barter MJ, Charlton SH, Cockell SJ, Tiniakos D, Zatorska M, Bedossa P, Brosnan MJ, Cobbold JF, Ekstedt M, Aithal GP, Clément K, Schattenberg JM, Boursier J, Ratziu VBugianesi E, Anstee QM, Daly AK; LITMUS Consortium Investigators; LITMUS Consortium Investigators. JHEP Rep. 2021 Nov 25;4(2):100409. doi: 10.1016/j.jhepr.2021.100409. eCollection 2022 Feb.

View Publication

Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD.

Natarajan Y, Loomba R. J Clin Exp Hepatol. 2022 Jan-Feb;12(1):174-179. doi: 10.1016/j.jceh.2021.08.002.

View Publication

Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.

Tamaki N, Ajmera V, Loomba R. Nat Rev Endocrinol. 2022 Jan;18(1):55-66. doi: 10.1038/s41574-021-00584-0.

View Publication

Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study.

Tan EX, Lee JW, Jumat NH, Chan WK, Treeprasertsuk S, Goh GB, Fan JG, Song MJ, Charatcharoenwitthaya P, Duseja A, Imajo K, Nakajima A, Seki Y, Kasama K, Kakizaki S, Lesmana LA, Zheng KI, Zheng MH, Koh CJ, Ho KY, Goh KL, Wong VW, Dan YY. Metabolism. 2022 Jan;126:154911. doi: 10.1016/j.metabol.2021.154911.

View Publication

Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation.

Foglia B, Sutti S, Cannito S, Rosso C, Maggiora M, Autelli R, Novo E, Bocca C, Villano G, Ramavath NN, Younes R, Tusa I, Rovida E, Pontisso P, Bugianesi E, Albano E, Parola M. Cell Mol Gastroenterol Hepatol. 2021 Oct 14:S2352-345X(21)00216-2. doi: 10.1016/j.jcmgh.2021.10.002.

View Publication

Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.

Duseja A, Singh SP, Mehta M, Shalimar, Venkataraman J, Mehta V, Devadas K, Kar SK, Goyal O, Nagral A, Saigal S, Nijhawan S, Praharaj D, Shukla A, Sharma B, Narayanasamy K, Kumar P, Rao PN, Arora A, Mehta R, Asati P, Ranjan P, Koshy A, Alam S, Mukewar S, Mukewar S, Mohan Prasad VG, Rastogi M, Sanyal AJ. Metab Syndr Relat Disord. 2022 Jan 25. doi: 10.1089/met.2021.0104.

View Publication

Long-Term Effects of the Changes in Hepatic Steatosis Status on the Risk of Incident Type 2 Diabetes Mellitus: a 15-Year Community-Based Prospective Cohort Study.

Min Chung S, Kyu Kang M, Jung J, Sung Yoon J, Chang Won K, Woo Lee H, Loomba R, Gil Park J, Sung Moon J. Diabetes Res Clin Pract. 2022 Jan 18:109208. doi: 10.1016/j.diabres.2022.109208.

View Publication

Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.

Di Maira G, Foglia B, Napione L, Turato C, Maggiora M, Sutti S, Novo E, Alvaro M, Autelli R, Colombatto S, Bussolino F, Carucci P, Gaia S, Rosso C, Biasiolo A, Pontisso P, Bugianesi E, Albano E, Marra F, Parola M, Cannito S. J Pathol. 2022 Jan 22. doi: 10.1002/path.5871.

View Publication

Derivation and validation of the NAFLD Cirrhosis Score (NCS) to distinguish bridging fibrosis from cirrhosis.

Labenz C, Toenges G, Zheng MH, Ding D, Myers RP, Galle PR, Armandi A, Ampuero J, Gómez MR, Bugianesi E, Anstee QM, Schattenberg JM. Eur J Intern Med. 2022 Jan 17:S0953-6205(21)00413-1. doi: 10.1016/j.ejim.2021.12.011.

View Publication

Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.

Boursier J, Hagström H, Ekstedt M, Moreau C, Bonacci M, Cure S, Ampuero J, Nasr P, Tallab L, Canivet CM, Kechagias S, Sánchez Y, Dincuff E, Lucena A, Roux M, Riou J, Trylesinski A, Romero-Gomez M. J Hepatol. 2022 Jan 18:S0168-8278(22)00002-2. doi: 10.1016/j.jhep.2021.12.031.

View Publication

Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.

Pennisi G, Enea M, Romero-Gomez M, Viganò M, Bugianesi E, Wong VW, Fracanzani AL, Sebastiani G, Boursier J, Berzigotti A, Eslam M, Ampuero J, Benmassaoud A, La Mantia C, Mendoza YP, George J, Craxì A, Camma' C, de Ledinghen V, Petta S. Aliment Pharmacol Ther. 2022 Jan 5. doi: 10.1111/apt.16763.

View Publication

Placebo effect on progression and regression in NASH: Evidence from a meta-analysis.

Ng CH, Xiao J, Lim WH, Chin YH, Yong JN, Tan DJH, Tay P, Syn N, Foo R, Chan M, Chew N, Tan EX, Huang DQ, Dan YY, Tamaki N, Siddiqui MS, Sanyal AJLoomba R, Noureddin M, Muthiah MD. Hepatology. 2022 Jan 6. doi: 10.1002/hep.32315.

View Publication

NASHFit: of an exercise training program to reduce clotting risk in patients with NASH.

Stine JG, Schreibman IR, Faust AJ, Dahmus J, Stern B, Soriano C, Rivas G, Hummer B, Kimball SR, Geyer NR, Chinchilli VM, Loomba R, Schmitz K, Sciamanna C. Hepatology. 2021 Dec 10. doi: 10.1002/hep.32274.

View Publication

The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?

Lazarus JV, Mark HE, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, Ekstedt M, Esmat G, George J, Marchesini G, Novak K, Ocama P, Ratziu V, Razavi H, Romero-Gómez M, Silva M, Spearman CW, Tacke F, Tsochatzis EA, Yilmaz Y, Younossi ZM, Wong VW, Zelber-Sagi S, Cortez-Pinto H, Anstee QM; NAFLD policy review collaborators. J Hepatol. 2021 Dec 8:S0168-8278(21)02168-1. doi: 10.1016/j.jhep.2021.10.025.

View Publication

Elevated liver enzymes and comorbidities in type 2 diabetes: Multicenter analysis of 51,645 patients of the DPV database.

Meyhöfer S, Eckert AJ, Hummel M, Laimer M, Roden M, Kress S, Seufert J, Meyhöfer SM, Holl RW. Diabetes Obes Metab. 2021 Dec 9. doi: 10.1111/dom.14616. Online ahead of print.PMID: 34882949 

View Publication

Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease.

Zhang YN, Fowler KJ, Boehringer AS, Montes V, Schlein AN, Covarrubias Y, Wolfson T, Hong CW, Valasek MA, Andre MP, Loomba R, Sirlin CB. Eur Radiol. 2021 Dec 2. doi: 10.1007/s00330-021-08369-9.

View Publication

An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD.

Hui Lim GE, Tang A, Ng CH, Chin YH, Lim WH, Hao Tan DJ, Yong JN, Xiao J, Wen-Min Lee C, Chan M, Chew NW, Xuan Tan EX, Siddiqui MS, Huang D, Noureddin M, Sanyal AJ, Muthiah MD. Clin Gastroenterol Hepatol. 2021 Dec 3:S1542-3565(21)01276-3. doi: 10.1016/j.cgh.2021.11.038.

View Publication

Evaluation of a Stepped Care Approach to Manage Depression and Diabetes Distress in Patients with Type 1 Diabetes and Type 2 Diabetes: Results of a Randomized Controlled Trial (ECCE HOMO Study).

Schmitt A, Kulzer B, Reimer A, Herder C, Roden M, Haak T, Hermanns N. Psychother Psychosom. 2021 Dec 7:1-16. doi: 10.1159/000520319.

View Publication

The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.

Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. Lancet. 2021 Dec 1:S0140-6736(21)01701-3. doi: 10.1016/S0140-6736(21)01701-3.

View Publication

Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready-to-use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males.

Hompesch M, Hawryluk A, Hernandez M, Uchil B, Wilmington A, Peterson L. Diabetes Obes Metab. 2021 Dec;23(12):2679-2686. doi: 10.1111/dom.14520.

View Publication

Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity – authors’ reply.

Flint A, Andersen G, Hockings P, Plum-Mörschel L, Loomba R. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1498. doi: 10.1111/apt.16669.

View Publication

Corrigendum to ‘Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis’ [J Hepatol 75 (2021) 865-878].

Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Taik P, Lee YA, Moeini A, Peix J, Faure-Dupuy S, Riedl T, Schuehle S, Oliveira CP, Alves VA, Boffetta P, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Dufour JF, Thung SN, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwalder M, Sanyal A, Friedman SL, Sia D, Llovet JM. J Hepatol. 2021 Dec;75(6):1515. doi: 10.1016/j.jhep.2021.09.014.

View Publication

Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis.

Kim HP, Idowu MO, Mospan AR, Allmon AG, Roden M, Newsome P, Lok AS, Thuluvath PJ, Taunk J, Fried MW, Sanyal AJ, Barritt AS 4th; TARGET-NASH Investigators. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1472-1480. doi: 10.1111/apt.16674.

View Publication

A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach.

Lazarus JV, Mark HE, Colombo M, Demaio S, Dillon JF, George J, Hagström H, Hocking S, Lee N, Nieuwenhuijsen MJ, Rinella ME, Romero-Gomez M, Soriano JB, Schattenberg JM, Tacke F, Tsochatzis EA, Valenti L, Zelber-Sagi S, Ashworth Dirac M, Huang TT. Aliment Pharmacol Ther. 2021 Dec 5. doi: 10.1111/apt.16720.

View Publication

A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy.

Guo F, Estévez-Vázquez O, Benedé-Ubieto R, Maya-Miles D, Zheng K, Gallego-Durán R, Rojas Á, Ampuero J, Romero-Gómez M, Philip K, Egbuniwe IU, Chen C, Simon J, Delgado TC, Martínez-Chantar ML, Sun J, Reissing J, Bruns T, Lamas-Paz A, Moral MGD, Woitok MM, Vaquero J, Regueiro JR, Liedtke C, Trautwein C, Bañares R, Cubero FJ, Nevzorova YA. Cancers (Basel). 2021 Dec 31;14(1):192. doi: 10.3390/cancers14010192.

View Publication

Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.

Govaere O, Petersen SK, Martinez-Lopez N, Wouters J, Van Haele M, Mancina RM, Jamialahmadi O, Bilkei-Gorzo O, Lassen PB, Darlay R, Peltier J, Palmer JM, Younes R, Tiniakos D, Aithal GP, Allison M, Vacca M, Göransson M, Berlinguer-Palmini R, Clark JE, Drinnan MJ, Yki-Järvinen H, Dufour JF, Ekstedt M, Francque S, Petta S, Bugianesi E, Schattenberg JM, Day CP, Cordell HJ, Topal B, Clément K, Romeo S, Ratziu V, Roskams T, Daly AK, Anstee QM, Trost M, Härtlova A. J Hepatol. 2021 Dec 20:S0168-8278(21)02254-6. doi: 10.1016/j.jhep.2021.12.012.

View Publication

Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population.

Graupera I, Thiele M, Serra-Burriel M, Caballeria L, Roulot D, Wong GL, Fabrellas N, Guha IN, Arslanow A, Expósito C, Hernández R, Aithal GP, Galle PR, Pera G, Wong VW, Lammert F, Ginès P, Castera L, Krag A; Investigators of the LiverScreen Consortium. Clin Gastroenterol Hepatol. 2021 Dec 29:S1542-3565(21)01358-6. doi: 10.1016/j.cgh.2021.12.034.

View Publication

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study.

Fouqueray P, Bolze S, Dubourg J, Hallakou-Bozec S, Theurey P, Grouin JM, Chevalier C, Gluais-Dagorn P, Moller DE, Cusi K. Cell Rep Med. 2021 Dec 21;2(12):100474. doi: 10.1016/j.xcrm.2021.100474.

View Publication

Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.

Loomba R, Ratziu V, Harrison SA; NASH Clinical Trial Design International Working Group. Gastroenterology. 2021 Nov 22:S0016-5085(21)03795-1. doi: 10.1053/j.gastro.2021.10.051.

View Publication

Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases.

Gallego-Durán R, Montero-Vallejo R, Maya-Miles D, Lucena A, Martin F, Ampuero J, Romero-Gómez M. Front Immunol. 2021 Nov 24;12:667354. doi: 10.3389/fimmu.2021.667354.

View Publication

Evaluating Outcomes Related to Donor and Recipient Metabolic Environment: Macrosteatotic Allograft and Nonalcoholic Steatohepatitis.

Brubaker AL, Loomba R. Liver Transpl. 2021 Nov 22. doi: 10.1002/lt.26371.

View Publication

Fatty Liver Disease: Diagnosis and Stratification.

Saiman Y, Duarte-Rojo A, Rinella ME. Annu Rev Med. 2021 Nov 22. doi: 10.1146/annurev-med-042220-020407.

View Publication

Outcomes of Non-alcoholic Steatohepatitis following Liver Transplantation. An Updated Meta-analysis and Systematic Review.

Yong JN, Lim WH, Ng CH, Hao Tan DJ, Xiao J, Lin Tay PW, Lin SY, Syn N, Chew N, Nah B, Dan YY, Huang DQ, Xuan Tan EX, Sanyal AJ, Noureddin M, Siddiqui MS, Muthiah MD. Clin Gastroenterol Hepatol. 2021 Nov 18:S1542-3565(21)01226-X. doi: 10.1016/j.cgh.2021.11.014.

View Publication

Differences in the prevalence of erectile dysfunction between novel subgroups of recent-onset diabetes.

Maalmi H, Herder C, Bönhof GJ, Strassburger K, Zaharia OP, Rathmann W, Burkart V, Szendroedi J, Roden M, Ziegler D; GDS Group. Diabetologia. 2021 Nov 20. doi: 10.1007/s00125-021-05607-z.

View Publication

Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.

Rinella M, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. J Hepatol. 2021 Nov 15:S0168-8278(21)02177-2. doi: 10.1016/j.jhep.2021.10.029.

View Publication

Liquid biomarkers for fibrotic NASH – progress in a complex field.

Golabi P, Paik JM, Eberly K, de Avila L, Alqahtani SA, Younossi ZM. Ann Hepatol. 2021 Nov 18;27(1):100556. doi: 10.1016/j.aohep.2021.100556.

View Publication

Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C.

Golabi P, Paik JM, Eberly K, de Avila L, Alqahtani SA, Younossi ZM. Ann Hepatol. 2021 Nov 18;27(1):100556. doi: 10.1016/j.aohep.2021.100556.

View Publication

Noninvasive Risk Stratification for Nonalcoholic Fatty Liver Disease Among Living Liver Donor Candidates: A Proposed Algorithm.

Danis N, Weeks SR, Kim A, Baghdadi A, Ghadimi M, Kamel IR, Saberi B, Woreta T, Garonzik-Wang J, Philosophe B, Gurakar A, Loomba R. Liver Transpl. 2021 Nov 9. doi: 10.1002/lt.26365.

View Publication

The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review.

Armandi A, Rosso C, Caviglia GP, Ribaldone DG, Bugianesi E. Front Endocrinol (Lausanne). 2021 Nov 10;12:716533. doi: 10.3389/fendo.2021.716533.

View Publication

Comparison of patient characteristics between East Asian and non-East Asian patients with insulin autoimmune syndrome.

Oest L, Roden M, Müssig K. Clin Endocrinol (Oxf). 2021 Nov 14. doi: 10.1111/cen.14634.

View Publication

Physical fitness and cardiovascular risk factors in the novel diabetes subgroups.

Saatmann N, Zaharia OP, Strassburger K, Pesta DH, Burkart V, Szendroedi J, Gerdes N, Kelm M, Roden M. J Clin Endocrinol Metab. 2021 Nov 8:dgab810. doi: 10.1210/clinem/dgab810.

View Publication

Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global NASH/NAFLD Registry.

Younossi ZM, Yilmaz Y, Yu ML, Wai-Sun Wong V, Fernandez MC, Isakov VA, Duseja AK, Mendez-Sanchez N, Eguchi Y, Bugianesi E, Burra P, George J, Fan JG, Papatheodoridis GV, Chan WK, Alswat K, Saeed HS, Singal AK, Romero-Gomez M, Gordon SC, Roberts SK, El Kassas M Sr, Kugelmas M, Ong JP, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. Clin Gastroenterol Hepatol. 2021 Nov 9:S1542-3565(21)01183-6. doi: 10.1016/j.cgh.2021.11.004.

View Publication

Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.

Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. Gastroenterology. 2021 Nov;161(5):1657-1669. doi: 10.1053/j.gastro.2021.07.049.

View Publication

EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.

Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N. J Hepatol. 2021 Nov 2:S0168-8278(21)02155-3. doi: 10.1016/j.jhep.2021.10.018.

View Publication

Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients.

Mowry CJ, Alonso C, Iruarrizaga-Lejarreta M, Ortiz P, Levitsky J, Rinella M. Transplant Direct. 2021 Nov 5;7(12):e784. doi: 10.1097/TXD.0000000000001227.

View Publication

The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma.

Lewinska M, Santos-Laso A, Arretxe E, Alonso C, Zhuravleva E, Jimenez-Agüero R, Eizaguirre E, Pareja MJ, Romero-Gómez M, Arrese M, Suppli MP, Knop FK, Oversoe SK, Villadsen GE, Decaens T, Carrilho FJ, de Oliveira CP, Sangro B, Macias RIR, Banales JM, Andersen JB. EBioMedicine. 2021 Nov;73:103661. doi: 10.1016/j.ebiom.2021.103661.

View Publication

The peroxisomal transporter ABCD3 plays a major role in hepatic dicarboxylic fatty acid metabolism and lipid homeostasis.

Ranea-Robles P, Chen H, Stauffer B, Yu C, Bhattacharya D, Friedman SL, Puchowicz M, Houten SM. J Inherit Metab Dis. 2021 Nov;44(6):1419-1433. doi: 10.1002/jimd.12440.

View Publication

Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis.

Zhu C, Kim K, Wang X, Bartolome A, Salomao M, Dongiovanni P, Meroni M, Graham MJ, Yates KP, Diehl AM, Schwabe RF, Tabas I, Valenti L, Lavine JE, Pajvani UB.
Sci Transl Med. 2018 Nov 21;10(468). pii: eaat0344. doi: 10.1126/scitranslmed.aat0344.

View Publication

Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies.

Schlesinger S, Neuenschwander M, Barbaresko J, Lang A, Maalmi H, Rathmann W, Roden M, Herder C. Diabetologia. 2021 Oct 31. doi: 10.1007/s00125-021-05592-3.   

View Publication

Dietary palmitate and oleate differently modulate insulin sensitivity in human skeletal muscle.

Sarabhai T, Koliaki C, Mastrototaro L, Kahl S, Pesta D, Apostolopoulou M, Wolkersdorfer M, Bönner AC, Bobrov P, Markgraf DF, Herder C, Roden M. Diabetologia. 2021 Oct 26. doi: 10.1007/s00125-021-05596-z.

View Publication

Advancing the global public health agenda for NAFLD: a consensus statement.

Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Nat Rev Gastroenterol Hepatol. 2021 Oct 27. doi: 10.1038/s41575-021-00523-4.

View Publication

Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis.

Bhattacharya D, Becker C, Readhead B, Goossens N, Novik J, Fiel MI, Cousens LP, Magnusson B, Backmark A, Hicks R, Dudley JT, Friedman SL. Sci Rep. 2021 Oct 21;11(1):20827. doi: 10.1038/s41598-021-99008-2.

View Publication

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.

Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205.

View Publication

Evolution of Fatty Liver Disease and Relationship With Lipoproteins and Clinical Outcomes in Hepatitis B/Human Immunodeficiency Virus Coinfection.

Khalili M, King WC, Kleiner DE, Chung RT, Bhan AK, Ghany MG, Sulkowski MS, Lisker-Melman M, Jain MK, Janssen HLA, Hinerman AS, Sanyal AJ, Sterling RK. Clin Infect Dis. 2021 Oct 25:ciab764. doi: 10.1093/cid/ciab764.

View Publication

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.

Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJLoomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205.

View Publication

Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.

Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, Loomba R, Chalasani N, Kowdley K, Hameed B, Wilson LA, Yates KP, Belt P, Lazo M, Kleiner DE, Behling C, Tonascia J; NASH Clinical Research Network (CRN). N Engl J Med. 2021 Oct 21;385(17):1559-1569. doi: 10.1056/NEJMoa2029349.

View Publication

Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.

Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, Han L, Jia C, Huss RS, Chung C, Wong VW, Okanoue T, Romero-Gomez M, Muir AJ, Afdhal NH, Bosch J, Goodman Z, Harrison SA, Younossi ZM, Myers RP. Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.

View Publication

Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong.

Luk AOY, Yip TCF, Zhang X, Kong APS, Wong VW, Ma RCW, Wong GL. BMJ Open. 2021 Oct 20;11(10):e052310. doi: 10.1136/bmjopen-2021-052310.

View Publication

Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease.

Sharpton SR, Tamaki N, Bettencourt R, Madamba E, Jung J, Liu A, Behling C, Valasek MA, Loomba R. Therap Adv Gastroenterol. 2021 Oct 8;14:17562848211050436. doi: 10.1177/17562848211050436. eCollection 2021.

View Publication

The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States.

Younossi ZM, Harring M, Younossi Y, Ong JP, Alqahtani SA, Stepanova M. Clin Gastroenterol Hepatol. 2021 Oct 16:S1542-3565(21)01131-9. doi: 10.1016/j.cgh.2021.10.018.

View Publication

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial.

Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, Arrese M, Fracanzani AL, Ben Bashat D, Lackner K, Gorfine T, Kadosh S, Oren R, Halperin M, Hayardeny L, Loomba R, Friedman S; ARREST investigator study group, Sanyal AJ. Nat Med. 2021 Oct;27(10):1825-1835. doi: 10.1038/s41591-021-01495-3.

View Publication

Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.

Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, Han L, Jia C, Huss RS, Chung C, Wong VW, Okanoue T, Romero-Gomez M, Muir AJ, Afdhal NH, Bosch J, Goodman Z, Harrison SA, Younossi ZM, Myers RP. Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.

View Publication

Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.

Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, Han L, Jia C, Huss RS, Chung C, Wong VW, Okanoue T, Romero-Gomez M, Muir AJ, Afdhal NH, Bosch J, Goodman Z, Harrison SA, Younossi ZM, Myers RP. Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.

View Publication

Targeting epigenetically maladapted vascular niche alleviates liver fibrosis in nonalcoholic steatohepatitis.

Zhang H, Ma Y, Cheng X, Wu D, Huang X, Chen B, Ren Y, Jiang W, Tang X, Bai T, Chen Y, Zhao Y, Zhang C, Xiao X, Liu J, Deng Y, Ye T, Chen L, Liu HM, Friedman SL, Chen L, Ding BS, Cao Z. Sci Transl Med. 2021 Oct 6;13(614):eabd1206. doi: 10.1126/scitranslmed.abd1206.

View Publication

Asian perspective on NAFLD-associated HCC.

Yip TC, Lee HW, Chan WK, Wong GL, Wong VW. J Hepatol. 2021 Oct 4:S0168-8278(21)02086-9. doi: 10.1016/j.jhep.2021.09.024.

View Publication

Association of genetic variations with NAFLD in lean individuals.

Lin H, Wong GL, Whatling C, Chan AW, Leung HH, Tse CH, Shu SS, Chim AM, Lai JC, Yip TC, Wong VW. Liver Int. 2021 Oct 5. doi: 10.1111/liv.15078.

View Publication

Randomized clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.

Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M, Vogl T, Loomba R, Plum-Mörschel L. Aliment Pharmacol Ther. 2021 Sep 27. doi: 10.1111/apt.16608.

View Publication

Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease.

Barb D, Repetto EM, Stokes ME, Shankar SS, Cusi K. Obesity (Silver Spring). 2021 Sep 23. doi: 10.1002/oby.23263.

View Publication

A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Non-alcoholic Fatty Liver Disease.

Kai Toh JZ, Pan XH, Lin Tay PW, Ng CH, Yong JN, Xiao J, Koh JH, Tan EY, Xuan Tan EX, Dan YY, Loh PH, Foo R, Chew NW, Sanyal AJ, Muthiah MD, Siddiqui MS. Clin Gastroenterol Hepatol. 2021 Sep 21:S1542-3565(21)01035-1. doi: 10.1016/j.cgh.2021.09.021.

View Publication

Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review.

Schattenberg JM, Anstee QM, Caussy C, Bugianesi E, Popovic B. Expert Rev Gastroenterol Hepatol. 2021 Sep 21:1-14. doi: 10.1080/17474124.2021.1974295.

View Publication

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.

Cusi K, Alkhouri N, Harrison SA, Fouqueray P, Moller DE, Hallakou-Bozec S, Bolze S, Grouin JM, Jeannin Megnien S, Dubourg J, Ratziu V. Lancet Gastroenterol Hepatol. 2021 Sep 21:S2468-1253(21)00300-9. doi: 10.1016/S2468-1253(21)00300-9.

View Publication

Cross-Talk Between Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: Implications for Future Trial Design.

Pellicori P, Vaduganathan M, Ferreira OP, Zannad F, Sanyal AJ. Diabetes Metab. 2021 Sep 17:101281. doi: 10.1016/j.diabet.2021.101281.

View Publication

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.

Nakajima A, Eguchi Y, Yoneda M, Imajo K, Tamaki N, Suganami H, Nojima T, Tanigawa R, Iizuka M, Iida Y, Loomba R. Aliment Pharmacol Ther. 2021 Sep 16. doi: 10.1111/apt.16596.

View Publication

What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?

Alkhouri N, Tincopa M, Loomba R, Harrison SA. Hepatol Commun. 2021 Sep 9. doi: 10.1002/hep4.1814.

View Publication

MRE plus FIB-4 (MEFIB) versus FAST in detection of candidates for pharmacological treatment of NASH-related fibrosis.

Tamaki N, Imajo K, Sharpton S, Jung J, Kawamura N, Yoneda M, Valasek MA, Behling C, Sirlin CB, Nakajima A, Loomba R. Hepatology. 2021 Sep 8. doi: 10.1002/hep.32145.

View Publication

Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies.

Lee YA, Friedman SL. J Intern Med. 2021 Sep 26. doi: 10.1111/joim.13380.

View Publication

Fatty Pancreas Is Independently Associated With Subsequent Diabetes Mellitus Development: A 10-Year Prospective Cohort Study.

Chan TT, Tse YK, Lui RN, Wong GL, Chim AM, Kong AP, Woo J, Yeung DK, Abrigo JM, Chu WC, Wong VW, Tang RS. Clin Gastroenterol Hepatol. 2021 Sep 25:S1542-3565(21)01041-7. doi: 10.1016/j.cgh.2021.09.027.

View Publication

A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.

Bosch J, Chung C, Carrasco-Zevallos OM, Harrison SA, Abdelmalek MF, Shiffman ML, Rockey DC, Shanis Z, Juyal D, Pokkalla H, Le QH, Resnick M, Montalto M, Beck AH, Wapinski I, Han L, Jia C, Goodman Z, Afdhal N, Myers RP, Sanyal AJ. Hepatology. 2021 Aug 1. doi: 10.1002/hep.32087.

View Publication

Hepatic Fat Reduction Due to Resmetirom in Patients with Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life.

Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Clin Gastroenterol Hepatol. 2021 Jul 27:S1542-3565(21)00821-1. doi: 10.1016/j.cgh.2021.07.039.

View Publication

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.

Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O'Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble G. Gastroenterology. 2021 Jul 20:S0016-5085(21)03276-5. doi: 10.1053/j.gastro.2021.07.025.

View Publication

Novel Antidiabetic Strategies and Diabetologists’ Views in Nonalcoholic Steatohepatitis.

Kahl S, Pützer J, Roden M. Semin Liver Dis. 2021 Jul 21. doi: 10.1055/s-0041-1732354.

View Publication

Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.

Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee QM, Ratziu V, Harrison S, Sanyal AJ, Schattenberg JM, Barritt AS, Noureddin M, Bonacci M, Cawkwell G, Wong B, Rinella M; REGENERATE Study Investigators. Clin Gastroenterol Hepatol. 2021 Jul 15:S1542-3565(21)00751-5. doi: 10.1016/j.cgh.2021.07.020.

View Publication

Risk difference of liver-related and cardiovascular events by liver fibrosis status in nonalcoholic fatty liver disease.

Tamaki N, Higuchi M, Kurosaki M, Loomba R, Izumi N; MRCH Liver Study Group, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Itakura J. Clin Gastroenterol Hepatol. 2021 Jul 16:S1542-3565(21)00752-7. doi: 10.1016/j.cgh.2021.07.021.

View Publication

Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD.

Vilarinho S, Ajmera V, Zheng M, Loomba R. Hepatology. 2021 Jul 7. doi: 10.1002/hep.32047.

View Publication

Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis.

Rivera-Esteban J, Armandi A, Augustin S, Bugianesi E.Liver Int. 2021 Jul 9. doi: 10.1111/liv.15013.

View Publication

PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH.

Gastaldelli A, Sabatini S, Carli F, Gaggini M, Bril F, Belfort-DeAguiar R, Positano V, Barb D, Kadiyala S, Harrison S, Cusi K. Liver Int. 2021 Jul 5. doi: 10.1111/liv.15005.

View Publication

Preparing for the NASH epidemic: A call to action.

Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Metabolism. 2021 Jul 6:154822. doi: 10.1016/j.metabol.2021.154822.

View Publication

A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease.

Younossi ZM, Ong JP, Takahashi H, Yilmaz Y, Eguchi Y, El Kassas M, Buti M, Diago M, Zheng MH, Fan JG, Yu ML, Wai-Sun Wong V, Alswat K, Chan WK, Mendez-Sanchez N, Burra P, Bugianesi E, Duseja AK, George J, Papatheodoridis GV, Saeed H, Castera L, Arrese M, Kugelmas M, Romero-Gomez M, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. Clin Gastroenterol Hepatol. 2021 Jul 3:S1542-3565(21)00719-9. doi: 10.1016/j.cgh.2021.06.048.

View Publication

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.

Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O'Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble G. 
Gastroenterology. 2021 Jul 20:S0016-5085(21)03276-5. doi: 10.1053/j.gastro.2021.07.025.

View Publication

Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes.

Bril F, McPhaul MJ, Kalavalapalli S, Lomonaco R, Barb D, Gray ME, Shiffman D, Rowland CM, Cusi K. J Clin Endocrinol Metab. 2021 Jun 30:dgab417. doi: 10.1210/clinem/dgab417.

View Publication

Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis.

Yu J, Zhu C, Wang X, Kim K, Bartolome A, Dongiovanni P, Yates KP, Valenti L, Carrer M, Sadowski T, Qiang L, Tabas I, Lavine JE, Pajvani UB. Sci Transl Med. 2021 Jun 23;13(599):eabe1692. doi: 10.1126/scitranslmed.abe1692.

View Publication

Defining comprehensive models of care for NAFLD.

Lazarus JV, Anstee QM, Hagström H, Cusi K, Cortez-Pinto H, Mark HE, Roden M, Tsochatzis EA, Wong VW, Younossi ZM, Zelber-Sagi S, Romero-Gómez M, Schattenberg JM. Nat Rev Gastroenterol Hepatol. 2021 Jun 25. doi: 10.1038/s41575-021-00477-7.

View Publication

Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD.

Jiao N, Loomba R, Yang ZH, Wu D, Fang S, Bettencourt R, Lan P, Zhu R, Zhu L. Physiol Genomics. 2021 Jun 21. doi: 10.1152/physiolgenomics.00011.2021.

View Publication

Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease.

Zhou YJ, Gao F, Liu WY, Wong GL, Mahadeva S, Raihan Nik Mustapha N, Wang XD, Chan WK, Wong VW, Zheng MH. Aliment Pharmacol Ther. 2021 Jun 21. doi: 10.1111/apt.16487.

View Publication

Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.

Dayton KA, Bril F, Barb D, Lai J, Kalavalapalli S, Cusi K. PLoS One. 2021 Jun 2;16(6):e0251449. doi: 10.1371/journal.pone.0251449.

View Publication

Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.

Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, Pennisi G, Liguori A, Francione P, Gallego-Durán R, Ampuero J, Garcia Blanco MJ, Aller R, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Pareja MJ, Zaki MYW, Grieco A, Fracanzani AL, Valenti L, Miele L, Fariselli P, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. J Hepatol. 2021 Jun 3:S0168-8278(21)00343-3. doi: 10.1016/j.jhep.2021.05.008.

View Publication

Natural history of NASH.

Armandi A, Bugianesi E. Liver Int. 2021 Jun;41 Suppl 1:78-82. doi: 10.1111/liv.14910.

View Publication

Non-alcoholic fatty liver disease in type 2 diabetes – A specific entity?

Schröder B, Kahl S, Roden M. Liver Int. 2021 Jun;41 Suppl 1:105-111. doi: 10.1111/liv.14846.

View Publication

Consensus scoring systems for nonalcoholic fatty liver disease: an unmet clinical need.

Zhou YJ, Wong VW, Zheng MH. Hepatobiliary Surg Nutr. 2021 Jun;10(3):388-390. doi: 10.21037/hbsn-21-80.

View Publication

New drugs for NASH.

Albhaisi SAM, Sanyal AJ. Liver Int. 2021 Jun;41 Suppl 1:112-118. doi: 10.1111/liv.14844.

View Publication

Management of NAFLD patients with advanced fibrosis.

Maya-Miles D, Ampuero J, Gallego-Durán R, Dingianna P, Romero-Gómez M. Liver Int. 2021 Jun;41 Suppl 1:95-104. doi: 10.1111/liv.14847.PMID: 34155801

View Publication

Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study.

Barritt AS, Watkins S, Gitlin N, Klein S, Lok AS, Loomba R, Schoen C, Reddy KR, Trinh HN, Mospan AR, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Hepatol Commun. 2021 Feb 21;5(6):938-946. doi: 10.1002/hep4.1689. eCollection 2021 Jun.

View Publication

Non-alcoholic fatty liver disease.

Powell EE, Wong VWRinella M. Lancet. 2021 Jun 5;397(10290):2212-2224. doi: 10.1016/S0140-6736(20)32511-3.

View Publication

Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.

Dayton KA, Bril F, Barb D, Lai J, Kalavalapalli S, Cusi K. PLoS One. 2021 Jun 2;16(6):e0251449. doi: 10.1371/journal.pone.0251449.

View Publication

Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.

Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, Pennisi G, Liguori A, Francione P, Gallego-Durán R, Ampuero J, Garcia Blanco MJ, Aller R, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Pareja MJ, Zaki MYW, Grieco A, Fracanzani AL, Valenti L, Miele L, Fariselli P, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. J Hepatol. 2021 Jun 3:S0168-8278(21)00343-3. doi: 10.1016/j.jhep.2021.05.008.

View Publication

The impact of genetic risk on liver fibrosis in non-alcoholic fatty liver disease as assessed by magnetic resonance elastography.

Ajmera V, Liu A, Bettencourt R, Dhar D, Richards L, Loomba R. Aliment Pharmacol Ther. 2021 Jul;54(1):68-77. doi: 10.1111/apt.16392. Epub 2021 May 11.

View Publication

Influence of Psychological Biomarkers on Therapeutic Adherence by Patients with Non-Alcoholic Fatty Liver Disease: A Moderated Mediation Model.

Funuyet-Salas J, Martín-Rodríguez A, Pérez-San-Gregorio MÁ, Romero-Gómez M. J Clin Med. 2021 May 20;10(10):2208. doi: 10.3390/jcm10102208.

View Publication

The Burden of Nonalcoholic Fatty Liver Disease in Asia, Middle East and North Africa: Data from Global Burden of Disease 2009-2019.

Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. J Hepatol. 2021 May 31:S0168-8278(21)00358-5. doi: 10.1016/j.jhep.2021.05.022.

View Publication

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.

Mózes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, Fournier C, Staufer K, Stauber RE, Bugianesi E, Younes R, Gaia S, Lupșor-Platon M, Petta S, Shima T, Okanoue T, Mahadeva S, Chan WK, Eddowes PJ, Hirschfield GM, Newsome PN, Wong VW, de Ledinghen V, Fan J, Shen F, Cobbold JF, Sumida Y, Okajima A, Schattenberg JM, Labenz C, Kim W, Lee MS, Wiegand J, Karlas T, Yılmaz Y, Aithal GP, Palaniyappan N, Cassinotto C, Aggarwal S, Garg H, Ooi GJ, Nakajima A, Yoneda M, Ziol M, Barget N, Geier A, Tuthill T, Brosnan MJ, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators. Gut. 2021 May 17:gutjnl-2021-324243. doi: 10.1136/gutjnl-2021-324243.

View Publication

Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.

Caviglia GP, Armandi A, Rosso C, Gaia S, Aneli S, Rolle E, Abate ML, Olivero A, Nicolosi A, Guariglia M, Ribaldone DG, Carucci P, Saracco GM, Bugianesi E. Cancers (Basel). 2021 May 11;13(10):2305. doi: 10.3390/cancers13102305.

View Publication

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis.

Selvaraj EA, Mózes FE, Ajmer Jayaswal AN, Zafarmand MH, Vali Y, Lee JA, Levick CK, Joseph Young LA, Palaniyappan N, Liu CH, Aithal GP, Romero-Gómez M, Brosnan MJ, Tuthill TA, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators. J Hepatol. 2021 May 12:S0168-8278(21)00309-3. doi: 10.1016/j.jhep.2021.04.044.

View Publication

Mechanisms and disease consequences of nonalcoholic fatty liver disease.

Loomba R, Friedman SL, Shulman GI. Cell. 2021 May 13;184(10):2537-2564. doi: 10.1016/j.cell.2021.04.015.

View Publication

Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis.

Albhaisi S, Sanyal AJ. Front Endocrinol (Lausanne). 2021 May 10;12:665987. doi: 10.3389/fendo.2021.665987.

View Publication

Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers.

Gil-Gómez A, Brescia P, Rescigno M, Romero-Gómez M. Semin Liver Dis. 2021 May;41(2):191-205. doi: 10.1055/s-0041-1723752.

View Publication

Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study.

Chiyanika C, Wong VW, Wong GL, Chan HL, Hui SCN, Yeung DKW, Chu WCW. Clin Transl Gastroenterol. 2021 Feb 17;12(2):e00300. doi: 10.14309/ctg.0000000000000300.

View Publication

Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease.

Alqahtani SA, Golabi P, Paik JM, Lam B, Moazez AH, Elariny HA, Goodman Z, Younossi ZM. Obes Surg. 2021 Feb 22. doi: 10.1007/s11695-020-04996-1.

View Publication

A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.

Taylor-Weiner A, Pokkalla H, Han L, Jia C, Huss R, Chung C, Elliott H, Glass B, Pethia K, Carrasco-Zevallos O, Shukla C, Khettry U, Najarian R, Taliano R, Subramanian GM, Myers RP, Wapinski I, Khosla A, Resnick M, Montalto MC, Anstee QM, Wong VW, Trauner M, Lawitz EJ, Harrison SA, Okanoue T, Romero-Gomez M, Goodman Z, Loomba R, Beck AH, Younossi ZM. Hepatology. 2021 Feb 11. doi: 10.1002/hep.31750.

View Publication

Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in five european countries in 2018: A cost-of-illness analysis.

Schattenberg JM, Lazarus JV, Newsome PN, Serfaty L, Aghemo A, Augustin S, Tsochatzis E, de Ledinghen V, Bugianesi E, Romero-Gomez M, Bantel H, Ryder SD, Boursier J, Leroy V, Crespo J, Castera L, Floros L, Atella V, Mestre-Ferrandiz J, Elliott R, Kautz A, Morgan A, Hartmanis S, Vasudevan S, Pezzullo L, Trylesinski A, Cure S, Higgins V, Ratziu V. Liver Int. 2021 Feb 15. doi: 10.1111/liv.14825.

View Publication

Therapeutic pipeline in nonalcoholic steatohepatitis.

Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Nat Rev Gastroenterol Hepatol. 2021 Feb 10. doi: 10.1038/s41575-020-00408-y.

View Publication

Simple non-invasive scoring systems and histologic scores in predicting mortality in NAFLD patients: A systematic review and meta-analysis.

Liu CH, Ampuero J, Pavlides M, Wong VW, Fan JG, Bai L, Li H, Wu DB, Zhou LY, Du LY, Yang TK, Jiang W, Shi Y, Gil-Gómez A, Zhang WT, Liang JX, Romero-Gómez M, Tang H. J Gastroenterol Hepatol. 2021 Feb 10. doi: 10.1111/jgh.15431.

View Publication

Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?

Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, McLeod D, Pareja MJ, Fracanzani AL, Aller R, Rosso C, Ampuero J, Gallego-Durán R, Armandi A, Caviglia GP, Zaki MYW, Liguori A, Francione P, Pennisi G, Grieco A, Birolo G, Fariselli P, Eslam M, Valenti L, George J, Romero-Gómez M, Anstee QM, Bugianesi E. Gut. 2021 Feb 4:gutjnl-2020-322564. doi: 10.1136/gutjnl-2020-322564.

View Publication

Non-invasive Tests to Phenotype Nonalcoholic Fatty Liver Disease – Sequence and Consequences of Arranging the Tools In the Tool Box.

Vuppalanchi R, Loomba R. Hepatology. 2021 Feb 5. doi: 10.1002/hep.31734.

View Publication

Nonalcoholic Fatty Liver Disease and Cardiovascular Disease.

Przybyszewski EM, Targher G, Roden M, Corey KE. Clin Liver Dis (Hoboken). 2021 Feb 1;17(1):19-22. doi: 10.1002/cld.1017.

View Publication

Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: A population -based study.

Julián MT, Pera G, Soldevila B, Caballería L, Julve J, Puig-Jové C, Morillas R, Torán P, Expósito C, Puig-Domingo M, Castelblanco E, Franch-Nadal J, Cusi K, Mauricio D, Alonso N. Eur J Endocrinol. 2021 Feb 1:EJE-20-1240.R1. doi: 10.1530/EJE-20-1240.

View Publication

NAFLD-related HCC.

Banini BA, Sanyal AJ. Adv Cancer Res. 2021;149:143-169. doi: 10.1016/bs.acr.2020.11.001.

View Publication

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour JF, Roden M, Sacks F, Tacke F. Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):24-39. doi: 10.1038/s41575-020-00366-5.

View Publication

Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort.

Malespin MH, Barritt AS 4th, Watkins SE, Schoen C, Tincopa MA, Corbin KD, Mospan AR, Munoz B, Trinh HN, Weiss LM, Reddy KR, Loomba R, Kemmer N, Lok AS.Clin Gastroenterol Hepatol. 2021 Jan 21:S1542-3565(21)00073-2. doi: 10.1016/j.cgh.2021.01.023.

View Publication

Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement.

Hagström H, Adams LA, Allen AM, Byrne CD, Chang Y, Grønbaek H, Ismail M, Jepsen P, Kanwal F, Kramer J, Lazarus JV, Long MT, Loomba R, Newsome PN, Rowe IA, Ryu S, Schattenberg JM, Serper M, Sheron N, Simon TG, Tapper EB, Wild S, Wong VW, Yilmaz Y, Zelber-Sagi S, Åberg F. Hepatology. 2021 Jan 23. doi: 10.1002/hep.31726.

View Publication

Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD).

Burz SD, Monnoye M, Philippe C, Farin W, Ratziu V, Strozzi F, Paillarse JM, Chêne L, Blottière HM, Gérard P. Microorganisms. 2021 Jan 19;9(1):199. doi: 10.3390/microorganisms9010199.

View Publication

NAFLD as a metabolic disease in humans: A literature review.

Cariou B, Byrne CD, Loomba R, Sanyal AJ. Diabetes Obes Metab. 2021 Jan 19. doi: 10.1111/dom.14322.

View Publication

Relevance of fructose intake in adolescence for fatty liver indices in young adulthood.

Perrar I, Buyken AE, Penczynski KJ, Remer T, Kuhnle GG, Herder C, Roden M, Della Corte K, Nöthlings U, Alexy U. Eur J Nutr. 2021 Jan 19. doi: 10.1007/s00394-020-02463-2.

View Publication

Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.

Petroff D, Blank V, Newsome PN, Shalimar, Voican CS, Thiele M, de Lédinghen V, Baumeler S, Chan WK, Perlemuter G, Cardoso AC, Aggarwal S, Sasso M, Eddowes PJ, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Cobbold JF, Naveau S, Lupsor-Platon M, Mueller S, Krag A, Irles-Depe M, Semela D, Wong GL, Wong VW, Villela-Nogueira CA, Garg H, Chazouillères O, Wiegand J, Karlas T. Lancet Gastroenterol Hepatol. 2021 Jan 15:S2468-1253(20)30357-5. doi: 10.1016/S2468-1253(20)30357-5.

View Publication

Management of non-alcoholic fatty liver disease.

Petroni ML, Brodosi L, Bugianesi E, Marchesini G. BMJ. 2021 Jan 18;372:m4747. doi: 10.1136/bmj.m4747.

View Publication

Yet more evidence that MAFLD is more than name change.

Eslam M, Ratziu V, George J. J Hepatol. 2021 Jan 13:S0168-8278(21)00008-8. doi: 10.1016/j.jhep.2020.12.025.

View Publication

Imaging Biomarkers of NAFLD, NASH, and Fibrosis.

Ajmera V, Loomba R. Mol Metab. 2021 Jan 15:101167. doi: 10.1016/j.molmet.2021.101167.

View Publication

Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis.

Govaere O, Cockell S, Tiniakos D, Queen R, Younes R, Vacca M, Alexander L, Ravaioli F, Palmer J, Petta S, Boursier J, Rosso C, Johnson K, Wonders K, Day CP, Ekstedt M, Orešič M, Darlay R, Cordell HJ, Marra F, Vidal-Puig A, Bedossa P, Schattenberg JM, Clément K, Allison M, Bugianesi E, Ratziu V, Daly AK, Anstee QM. Sci Transl Med. 2020 Dec 2;12(572):eaba4448. doi: 10.1126/scitranslmed.aba4448.

View Publication

Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart.

Cusi K, Godinez Leiva E. Curr Opin Lipidol. 2020 Dec;31(6):364-366. doi: 10.1097/MOL.0000000000000717.

View Publication

Identification of a metabolic, transcriptomic and molecular signature of PNPLA3-mediated acceleration of steatohepatitis.

Banini BA, P Kumar D, Cazanave S, Seneshaw M, Mirshahi F, Santhekadur PK, Wang L, Guan HP, Oseini A, Alonso C, Bedossa P, Koduru SV, Min HK, Sanyal AJ. Hepatology. 2020 Nov 1. doi: 10.1002/hep.31609.

View Publication

Role of ceramide-to-dihydroceramide ratios for insulin resistance and non-alcoholic fatty liver disease in humans.

Apostolopoulou M, Gordillo R, Gancheva S, Strassburger K, Herder C, Esposito I, Schlensak M, Scherer PE, Roden M. BMJ Open Diabetes Res Care. 2020 Nov;8(2):e001860. doi: 10.1136/bmjdrc-2020-001860.

View Publication

“The predictive value of significant fibrosis for metabolic disturbances in NAFLD patients”.

Ampuero J, Gallego-Durán R, Romero-Gómez M. J Hepatol. 2020 Dec 24:S0168-8278(20)33895-2. doi: 10.1016/j.jhep.2020.12.020.

View Publication

RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.

Afonso MB, Rodrigues PM, Mateus-Pinheiro M, Simão AL, Gaspar MM, Majdi A, Arretxe E, Alonso C, Santos A, Jimenez-Agüero R, Eizaguirre E, Bujanda L, Pareja MJ, Banales J, Ratziu V, Gautheron J, Castro RE, Rodrigues CM. Gut. 2020 Dec 24:gutjnl-2020-321767. doi: 10.1136/gutjnl-2020-321767.

View Publication

Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension.

Elkrief L, Lazareth M, Chevret S, Paradis V, Magaz M, Blaise L, Rubbia-Brandt L, Moga L, Durand F, Payancé A, Plessier A, Chaffaut C, Valla D, Malphettes M, Diaz A, Nault JC, Nahon P, Audureau E, Ratziu V, Castera L, Garcia Pagan JC, Ganne-Carrie N, Rautou PE; ANRS CO12 CirVir group.Hepatology. 2020 Dec 21. doi: 10.1002/hep.31688.

View Publication

Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes.

Carlier A, Phan F, Szpigel A, Hajduch E, Salem JE, Gautheron J, Le Goff W, Guérin M, Lachkar F, Ratziu V, Hartemann A, Ferré P, Foufelle F, Bourron O. Cell Rep Med. 2020 Dec 22;1(9):100154. doi: 10.1016/j.xcrm.2020.100154.

View Publication

Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.

Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, Portillo Romero J, Schmidt S, Chang KL, Samraj G, Malaty J, Huber K, Bedossa P, Kalavalapalli S, Marte J, Barb D, Poulton D, Fanous N, Cusi K. Diabetes Care. 2020 Dec 21:dc201997. doi: 10.2337/dc20-1997.

View Publication

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.

Huang DQ, El-Serag HB, Loomba R. Nat Rev Gastroenterol Hepatol. 2020 Dec 21. doi: 10.1038/s41575-020-00381-6.

View Publication

Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease.

Kazankov K, Rosso C, Younes R, Armandi A, Hagström H, Møller HJ, Stål P, Bugianesi E, Grønbæk H. Front Med (Lausanne). 2020 Dec 18;7:616212. doi: 10.3389/fmed.2020.616212.

View Publication

Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study.

Doward LC, Balp MM, Twiss J, Slota C, Cryer D, Brass CA, Anstee QM, Sanyal AJ. Patient. 2020 Dec 18. doi: 10.1007/s40271-020-00485-w.

View Publication

Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.

Romero-Gomez M, Kachru N, Zamorano MA, Darba J, Shreay S. Medicine (Baltimore). 2020 Dec 11;99(50):e23506. doi: 10.1097/MD.0000000000023506.

View Publication

Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease.

Bayoumi A, Jalil I, Metwally M, Adams LA, Aller R, García-Monzón C, Arias-Loste MT, Miele L, Petta S, Craxì A, Gallego-Durán R, Fischer J, Berg T, Qiao L, Liddle C, Bugianesi E, Romero-Gomez M, George J, Eslam M. PLoS One. 2020 Dec 11;15(12):e0243590. doi: 10.1371/journal.pone.0243590.

View Publication

AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review.

Younossi ZM, Corey KE, Lim JK. Gastroenterology. 2020 Dec 9:S0016-5085(20)35538-4. doi: 10.1053/j.gastro.2020.11.051.

View Publication

Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.

Romero-Gomez M, Kachru N, Zamorano MA, Darba J, Shreay S. Medicine (Baltimore). 2020 Dec 11;99(50):e23506. doi: 10.1097/MD.0000000000023506.

View Publication

Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non-alcoholic fatty liver disease: results from two early phase randomized trials.

Beysen C, Schroeder P, Wu E, Brevard J, Ribadeneira M, Lu W, Dole K, O'Reilly TE, Morrow L, Hompesch M, Hellerstein MK, Li K, Johansson L, Kelly PF. Diabetes Obes Metab. 2020 Dec 2. doi: 10.1111/dom.14272.

View Publication

The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH).

Younossi ZM, Anstee QM, Wai-Sun Wong V, Trauner M, Lawitz EJ, Harrison SA, Camargo M, Kersey K, Subramanian GM, Myers RP, Stepanova M. Gastroenterology. 2020 Dec 8:S0016-5085(20)35529-3. doi: 10.1053/j.gastro.2020.12.003.

View Publication

Non-alcoholic fatty liver disease: Not time for an obituary just yet!

Singh SP, Anirvan P, Reddy KR, Conjeevaram HS, Marchesini G, Rinella ME, Madan K, Petroni ML, Al-Mahtab M, Caldwell SH, Aithal GP, Hamid SS, Farrell GC, Satapathy SK, Duseja A, Acharya SK, Dassanayake AS, Goh KL. J Hepatol. 2020 Dec 16:S0168-8278(20)33729-6. doi: 10.1016/j.jhep.2020.10.015.

View Publication

Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?

Singh SP, Anirvan P, Reddy KR, Conjeevaram HS, Marchesini G, Rinella ME, Madan K, Petroni ML, Al-Mahtab M, Caldwell SH, Aithal GP, Hamid SS, Farrell GC, Satapathy SK, Duseja A, Acharya SK, Dassanayake AS, Goh KL. J Hepatol. 2020 Dec 16:S0168-8278(20)33729-6. doi: 10.1016/j.jhep.2020.10.015.

View Publication

Sex Hormone Relations to Histologic Severity of Pediatric Nonalcoholic Fatty Liver Disease.

Mueller NT, Liu T, Mitchel EB, Yates KP, Suzuki A, Behling C, Lavine JE. J Clin Endocrinol Metab. 2020 Nov 1;105(11):dgaa574. doi: 10.1210/clinem/dgaa574.

View Publication

A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients.

Eslam M, Wong GL, Hashem AM, Chan HL, Nielsen MJ, Leeming DJ, Chan AW, Chen Y, Duffin KL, Karsdal M, Schattenberg JM, George J, Wong VW. Am J Gastroenterol. 2020 Nov 26. doi: 10.14309/ajg.0000000000001059.

View Publication

Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus.

Kupriyanova Y, Zaharia OP, Bobrov P, Karusheva Y, Burkart V, Szendroedi J, Hwang JH, Roden M; GDS group. J Hepatol. 2020 Nov 28:S0168-8278(20)33817-4. doi: 10.1016/j.jhep.2020.11.030.

View Publication

Overall clinical and economic impact of non-alcoholic fatty liver disease.

Sicras-Mainar A, Aller R, Crespo J, Calleja JL, Turnes J, Romero-Gómez M, Augustín S. Rev Esp Enferm Dig. 2020 Nov 23. doi: 10.17235/reed.2020.7238/2020.

View Publication

Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.

Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, Santoro L, Maier S, Liguori A, Meroni M, Borroni V, D'Ambrosio R, Spagnuolo R, Alisi A, Federico A, Bugianesi E, Petta S, Miele L, Vespasiani-Gentilucci U, Anstee QM, Stickel F, Hampe J, Fischer J, Berg T, Fracanzani AL, Soardo G, Reeves H, Prati D, Romeo S, Valenti L.J Hepatol. 2020 Nov 25:S0168-8278(20)33811-3. doi: 10.1016/j.jhep.2020.11.024.

View Publication

MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.

Jung J,Loomba RR, Imajo K, Madamba E, Gandhi S, Bettencourt R, Singh S, Hernandez C, Valasek MA, Behling C, Richards L, Fowler K, Sirlin CB, Nakajima A, Loomba R. Gut. 2020 Nov 19:gutjnl-2020-322976. doi: 10.1136/gutjnl-2020-322976.

View Publication

Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P.

Caviglia GP, Rosso C, Armandi A, Gaggini M, Carli F, Abate ML, Olivero A, Ribaldone DG, Saracco GM, Gastaldelli A, Bugianesi E. Int J Mol Sci. 2020 Nov 22;21(22):E8838. doi: 10.3390/ijms21228838.

View Publication

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA; NN9931-4296 Investigators. N Engl J Med. 2020 Nov 13. doi: 10.1056/NEJMoa2028395.

View Publication

Non-alcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.

Pafili K, Roden M. Mol Metab. 2020 Nov 18:101122. doi: 10.1016/j.molmet.2020.101122.

View Publication

MRI-PDFF treatment response criteria in nonalcoholic steatohepatitis.

Loomba R. Hepatology. 2020 Nov 11. doi: 10.1002/hep.31624.

View Publication

Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice.

Xanthakos SA, Lavine JE, Yates KP, Schwimmer JB, Molleston JP, Rosenthal P, Murray KF, Vos MB, Jain AK, Scheimann AO, Miloh T, Fishbein M, Behling CA, Brunt EM, Sanyal AJ, Tonascia J; NASH Clinical Research Network. Gastroenterology. 2020 Nov;159(5):1731-1751.e10. doi: 10.1053/j.gastro.2020.07.034.

View Publication

Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH.

Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G, Bhandari BR, Gunn N, Caldwell SH, Goodman Z, Wapinski I, Resnick M, Beck AH, Ding D, Jia C, Chuang JC, Huss RS, Chung C, Subramanian GM, Myers RP, Patel K, Borg BB, Ghalib R, Kabler H, Poulos J, Younes Z, Elkhashab M, Hassanein T, Iyer R, Ruane P, Shiffman ML, Strasser S, Wong VW, Alkhouri N; ATLAS Investigators. Hepatology. 2020 Nov 10. doi: 10.1002/hep.31622.

View Publication

Clinical utility of change in nonalcoholic fatty liver disease activity score and change in fibrosis in NAFLD.

Tamaki N, Munaganuru N, Jung J, Yonan AQ, Bettencourt R, Ajmera V, Valasek MA, Behling C, Loomba R. Clin Gastroenterol Hepatol. 2020 Nov 3:S1542-3565(20)31518-4. doi: 10.1016/j.cgh.2020.11.005.

View Publication

A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients with Nonalcoholic Steatohepatitis.

Siddiqui MS, Idowu MO, Parmar D, Borg BB, Denham D, Loo NM, Lazas D, Younes Z, Sanyal AJ. Clin Gastroenterol Hepatol. 2020 Nov 2:S1542-3565(20)31509-3. doi: 10.1016/j.cgh.2020.10.051.

View Publication

The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease.

Hardy T, Wonders K, Younes R, Aithal GP, Aller R, Allison M, Bedossa P, Betsou F, Boursier J, Brosnan MJ, Burt A, Cobbold J, Cortez-Pinto H, Day CP, Dufour JF, Ekstedt M, Francque S, Harrison S, Miele L, Nasr P, Papatheodoridis G, Petta S, Tiniakos D, Torstenson R, Valenti L, Holleboom AG, Yki-Jarvinen H, Geier A, Romero-Gomez M, Ratziu V, Bugianesi E, Schattenberg JM, Anstee QM; LITMUS Consortium. Contemp Clin Trials. 2020 Oct 9;98:106175. doi: 10.1016/j.cct.2020.106175.

View Publication

3D analysis of microvasculature in murine liver fibrosis models using synchrotron radiation-based microtomography.

Wagner WL, Föhst S, Hock J, Kim YO, Popov Y, Schuppan D, Schladitz K, Redenbach C, Ackermann M. Angiogenesis. 2020 Oct 10. doi: 10.1007/s10456-020-09751-9.

View Publication

Expert Panel Review on Non-Alcoholic Fatty Liver Disease in Persons with HIV.

Lake JE, Overton T, Naggie S, Sulkowski M, Loomba R, Kleiner DE, Price JC, Chew KW, Chung RT, Corey KE. Clin Gastroenterol Hepatol. 2020 Oct 15:S1542-3565(20)31431-2. doi: 10.1016/j.cgh.2020.10.018.

View Publication

Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers.

Harrison SA, Calanna S, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal A, Sejling AS, Newsome PN. Contemp Clin Trials. 2020 Oct 8:106174. doi: 10.1016/j.cct.2020.106174.

View Publication

Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.

Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Mendez-Sanchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M. Ann Hepatol. 2020 Oct 5:S1665-2681(20)30177-0. doi: 10.1016/j.aohep.2020.09.006.

View Publication

In vivo absolute quantification of hepatic γ-ATP concentration in mice using 31 P MRS at 11.7 T.

Rothe M, Wessel C, Cames S, Szendroedi J, Burkart V, Hwang JH, Roden M. NMR Biomed. 2020 Oct 6:e4422. doi: 10.1002/nbm.4422.

View Publication

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. Hepatol Int. 2020 Oct 1. doi: 10.1007/s12072-020-10094-2.

View Publication

Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.

Budd J, Cusi K. Curr Diab Rep. 2020 Oct 5;20(11):59. doi: 10.1007/s11892-020-01349-1.

View Publication

ABIDE: an accurate predictive model of liver decompensation in patients with non-alcoholic fatty liver-related cirrhosis.

Calzadilla-Bertot L, Vilar-Gomez E, Wong VW, Romero-Gomez M, Aller-de la Fuente R, Wong GL, Castellanos M, Eslam M, Desai AP, Jeffrey GP, George J, Chalasani N, Adams LA. Hepatology. 2020 Sep 25. doi: 10.1002/hep.31576.

View Publication

Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard.

Ajmera VH, Cachay ER, Ramers CB, Bassirian S, Singh S, Bettencourt R, Richards L, Hamilton G, Middleton M, Fowler K, Sirlin C, Loomba R. Clin Infect Dis. 2020 Sep 25:ciaa429. doi: 10.1093/cid/ciaa429.

View Publication

Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease.

Patel S, Siddiqui MB, Roman JH, Zhang E, Lee E, Shen S, Faridnia M, Mintini RJ, Boyett S, Idowu MO, Sanyal AJ, Luketic VA, Siddiqui MS. Clin Gastroenterol Hepatol. 2020 Sep 29:S1542-3565(20)31369-0. doi: 10.1016/j.cgh.2020.09.039.

View Publication

The times they are a-changin’ (for NAFLD as well).

Ratziu V, Rinella M, Beuers U, Loomba R, Anstee QM, Harrison S, Francque S, Sanyal A, Newsome PN, Younossi Z. J Hepatol. 2020 Sep 2:S0168-8278(20)33599-6. doi: 10.1016/j.jhep.2020.08.028.

View Publication

Dietary Rapeseed Oil Supplementation Reduces Hepatic Steatosis in Obese Men – A Randomized Controlled Trial.

Kruse M, Kemper M, Gancheva S, Osterhoff M, Dannenberger D, Markgraf D, Machann J, Hierholzer J, Roden M, Pfeiffer AFH. Mol Nutr Food Res. 2020 Sep 13:e2000419. doi: 10.1002/mnfr.202000419.

View Publication

Clinical endpoints are necessary in the interim analysis of REGENERATE – Authors’ reply.

Ratziu V, Younossi ZM, Campagna JA, MacConell L, Sanyal AJ. Lancet. 2020 Sep 5;396(10252):663-664. doi: 10.1016/S0140-6736(20)30807-2.

View Publication

A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease.

Maev IV, Samsonov AA, Lazebnik LB, Golovanova EV, Pavlov CS, Vovk EI, Ratziu V, Starostin KM. Adv Ther. 2020 Sep 16. doi: 10.1007/s12325-020-01493-w.

View Publication

CPAP Did Not Improve Nonalcoholic Fatty Liver Disease in Patients with Obstructive Sleep Apnea: A Randomized Clinical Trial.

Ng SS, Wong VW, Wong GL, Chu WC, Chan TO, To KW, Ko FW, Chan KP, Hui DS. Am J Respir Crit Care Med. 2020 Sep 14. doi: 10.1164/rccm.202005-1868OC.

View Publication

Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts.

Calleja-Panero JL, Andrade RJ, Bañares R, Crespo J, Esteban R, Jarque I, Mingot-Castellano ME, Romero-Gómez M, Muñoz-Peñín R, Bentley R, Shepherd J, Gil Aguirre A. Rev Esp Enferm Dig. 2020 Sep 21;112. doi: 10.17235/reed.2020.6895/2020.

View Publication

Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices.

Younossi ZM, Corey KE, Alkhouri N, Noureddin M, Jacobson I, Lam B, Clement S, Basu R, Gordon SC, Ravendhra N, Puri P, Rinella M, Scudera P, Singal AK, Henry L; US Members of the Global Nash Council. Aliment Pharmacol Ther. 2020 Aug;52(3):513-526. doi: 10.1111/apt.15830. Epub 2020 Jun 29.PMID: 32598051

View Publication

From NAFLD to MAFLD: a “redefining” moment for fatty liver disease.

Zheng KI, Fan JG, Shi JP, Wong VW, Eslam M, George J, Zheng MH. Chin Med J (Engl). 2020 Jul 21. doi: 10.1097/CM9.0000000000000981. Online ahead of print.PMID: 32701591 

View Publication

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH.

Hydes TJ, Ravi S, Loomba R, E Gray M. Clin Mol Hepatol. 2020 Jul 17. doi: 10.3350/cmh.2020.0067. Online ahead of print.PMID: 32674529 

View Publication

Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice.

Perdomo C, D'Ingianna P, Escalada J, Petta S, Romero Gómez M, Ampuero J. Pol Arch Intern Med. 2020 Jul 14. doi: 10.20452/pamw.15510. Online ahead of print.PMID: 32666779

View Publication

Physical Activity, Measured Objectively, is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease.

Kim D, Murag S, Cholankeril G, Cheung A, Harrison SA, Younossi ZM, Ahmed A. Clin Gastroenterol Hepatol. 2020 Jul 16:S1542-3565(20)30985-X. doi: 10.1016/j.cgh.2020.07.023. Online ahead of print.PMID: 32683103

View Publication

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.

Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, Kayali Z, Wong VW, Greenbloom S, Jayakumar S, Shiffman ML, Freilich B, Lawitz EJ, Gane EJ, Harting E, Xu J, Billin AN, Chung C, Djedjos CS, Subramanian GM, Myers RP, Middleton MS, Rinella M, Noureddin M. Hepatology. 2020 Jul;72(1):58-71. doi: 10.1002/hep.31205.PMID: 32115759

View Publication

MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study.

Han MAT, Vipani A, Noureddin N, Ramirez K, Gornbein J, Saouaf R, Baniesh N, Cummings-John O, Okubote T, Setiawan VW, Rotman Y, Loomba R, Alkhouri N, Noureddin M. Liver Int. 2020 Jul 11. doi: 10.1111/liv.14593. Online ahead of print.PMID: 32652744

View Publication

The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology.

Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, Giovo I, Uschner FE, Jimenez C, Mookerjee R, Gustot T, Albillos A, Bañares R, Janicko M, Steib C, Reiberger T, Acevedo J, Gatti P, Bernal W, Zeuzem S, Zipprich A, Piano S, Berg T, Bruns T, Bendtsen F, Coenraad M, Merli M, Stauber R, Zoller H, Ramos JP, Solé C, Soriano G, de Gottardi A, Gronbaek H, Saliba F, Trautwein C, Özdogan OC, Francque S, Ryder S, Nahon P, Romero-Gomez M, Van Vlierberghe H, Francoz C, Manns M, Garcia E, Tufoni M, Amoros A, Pavesi M, Sanchez C, Curto A, Pitarch C, Putignano A, Moreno E, Shawcross D, Aguilar F, Claria J, Ponzo P, Jansen C, Vitalis Z, Zaccherini G, Balogh B, Vargas V, Montagnese S, Alessandria C, Bernardi M, Ginès P, Jalan R, Moreau R, Angeli P, Arroyo V; PREDICT STUDY group of the EASL-CLIF CONSORTIUM. J Hepatol. 2020 Jul 13:S0168-8278(20)30384-6. doi: 10.1016/j.jhep.2020.06.013. Online ahead of print.PMID: 32673741 

View Publication

Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.

Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Albillos A, Francés R, Fernández-Rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Hernandez-Guerra M, Augustín S, Bañales J, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero-Gómez M; HEPAmet Registry. J Hepatol. 2020 Jul;73(1):17-25. doi: 10.1016/j.jhep.2020.02.028.

View Publication

Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease.

Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, Kasper P, Roderburg C, Tacke F, Steffen HM, Goeser T, Abraldes JG, Tu XM, Loomba R, Stärkel P, Pride D, Fouts DE, Schnabl B. Gastroenterology. 2020 Jul 8:S0016-5085(20)34923-4. doi: 10.1053/j.gastro.2020.07.005. Online ahead of print.PMID: 32652145

View Publication

Review article: The impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.

Connelly MA, Velez Rivera J, Guyton JR, Siddiqui MS, Sanyal AJ. Aliment Pharmacol Ther. 2020 Jul 8. doi: 10.1111/apt.15935. Online ahead of print.PMID: 32638417 

View Publication

Real-World Burden of Nonalcoholic Steatohepatitis.

Geier A, Rinella M, Balp MM, McKenna SJ, Brass C, Przybysz R, Cai J, Knight A, Gavaghan M, Howe T, Rosen D, Ratziu V. Clin Gastroenterol Hepatol. 2020 Jul 4:S1542-3565(20)30928-9. doi: 10.1016/j.cgh.2020.06.064. Online ahead of print.PMID: 32634622

View Publication

Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.

Yamamura S, Nakano D, Hashida R, Tsutsumi T, Kawaguchi T, Okada M, Isoda H, Takahashi H, Matsuse H, Eguchi Y, Sumida Y, Nakajima A, Gerber L, Younossi ZM, Torimura T. J Gastroenterol Hepatol. 2020 Jul 6. doi: 10.1111/jgh.15172. Online ahead of print.PMID: 32627871 

View Publication

Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease.

Petta S, Sebastiani G, Viganò M, Ampuero J, Wai-Sun Wong V, Boursier J, Berzigotti A, Bugianesi E, Fracanzani AL, Cammà C, Enea M, Grottes MD, Di Marco V, Younes R, Keyrouz A, Mazzola S, Mendoza Y, Pennisi G, Romero-Gomez M, Craxì A, de Ledinghen V. Clin Gastroenterol Hepatol. 2020 Jul 1:S1542-3565(20)30908-3. doi: 10.1016/j.cgh.2020.06.045. Online ahead of print.PMID: 32621970

View Publication

Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus.

Bajaj JS, Lauridsen M, Tapper EB, Duarte-Rojo A, Rahimi RS, Tandon P, Shawcross DL, Thabut D, Dhiman RK, Romero-Gomez M, Sharma BC, Montagnese S. Am J Gastroenterol. 2020 Jul;115(7):989-1002. doi: 10.14309/ajg.0000000000000603.PMID: 32618647

View Publication

What Has the COVID-19 Pandemic Taught Us so Far? Addressing the Problem from a Hepatologist’s Perspective.

Méndez-Sánchez N, Valencia-Rodríguez A, Qi X, Yoshida EM, Romero-Gómez M, George J, Eslam M, Abenavoli L, Xie W, Teschke R, Carrion AF, Keaveny AP.
J Clin Transl Hepatol. 2020 Jun 28;8(2):0024. doi: 10.14218/JCTH.2020.00024. Epub 2020 Apr 11.

View Publication

Mitochondrial oxidative injury: A key player in nonalcoholic fatty liver disease.

Dornas W, Schuppan D. Am J Physiol Gastrointest Liver Physiol. 2020 Jun 29. doi: 10.1152/ajpgi.00121.2020. Online ahead of print.PMID: 32597705

View Publication

A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis.

Oh TG, Kim SM, Caussy C, Fu T, Guo J, Bassirian S, Singh S, Madamba EV, Bettencourt R, Richards L, Raffatellu M, Dorrestein PC, Yu RT, Atkins AR, Huan T, Brenner DA, Sirlin CB, Knight R, Downes M, Evans RM, Loomba R. Cell Metab. 2020 Jun 30:S1550-4131(20)30306-5. doi: 10.1016/j.cmet.2020.06.005. Online ahead of print.PMID: 32610095

View Publication

Metabolic liver disease in diabetes – From mechanisms to clinical trials.

Dewidar B, Kahl S, Pafili K, Roden M. Metabolism. 2020 Jun 20:154299. doi: 10.1016/j.metabol.2020.154299. Online ahead of print.PMID: 32569680 

View Publication

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.

Loomba R, Morgan E, Watts L, Xia S, Hannan LA, Geary RS, Baker BF, Bhanot S. Lancet Gastroenterol Hepatol. 2020 Jun 15:S2468-1253(20)30186-2. doi: 10.1016/S2468-1253(20)30186-2. Online ahead of print.PMID: 32553151

View Publication

From NAFLD to MAFLD: Implications of a premature change in terminology.

Younossi ZM, Rinella ME, Sanyal A, Harrison SA, Brunt E, Goodman Z, Cohen DE, Loomba R. Hepatology. 2020 Jun 16. doi: 10.1002/hep.31420. Online ahead of print.PMID: 32544255

View Publication

Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients.

Gómez-Hurtado I, Gallego-Durán R, Zapater P, Ampuero J, Aller R, Crespo J, Arias-Loste M, García-Monzón C, Bellot P, González-Rodríguez Á, Juanola O, Romero-Gómez M, Francés R. Liver Int. 2020 Jun 19. doi: 10.1111/liv.14571. Online ahead of print.PMID: 32559006

View Publication

Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong.

Tampi RP, Wong VW, Wong GL, Shu SS, Chan HL, Fung J, Stepanova M, Younossi ZM. Hepatol Res. 2020 Jun 14. doi: 10.1111/hepr.13535. Online ahead of print.PMID: 32537840

View Publication

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.

Harrison SA, Goodman Z, Jabbar A, Vemulapalli R, Younes ZH, Freilich B, Sheikh MY, Schattenberg JM, Kayali Z, Zivony A, Sheikh A, Garcia-Samaniego J, Satapathy SK, Therapondos G, Mena E, Schuppan D, Robinson J, Chan JL, Hagerty DT, Sanyal AJ.
J Hepatol. 2020 May;72(5):816-827. doi: 10.1016/j.jhep.2019.11.024. Epub 2019 Dec 27. 

View Publication

Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high-fat diet in the genetically diverse Collaborative Cross mouse model.

de Conti A, Tryndyak V, Willett RA, Borowa-Mazgaj B, Watson A, Patton R, Khare S, Muskhelishvili L, Olson GR, Avigan MI, Cerniglia CE, Ross SA, Sanyal AJ, Beland FA, Rusyn I, Pogribny IP.
FASEB J. 2020 Apr 18. doi: 10.1096/fj.202000194R.

View Publication

Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population.

Sayiner M, Arshad T, Golabi P, Paik J, Farhat F, Younossi ZM.
Hepatol Int. 2020 Apr 16. doi: 10.1007/s12072-020-10038-w.

View Publication

Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.

Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT.
Hepatology. 2020 Apr 16. doi: 10.1002/hep.31281.

View Publication

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.

Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, Karanikas CA, Duffin KL, Robins DA, Haupt A.
Diabetes Care. 2020 Apr 14. pii: dc191892. doi: 10.2337/dc19-1892.

View Publication

Have incidence rates of liver cancer peaked in the United States?

Petrick JL, Florio AA, Loomba R, McGlynn KA.
Cancer. 2020 Apr 15. doi: 10.1002/cncr.32794.

View Publication

Longitudinal relationship of amino acids and indole metabolites with long-term body mass index and cardiometabolic risk markers in young individuals.

Oluwagbemigun K, Anesi A, Ulaszewska M, Clarke G, Alexy U, Schmid M, Roden M, Herder C, Mattivi F, Nöthlings U.
Sci Rep. 2020 Apr 14;10(1):6399. doi: 10.1038/s41598-020-63313-z.

View Publication

Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma.

Nardo AD, Grün NG, Zeyda M, Dumanic M, Oberhuber G, Rivelles E, Helbich TH, Markgraf DF, Roden M, Claudel T, Trauner M, Stulnig TM.
Liver Int. 2020 Apr 13. doi: 10.1111/liv.14464.

View Publication

A new definition for metabolic associated fatty liver disease: an international expert consensus statement.

Eslam M, Newsome PN, Anstee QM, Targher G, Gomez MR, Zelber-Sagi S, Wong VW, Dufour JF, Schattenberg J, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Gronbaek H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J.
J Hepatol. 2020 Apr 8. pii: S0168-8278(20)30201-4. doi: 10.1016/j.jhep.2020.03.039.

View Publication

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort.

Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, Burt AD, Bedossa P, Palmer J, Liu YL, Aithal GP, Allison M, Yki-Järvinen H, Vacca M, Dufour JF, Invernizzi P, Prati D, Ekstedt M, Kechagias S, Francque S, Petta S, Bugianesi E, Clement K, Ratziu V, Schattenberg JM, Valenti L, Day CP, Cordell HJ, Daly AK; EPoS Consortium Investigators.
J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30213-0. doi: 10.1016/j.jhep.2020.04.003.

View Publication

Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis.

Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, Brosnan MJ, Böcskei Z, Anstee QM, Bossuyt PM, Zafarmand MH; LITMUS systematic review team, Pavlides M, Levick C, Duffin K, Hyde C, Bauer T, Bedossa P, Leeming D, Daly A, Hanf R, Ortiz P, Oresic M, Schuppan D, Hanauer G, Chen Y, Shumbayawonda E, Bjerring PN, Zwinderman K.
J Hepatol. 2020 Apr 7. pii: S0168-8278(20)30198-7. doi: 10.1016/j.jhep.2020.03.036.

View Publication

Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed.

Ratziu V.
Hepatology. 2020 Apr;71(4):1146-1149. doi: 10.1002/hep.31213.

View Publication

Modelling NAFLD disease burden in four Asian regions-2019-2030.

Estes C, Chan HLY, Chien RN, Chuang WL, Fung J, Goh GB, Hu TH, Huang JF, Jang BK, Jun DW, Kao JH, Lee JW, Lin HC, Razavi-Shearer K, Seto WK, Wong GL, Wong VW, Razavi H.
Aliment Pharmacol Ther. 2020 Apr;51(8):801-811. doi: 10.1111/apt.15673.

View Publication

Increased Release of Proinflammatory Proteins in Primary Human Adipocytes and Activation of the Inflammatory NFĸB, p38, and ERK Pathways upon Omentin Treatment.

Niersmann C, Röhrig K, Blüher M, Roden M, Herder C, Carstensen-Kirberg M.
Obes Facts. 2020 Apr 6:1-16. doi: 10.1159/000506405.

View Publication

Collagen biology and non-invasive biomarkers of liver fibrosis.

Karsdal MA, Daniels SJ, Holm Nielsen S, Bager C, Rasmussen DGK, Loomba R, Surabattula R, Villesen IF, Luo Y, Shevell D, Gudmann NS, Nielsen MJ, George J, Christian R, Leeming DJ, Schuppan D.
Liver Int. 2020 Apr;40(4):736-750. doi: 10.1111/liv.14390.

View Publication

Circulating extracellular vesicles carrying sphingolipid cargo for the diagnosis and dynamic risk profiling of alcoholic hepatitis.

Sehrawat TS, Arab JP, Liu M, Amrollahi P, Wan M, Fan J, Nakao Y, Pose E, Navarro-Corcuera A, Dasgupta D, Liao CY, He L, Mauer AS, Avitabile E, Ventura-Cots M, Bataller RA, Sanyal AJ, Chalasani NP, Heimbach JK, Watt KD, Gores GJ, Gines P, Kamath PS, Simonetto DA, Hu TY, Shah VH, Malhi H.
Hepatology. 2020 Apr 4. doi: 10.1002/hep.31256.

View Publication

Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease.

Rosso C, Caviglia GP, Younes R, Foglia B, Blanco MJG, Ribaldone DG, Bugianesi E.
Clin Lab. 2020 Apr 1;66(4). doi: 10.7754/Clin.Lab.2019.190922.

View Publication

Outcomes of liver transplantation by insurance types in the United States.

Stepanova M, Al Qahtani S, Mishra A, Younossi I, Venkatesan C, Younossi ZM.
Am J Manag Care. 2020 Apr 1;26(4):e121-e126. doi: 10.37765/ajmc.2020.42839.
PMID: 32270989

View Publication

Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy.

Sattari M, Bril F, Egerman R, Kalavalapalli S, Cusi K.
J Investig Med. 2020 Mar;68(3):743-747. doi: 10.1136/jim-2019-001186. Epub 2019 Dec 17.

View Publication

Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges.

Goldner D, Lavine JE.
Gastroenterology. 2020 Mar 20. pii: S0016-5085(20)30168-2. doi: 10.1053/j.gastro.2020.01.048.

View Publication

Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis.

Chen W, Yang A, Jia J, Popov YV, Schuppan D, You H.
Hepatology. 2020 Mar 16. doi: 10.1002/hep.31236. [Epub ahead of print] Review.
PMID: 32176358

View Publication

Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat with Radiofrequency Ultrasound Data Using One-dimensional Convolutional Neural Networks.

Han A, Byra M, Heba E, Andre MP, Erdman JW Jr, Loomba R, Sirlin CB, O'Brien WD Jr.
Radiology. 2020 Feb 25:191160. doi: 10.1148/radiol.2020191160.

View Publication

Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study.

VanWagner LB, Wilcox JE, Ning H, Lewis CE, Carr JJ, Rinella ME, Shah SJ, Lima JAC, Lloyd-Jones DM.
J Am Heart Assoc. 2020 Feb 18;9(4):e014279. doi: 10.1161/JAHA.119.014279.

View Publication

Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly.

Simon J, Nuñez-García M, Fernández-Tussy P, Barbier-Torres L, Fernández-Ramos D, Gómez-Santos B, Buqué X, Lopitz-Otsoa F, Goikoetxea-Usandizaga N, Serrano-Macia M, Rodriguez-Agudo R, Bizkarguenaga M, Zubiete-Franco I, Gutiérrez-de Juan V, Cabrera D, Alonso C, Iruzubieta P, Romero-Gomez M, van Liempd S, Castro A, Nogueiras R, Varela-Rey M, Falcón-Pérez JM, Villa E, Crespo J, Lu SC, Mato JM, Aspichueta P, Delgado TC, Martínez-Chantar ML.
Cell Metab. 2020 Feb 20. pii: S1550-4131(20)30056-5. doi: 10.1016/j.cmet.2020.01.013.

View Publication

Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease.

Musolino V, Gliozzi M, Scarano F, Bosco F, Scicchitano M, Nucera S, Carresi C, Ruga S, Zito MC, Maiuolo J, Macrì R, Amodio N, Juli G, Tassone P, Mollace R, Caffrey R, Marioneaux J, Walker R, Ehrlich J, Palma E, Muscoli C, Bedossa P, Salvemini D, Mollace V, Sanyal AJ.
Sci Rep. 2020 Feb 13;10(1):2565. doi: 10.1038/s41598-020-59485-3.

View Publication

Advances in non-invasive assessment of hepatic fibrosis.

Loomba R, Adams LA.
Gut. 2020 Feb 17. pii: gutjnl-2018-317593. doi: 10.1136/gutjnl-2018-317593.

View Publication

NAFLD 2020: The State of the Disease.

Cotter TG, Rinella M.
Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30223-7. doi: 10.1053/j.gastro.2020.01.052.

View Publication

An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis.

Zhao P, Sun X, Chaggan C, Liao Z, In Wong K, He F, Singh S, Loomba R, Karin M, Witztum JL, Saltiel AR.
Science. 2020 Feb 7;367(6478):652-660. doi: 10.1126/science.aay0542.

View Publication

Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of Nonalcoholic Fatty Liver Disease.

Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM.
Hepatology. 2020 Feb 11. doi: 10.1002/hep.31173.

View Publication

MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease.

Eslam M, Sanyal AJ, George J; an international consensus panel.
Gastroenterology. 2020 Feb 7. pii: S0016-5085(20)30171-2. doi: 10.1053/j.gastro.2019.11.312.

View Publication

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis.

Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wai-Sun Wong V, Peleg N, Shlomai A, Sebastiani G, Seko Y, Bhala N, Younossi ZM, Anstee QM, McPherson S, Newsome PN; Collaborators.
Gastroenterology. 2020 Feb 3. pii: S0016-5085(20)30137-2. doi: 10.1053/j.gastro.2020.01.043.

View Publication

Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US.

Han A, Zhang YN, Boehringer AS, Montes V, Andre MP, Erdman JW Jr, Loomba R, Valasek MA, Sirlin CB, O'Brien WD Jr.
Radiology. 2020 Feb 4:191152. doi: 10.1148/radiol.2020191152.

View Publication

Investigating fibrosis and inflammation in an ex vivo NASH murine model.

Gore E, Bigaeva E, Oldenburger A, Jansen YJM, Schuppan D, Boersema M, Rippmann JF, Broermann A, Olinga P.
Am J Physiol Gastrointest Liver Physiol. 2020 Feb 1;318(2):G336-G351. doi: 10.1152/ajpgi.00209.2019.

View Publication

Non-Alcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?

Budd J, Cusi K.
Am J Med. 2020 Feb 1. pii: S0002-9343(20)30100-5. doi: 10.1016/j.amjmed.2020.01.007.

View Publication

The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management.

Berná G, Romero-Gomez M.
Liver Int. 2020 Feb;40 Suppl 1:102-108. doi: 10.1111/liv.14360. Review.

View Publication

Current management of non-alcoholic steatohepatitis.

Muthiah MD, Sanyal AJ.
Liver Int. 2020 Feb;40 Suppl 1:89-95. doi: 10.1111/liv.14355.

View Publication

New drugs for non-alcoholic steatohepatitis.

Cardoso AC, de Figueiredo-Mendes C, A Villela-Nogueira C, Sanyal AJ.

Liver Int. 2020 Feb;40 Suppl 1:96-101. doi: 10.1111/liv.14354.

View Publication

Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes.

Cusi K.
Diabetes Care. 2020 Feb;43(2):275-279. doi: 10.2337/dci19-0064.

View Publication

Role of Exercise in Mitigating Pediatric Nonalcoholic Fatty Liver Disease.

Vittorio JM, Lavine JE.
Diabetes Care. 2020 Feb;43(2):280-282. doi: 10.2337/dci19-0029.

View Publication

A diabetologist’s perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions.

Cusi K.
Liver Int. 2020 Feb;40 Suppl 1:82-88. doi: 10.1111/liv.14350.

View Publication

β-arrestin: Dr Jekyll and Mr Hyde in NASH and fibrosis.

Abe H, Schuppan D.
J Hepatol. 2020 May;72(5):813-815. doi: 10.1016/j.jhep.2020.01.016. Epub 2020 Feb 28.

View Publication

Fatty liver disease: putting the spotlight on a silent menace for young adults.

Bugianesi E.
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):236-238. doi: 10.1016/S2468-1253(19)30420-0. Epub 2020 Jan 15. No abstract available.
PMID: 31954686

View Publication

Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis.

Loomba R, Neuschwander-Tetri BA, Sanyal A, Chalasani N, Diehl AM, Terrault N, Kowdley K, Dasarathy S, Kleiner D, Behling C, Lavine J, Van Natta M, Middleton M, Tonascia J, Sirlin C; NASH Clinical Research Network.
Hepatology. 2020 Jan 21. doi: 10.1002/hep.31121.

View Publication

AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review.

Loomba R, Lim JK, Patton H, El-Serag HB.
Gastroenterology. 2020 Jan 29. pii: S0016-5085(20)30127-X. doi: 10.1053/j.gastro.2019.12.053.

View Publication

Collagen biology and non-invasive biomarkers of liver fibrosis.

Karsdal MA, Daniels SJ, Holm Nielsen S, Bager C, Rasmussen DGK, Loomba R, Surabattula R, Villesen IF, Luo Y, Shevell D, Gudmann NS, Nielsen MJ, George J, Christian R, Leeming DJ, Schuppan D.
Liver Int. 2020 Jan 29. doi: 10.1111/liv.14390.

View Publication

Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.

Ratziu V, Sanyal A, Harrison SA, Wong VW, Francque S, Goodman Z, Aithal GP, Kowdley KV, Seyedkazemi S, Fischer L, Loomba R, Abdelmalek MF, Tacke F.
Hepatology. 2020 Jan 13. doi: 10.1002/hep.31108.

View Publication

Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study.

Cleveland ER, Ning H, Vos MB, Lewis CE, Rinella ME, Carr JJ, Lloyd-Jones DM, VanWagner LB.
J Gen Intern Med. 2019 Dec;34(12):2772-2778. doi: 10.1007/s11606-019-05340-9.

View Publication

Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.

Vos MB, Dimick-Santos L, Mehta R, Omokaro SO, Taminiau J, Schabel E, Kleiner DE, Szitanyi P, Socha P, Schwimmer JB, Noviello S, Silberg DG, Torstenson R, Miller V, Lavine JE; Liver Forum Pediatric Working Group.
Gastroenterology. 2019 Dec;157(6):1448-1456.e1. doi: 10.1053/j.gastro.2019.08.048.

View Publication

Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.

Rosso C, Kazankov K, Younes R, Esmaili S, Marietti M, Sacco M, Carli F, Gaggini M, Salomone F, Møller HJ, Abate ML, Vilstrup H, Gastaldelli A, George J, Grønbæk H, Bugianesi E.
J Hepatol. 2019 Nov;71(5):1012-1021. doi: 10.1016/j.jhep.2019.06.031.

View Publication

The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease.

Paik JM, Deshpande R, Golabi P, Younossi I, Henry L, Younossi ZM.
Aliment Pharmacol Ther. 2019 Nov 29. doi: 10.1111/apt.15580.

View Publication

The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD.

Balakrishnan M, Loomba R.
J Clin Gastroenterol. 2019 Nov 26. doi: 10.1097/MCG.0000000000001284.

View Publication

Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

Poynard T, Peta V, Deckmyn O, Pais R, Ngo Y, Charlotte F, Ngo A, Munteanu M, Imbert-Bismut F, Monneret D, Housset C, Thabut D, Valla D, Boitard C, Castera L, Ratziu V; FLIP consortium, the FibroFrance Group, the EPIC-3 program and the QUID-NASH group.
Eur J Gastroenterol Hepatol. 2019 Nov 25. doi: 10.1097/MEG.0000000000001606.

View Publication

Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.

Majdi A, Aoudjehane L, Ratziu V, Islam T, Afonso MB, Conti F, Mestiri T, Lagouge M, Foufelle F, Ballenghien F, Ledent T, Moldes M, Cadoret A, Fouassier L, Delaunay JL, Aït-Slimane T, Courtois G, Fève B, Scatton O, Prip-Buus C, Rodrigues CMP, Housset C, Gautheron J.
J Hepatol. 2019 Nov 21. pii: S0168-8278(19)30678-6. doi: 10.1016/j.jhep.2019.11.008.

View Publication

Dietary wheat amylase trypsin inhibitors promote features of murine non-alcoholic fatty liver disease.

Ashfaq-Khan M, Aslam M, Qureshi MA, Senkowski MS, Yen-Weng S, Strand S, Kim YO, Pickert G, Schattenberg JM, Schuppan D.
Sci Rep. 2019 Nov 25;9(1):17463. doi: 10.1038/s41598-019-53323-x.

View Publication

A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.

Pedrosa M, Seyedkazemi S, Francque S, Sanyal ARinella M, Charlton M, Loomba RRatziu V, Kochuparampil J, Fischer L, Vaidyanathan S, Anstee QM.
Contemp Clin Trials. 2019 Nov 13;88:105889. doi: 10.1016/j.cct.2019.105889.  

View Publication

Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes.

Younossi ZM, Tampi RP, Nader F, Younossi IM, Cable R, Srishord M, Racila A.
Liver Int. 2019 Nov 9. doi: 10.1111/liv.14292.   

View Publication

Hepatocellular carcinoma and non-alcoholic fatty liver disease.

Golabi P, Rhea L, Henry L, Younossi ZM.
Hepatol Int. 2019 Nov;13(6):688-694. doi: 10.1007/s12072-019-09995-8.

View Publication

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.

Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, Lee BH, Loomba R, Cusi K, Kolterman O, Cotter G, Dittrich HC.
J Hepatol. 2019 Nov 4. pii: S0168-8278(19)30650-6. doi: 10.1016/j.jhep.2019.10.023.

View Publication

Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.

Bril F, McPhaul MJ, Caulfield MP, Clark VC, Soldevilla-Pico C, Firpi-Morell RJ, Lai J, Shiffman D, Rowland CM, Cusi K.
Diabetes Care. 2019 Oct 11. pii: dc191071. doi: 10.2337/dc19-1071

View Publication

Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.

Bril F, Barb D, Lomonaco R, Lai J, Cusi K.
J Hepatol. 2019 Oct 4. pii: S0168-8278(19)30584-7. doi: 10.1016/j.jhep.2019.09.018

View Publication

Toward More Accurate Nomenclature for Fatty Liver Diseases

Eslam M, Sanyal AJ, George J.
Gastroenterology. 2019 Sep;157(3):590-593. doi: 10.1053/j.gastro.2019.05.064.

View Publication

Editorial: It is not a wide-open field for incretins – collateral benefits favour the use of metformin in advanced non-alcoholic steatohepatitis

Ratziu V, Pais R.
Aliment Pharmacol Ther. 2019 Sep;50(5):611-612. doi: 10.1111/apt.15414.

View Publication

Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis

Borowa-Mazgaj B, de Conti A, Tryndyak V, Steward CR, Jimenez L, Melnyk S, Seneshaw M, Mirshahi F, Rusyn I, Beland FA, Sanyal AJ, Pogribny IP.
Toxicol Sci. 2019 Aug 1;170(2):273-282. doi: 10.1093/toxsci/kfz110.

View Publication

Non-alcoholic fatty liver disease in Asia: How is it different from the West?

Wong GL, Wong VW.
J Gastroenterol Hepatol. 2019 Aug;34(8):1267-1268. doi: 10.1111/jgh.14813.

View Publication

Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial

Bril F, Biernacki DM, Kalavalapalli S, Lomonaco R, Subbarayan SK, Lai J, Tio F, Suman A, Orsak BK, Hecht J, Cusi K.
Diabetes Care. 2019 Aug;42(8):1481-1488. doi: 10.2337/dc19-0167.

View Publication

Degradation of splicing factor SRSF3 contributes to progressive liver disease

Kumar D, Das M, Sauceda C, Ellies LG, Kuo K, Parwal P, Kaur M, Jih L, Bandyopadhyay GK, Burton D, Loomba R, Osborn O, Webster NJ.
J Clin Invest. 2019 Aug 8;130. pii: 127374. doi: 10.1172/JCI127374.

View Publication

FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice

Rohrbach TD, Asgharpour A, Maczis MA, Montefusco D, Cowart LA, Bedossa P, Sanyal AJ, Spiegel S.
J Lipid Res. 2019 Jul;60(7):1311-1322. doi: 10.1194/jlr.M093799.

View Publication

Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease

Nobili V, Mantovani A, Cianfarani S, Alisi A, Mosca A, Sartorelli MR, Maffeis C, Loomba R, Byrne CD, Targher G.
J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30395-2. doi: 10.1016/j.jhep.2019.06.023.

View Publication

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials

Anstee QM, Lawitz EJ, Alkhouri N, Wong VW, Romero-Gomez M, Okanoue T, Trauner M, Kersey K, Li G, Han L, Jia C, Wang L, Chen G, Subramanian GM, Myers RP, Djedjos CS, Kohli A, Bzowej N, Younes Z, Sarin S, Shiffman ML, Harrison SA, Afdhal NH, Goodman Z, Younossi ZM.
Hepatology. 2019 Jul 4. doi: 10.1002/hep.30842.

View Publication

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A.
Aliment Pharmacol Ther. 2019 Jul;50(2):193-203. doi: 10.1111/apt.15316

View Publication

Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications

Jayakumar S, Loomba R.
Aliment Pharmacol Ther. 2019 Jul;50(2):144-158. doi: 10.1111/apt.15314.

View Publication

A new bile acid treatment for non-alcoholic fatty liver disease

Chan WK, Wong VW.
Lancet Gastroenterol Hepatol. 2019 Jul 22. pii: S2468-1253(19)30183-9. doi: 10.1016/S2468-1253(19)30183-9.

View Publication

Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes

Bril F, Leeming DJ, Karsdal MA, Kalavalapalli S, Barb D, Lai J, Rabe M, Cusi K.
Diabetes Care. 2019 Jul;42(7):1348-1351. doi: 10.2337/dc18-2578.

View Publication

Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease

Khoo S, Wong VW, Goh GB, Fan J, Chan WK, Seto WK, Chow WC.
J Gastroenterol Hepatol. 2019 Jul 23. doi: 10.1111/jgh.14794.

View Publication

Neurocognitive Deficits in a Cohort With Class 2 and Class 3 Obesity: Contributions of Type 2 Diabetes and Other Comorbidities

Fernando HJ, Cohen RA, Gullett JM, Friedman J, Ayzengart A, Porges E, Woods AJ, Gunstad J, Ochoa CM, Cusi K, Gonzalez-Louis R, Donahoo WT.
Obesity (Silver Spring). 2019 Jul;27(7):1099-1106. doi: 10.1002/oby.22508.

View Publication

REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis

Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Younossi Z.
Contemp Clin Trials. 2019 Jun 29;84:105803. doi: 10.1016/j.cct.2019.06.017.

View Publication

Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention

Mouzaki M, Loomba R.
Therap Adv Gastroenterol. 2019 Jun 23;12:1756284819858470. doi: 10.1177/1756284819858470. eCollection 2019.  

View Publication

Development and Validation of Hepamet Fibrosis Scoring System A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

Ampuero J, Pais R, Aller R, Gallego-Durán R, Crespo J, García-Monzón C, Boursier J, Vilar E, Petta S, Ming-Hua Z, Escudero D, Calleja JL, Aspichueta P, Diago M, Rosales JM, Caballería J, Gómez-Camarero J, Lo Iacono O, Benlloch S, Albillos A, Turnes J, Banales JM, Ratziu V, Romero-Gómez M; HEPAmet Registry.
Clin Gastroenterol Hepatol. 2019 Jun 11. pii: S1542-3565(19)30602-0. doi: 10.1016/j.cgh.2019.05.051.

View Publication

Past, present and future perspectives in nonalcoholic fatty liver disease.

Sanyal AJ.
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):377-386. doi: 10.1038/s41575-019-0144-8.

View Publication

Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.

Cusi K.
Hepatology. 2019 Jun;69(6):2318-2322. doi: 10.1002/hep.30670.

View Publication

Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.

Kalavalapalli S, Bril F, Guingab J, Vergara A, Garrett TJ, Sunny NE, Cusi K.
J Endocrinol. 2019 Jun 1;241(3):293-305. doi: 10.1530/JOE-19-0007.

View Publication

Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma.

Liang LY, Wong VW, Tse YK, Yip TC, Lui GC, Chan HL, Wong GL.
Aliment Pharmacol Ther. 2019 Jun;49(12):1509-1517. doi: 10.1111/apt.15269.

View Publication

Are Non-alcoholic Fatty Liver Disease and Alcoholic Fatty Liver Disease More Than Just Semantics?

Eslam M, Sanyal AJ, George J.
Gastroenterology. 2019 May 31. pii: S0016-5085(19)40982-7. doi: 10.1053/j.gastro.2019.05.064

View Publication

Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis.

Farrell G, Schattenberg JM, Leclercq I, Yeh MM, Goldin R, Teoh N, Schuppan D.
Hepatology. 2019 May;69(5):2241-2257. doi: 10.1002/hep.30333.

View Publication

Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease.

Bashir M, Wolfson T4, Gamst AC, Fowler KJ, Ohliger M, Shah SN, Alazraki A, Trout AT, Behling C, Allende DS, Loomba R, Sanyal A, Schwimmer J, Lavine JE, Shen W, Tonascia J, Van Natta ML, Mamidipalli A, Hooker J, Kowdley KV, Middleton MS, Sirlin CB; NASH Clinical Research Network (NASH CRN).
J Magn Reson Imaging. 2019 May;49(5):1456-1466. doi: 10.1002/jmri.26312.

View Publication

Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum.

Cheung A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, Rinella M, Harrison S, Ratziu V, Sanyal AJ, Loomba R, Jeannin Megnien S, Torstenson R, Miller V; Liver Forum Case Definitions Working Group.
Hepatology. 2019 Apr 29. doi: 10.1002/hep.30672.

View Publication

Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, Necsoi C, Campa P, Huefner AD, Schulze Zur Wiesch J, Rougier H, Bastard JP, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D; ANRS-ECHAM Group.
J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):e86-e94. doi: 10.1097/QAI.0000000000001936.

View Publication

Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models.

Gallego-Durán R, Álvarez-Amor L, Gil-Gómez A, Rojas Á, Muñoz-Hernández R, Cádernas-García A, Maya-Miles D, Montero-Vallejo R, Gato S, Sánchez Torrijos Y, Ampuero J, Martín F, Romero-Gómez M.
Rev Esp Enferm Dig. 2019 Apr;111(4):301-307. doi: 10.17235/reed.2019.6083/2018.

View Publication

Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria.

Sánchez-Torrijos Y, Ampuero J, Pérez Palacios D, Gallego-Durán R, Romero-Gómez M.
Rev Esp Enferm Dig. 2019 Apr;111(4):270-274. doi: 10.17235/reed.2019.6088/2018.

View Publication

Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD).

Fernández Rodríguez CM, Aller R, Gutiérrez García ML, Ampuero J, Gómez-Camarero J, Martín-Mateos RMª, Burgos-Santamaría D, Rosales JM, Aspichueta P, Buque X, Latorre M, Andrade RJ, Hernández-Guerra M, Romero-Gómez M.
Rev Esp Enferm Dig. 2019 Apr;111(4):264-269. doi: 10.17235/reed.2019.5965/2018.

View Publication

Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.

Regev A, Palmer M, Avigan MI, Dimick-Santos L, Treem WR, Marcinak JF, Seekins D, Krishna G, Anania FA, Freston JW, Lewis JH, Sanyal AJ, Chalasani N.
Aliment Pharmacol Ther. 2019 Mar;49(6):702-713. doi: 10.1111/apt.15153.

View Publication

Plasma Fibroblast Growth Factor 21 is Associated with Severity of Nonalcoholic Steatohepatitis in Patients with Obesity and Type 2 Diabetes.

Barb D, Bril F, Kalavalapalli S, Cusi K.
J Clin Endocrinol Metab. 2019 Mar 8. pii: jc.2018-02414. doi: 10.1210/jc.2018-02414.

View Publication

The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis.

Poynard T, Peta V, Munteanu M, Charlotte F, Ngo Y, Ngo A, Perazzo H, Deckmyn O, Pais R, Mathurin P, Myers R, Loomba R, Ratziu V; FLIP consortium, the FibroFrance-CPAM group, the FibroFrance-Obese group, and the Selonsertib group.
Eur J Gastroenterol Hepatol. 2019 Mar;31(3):393-402. doi: 10.1097/MEG.0000000000001304.

View Publication

The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Kazankov K, Jørgensen SMD, Thomsen KL, Møller HJ, Vilstrup H, George J, Schuppan D, Grønbæk H.
Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):145-159. doi: 10.1038/s41575-018-0082-x.

View Publication

Reduced Patient-Reported Outcome Scores Associate with Level of Fibrosis in Patients with Nonalcoholic Steatohepatitis.

Younossi ZM, Stepanova M, Anstee QM, Lawitz EJ, Wai-Sun Wong V, Romero-Gomez M, Kersey K, Li G, Subramanian GM, Myers RP, Djedjos CS, Okanoue T, Trauner M, Goodman Z, Harrison SA.
Clin Gastroenterol Hepatol. 2019 Feb 16. pii: S1542-3565(19)30187-9. doi: 10.1016/j.cgh.2019.02.024.

View Publication

Non-Invasive Assessment of Liver Disease in Patients with NAFLD.

Castera L, Friedrich-Rust M, Loomba R.
Gastroenterology. 2019 Jan 17. pii: S0016-5085(19)30051-4. doi: 10.1053/j.gastro.2018.12.036.

View Publication

Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis.

Ratziu V, Ghabril M, Romero-Gomez M, Svegliati-Baroni G.
Transplantation. 2019 Jan;103(1):28-38. doi: 10.1097/TP.0000000000002483.

View Publication

Diagnostic Accuracy of Non-Invasive Fibrosis Models to Detect Change in Fibrosis Stage.

Siddiqui MS, Yamada G, Vuppalanchi R, Van Natta M, Loomba R, Guy C, Brandman D, Tonanscia J, Chalasani N, Neuschander-Tetri B, Sanyal AJ; NASH Clinical Research Network.
Clin Gastroenterol Hepatol. 2019 Jan 4. pii: S1542-3565(19)30004-7. doi: 10.1016/j.cgh.2018.12.031.

View Publication

Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis.

Banini B, Cazanave SC, Yates KP, Asgharpour A, Vincent R, Mirshahi F, Le P, Contos MJ, Tonascia J, Chalasani NP, Kowdley KV, McCullough AJ, Behling CA, Schwimmer JB, Lavine JE, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN).
J Clin Gastroenterol. 2018 Dec 21. doi: 10.1097/MCG.0000000000001142.

View Publication